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Abstract 
Healthcare-associated infections affect 4 million patients annually in the EU 
and result in an estimated 37,000 deaths per year.  Of particular concern are 
the rapidly increasing resistance rates of Gram-negative bacterial pathogens 
to many, or even all, commonly used antibiotics, with a corresponding 
decrease in the design/development of new antibiotic compounds.  Thus, there 
remains an urgent need for novel therapies for these ‘hard to treat’ infections.  
Fortunately, polypeptide antibiotics, such as colistin and polymyxin B, still 
retain potent antimicrobial activity against multidrug resistant (MDR) Gram-
negative pathogens.  In addition, polymer therapeutics are finding increasing 
utility as antimicrobial agents.  The aim of this thesis was to generate and 
characterise an alginate oligosaccharide (“OligoG”)-polymyxin conjugate 
library to optimise the antimicrobial functions of these last resort drugs.  
Reproducible conjugation of polymyxin to OligoG was achieved using amide 
or ester cross-linkers, producing conjugates with 6.1-12.9% (w/w) antibiotic 
loading and molecular weights of 14,500-27,000 g/mol (relative to pullulan MW 
standards).  TNFα ELISA and MTT assays revealed that OligoG conjugation 
significantly decreased inflammatory cytokine production and cytotoxicity of 
colistin (2.2-9.3-fold) and polymyxin B (2.9-27.2-fold) from a human kidney cell 
line.  Minimum inhibitory concentration (MIC) assays and bacterial growth 
curves demonstrated that antimicrobial activity of the OligoG-polymyxin 
conjugates was similar to that of the parent antibiotic, but with more sustained 
bacterial growth inhibition.  Importantly, ester-linked conjugates showed full 
retention of the antibiotic’s antimicrobial activity, while the MIC of the amide-
linked conjugates increased by more than 2 log-fold.  Confocal laser scanning 
microscopy revealed that both amide- and ester-linked colistin conjugates 
significantly disrupted the formation of P. aeruginosa biofilms and induced 
bacterial death.  An in vitro ‘time-to-kill’ experiment using A. baumannii 
indicated that colistin and OligoG-ester-colistin conjugates reduced viable 
bacterial counts (~2 fold) after 4 h, with no significant activity observed with 
OligoG-amide-colistin conjugates. OligoG-induced disruption of the 3-
dimensional architecture and clumping of P. aeruginosa and E. coli biofilms 
was demonstrated using a Transwell diffusion model and biofilm disruption 
assays, while fluorescent labelling of OligoG confirmed its rapid diffusion and 
distribution within the whole biofilm structure.  
These studies confirm that bi-functional polymer therapeutics such as OligoG-
polymyxin conjugates have potential benefits in the treatment of MDR Gram-
negative bacterial infections.  
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1.1 Introduction  
Infections with multidrug-resistant (MDR) bacteria represent a significant 
cause of morbidity and mortality worldwide, accounting for more than 700,000 
deaths annually (O’Neill, 2014, O’Neill, 2016, Zaman et al., 2017).  The 
economic burden of antibiotic resistance and its associated productivity losses 
in Europe and the USA have been estimated to be 1.5€ billion and $55 billion 
per annum, respectively (Gandra et al., 2014, Smith and Coast, 2013).  
Excessive use and misuse of antibiotics in human medicine, as well as in 
agriculture, animal husbandry and veterinary fields has contributed to a 
dramatic increase in antimicrobial resistance (Figure 1.1), the treatment of 
which, in turn, requires high doses of multiple antibiotics that can cause 
serious toxicity and death (Zaman et al., 2017).  The lack of development of 
new therapeutics to treat MDR bacterial infections, especially those caused by 
Gram-negative bacteria, is a major clinical challenge.  As highlighted by the 
World Health Organisation (WHO), carbapenem-resistant Acinetobacter 
baumannii (A. baumannii) and Pseudomonas aeruginosa (P. aeruginosa), as 
well as extended spectrum β-lactamase-producing and carbapenem-resistant 
Klebsiella pneumoniae (K. pneumoniae) and Escherichia coli (E. coli) are the 
biggest threats to public health (WHO, 2017).  Infections caused by MDR 
pathogens are not only associated with poor patient prognosis, high healthcare 
costs, elevated morbidity and mortality rates, but also increased persistence 
and chronicity of infection due to bacterial tolerance and limited therapeutic 
options (Tanwar et al., 2014).  The discovery of new antimicrobial agents, or 
chemical modification of existing antibiotics, is urgently required to potentiate 
treatment against these increasingly life-threatening infectious diseases. 
Every year in the United States, more than 40 million people are prescribed 
antibiotics for respiratory tract infections, however, over 65% of these are 
inappropriately prescribed (Shapiro et al., 2014).  As a result, the number of 
life-threatening MDR, as well as extensively- or pan-drug resistant infections 
is increasing, while development of novel antimicrobial agents is decreasing 
(Schäberle and Hack, 2014).  More than 20 classes of novel antibiotics were 
marketed between 1940 and 1962 and this is therefore considered the 
3 
 
 
  
 
Figure 1.1  A timeline of antimicrobial discovery and emergence of 
resistance.  (Adapted from Ventola, 2015). 
 
Figure 1.1  A timeline of antimicrobial discovery and emergence of 
resistance.  Adapted from (Ventola, 2015). 
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‘golden era’ of antibiotic discovery (Zaman et al., 2017).  Since then, many 
derivatives and analogues have been marketed, with only a few new classes 
of antibiotics approved for clinical use (Niranjana et al., 2018).  To address the 
lack of innovative antimicrobial agents in the clinical development pipeline, 
Infectious Diseases Society of America (IDSA) launched the “10 × ‘20” initiative 
in 2010 to support the development of 10 new, safe and effective classes of 
systemic antibiotics by 2020 (IDSA, 2010).  Unfortunately, the lack of diverse 
novel metabolic or structural targets, limited duration of therapy, inevitable 
emergence of resistance and escalation of the approval requirements during 
clinical trials have, not only substantially stifled advances in novel antimicrobial 
development, but also make antibiotic discovery financially unattractive 
(Coates et al., 2011, Fair and Tor, 2014).  Less than 5% of total venture capital 
investment by the pharmaceutical companies was attributed to the research 
and development of novel antimicrobials between 2003 and 2013 (O’Neill, 
2016).  If the issue is not rapidly addressed, it is estimated that, by 2050, 
antimicrobial resistance could cause 10 million extra deaths each year, 
(more than currently caused by cancer), with costs to the world economy of 
$100 trillion dollars (O’Neill, 2014).  This further highlights the urgent need 
for alternative and efficient approaches to deliver antibiotics to the site of 
infection. 
According to the Infectious Diseases Society of America, Enterococcus 
faecium (E. faecium), Staphylococcus aureus (S. aureus), K. pneumoniae, A. 
baumannii, P. aeruginosa and Enterobacter spp., referred to as the ‘ESKAPE 
bacteria’, are the main bacterial pathogens responsible for life-threatening 
hospital-acquired infections, especially amongst chronically ill or 
immunosuppressed patients (Boucher et al., 2009, Pendleton et al., 2013, 
Rice, 2008).  Bacterial infections and airway inflammation are the main factors 
causing premature death in patients with chronic respiratory diseases such as 
cystic fibrosis or chronic obstructive pulmonary disease.  Here, an altered 
ability to clear the thick accumulated mucus from the respiratory tract, along 
with chronic bacterial infections by Gram-negative MDR pathogens such as P. 
aeruginosa, K. pneumoniae and E. coli, lead to a decline in pulmonary function, 
and eventually, lung damage and death (Pritchard et al., 2016).  
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Cationic polypeptide antibiotics, such colistin (polymyxin E) and polymyxin B, 
were isolated from Paenibacillus polymyxa in the 1940s.  They exhibit a potent, 
detergent-like antimicrobial activity against Gram-negative bacteria, resulting 
in neutralisation of lipopolysaccharide (LPS), destabilisation of the outer 
membrane and leakage of the intracellular contents (Kádár et al., 2013).  
Despite initial widespread use of colistin after its discovery in 1947, serious 
adverse effects, such as nephrotoxicity and neurotoxicity, led to its use being 
discontinued in the 1970s (Gurjar, 2015, Stansly et al., 1947, Taneja and Kaur, 
2016).   
To overcome antibiotic resistance, this study aimed to develop new strategies 
to exploit the ability of alginate oligomers to potentiate (enhance) antibiotic 
treatment and impede bacterial adherence/biofilm development, by acting as 
stimuli-responsive carriers of polymyxins. 
 
1.2 Antibiotics in clinical development 
Antibiotics can be classified based on their mode of action, bacterial spectrum, 
chemical structure or target site (Ullah and Ali, 2017).  Typically, antibiotics 
listed in the same structural class share common characteristics of toxicity and 
efficacy and exhibit similar allergic patterns.  The major structural classes of 
antibiotics are beta-lactams, aminoglycosides, tetracyclines, macrolides, 
fluoroquinolones, sulphonamides, glycopeptides and polypeptides (Etebu and 
Arikekpar, 2016).  Antimicrobials can be classified as ‘broad spectrum’ if they 
are active towards both Gram-positive and Gram-negative bacteria, such as 
tetracyclines, or ‘narrow spectrum’ if they are only active against a specific type 
of bacteria, such as glycopeptides.  The latter are preferable clinically, since 
they contribute less to the development of resistance.  The polymyxin 
antibiotics target the cell envelope and are bactericidal, while other 
antimicrobials, such as azithromycin, inhibit protein synthesis and thus, 
bacterial growth and are bacteriostatic (Etebu and Arikekpar, 2016, Ullah and 
Ali, 2017).  Antibiotics are generally designed to target fundamental metabolic 
and/or physiological functions in the bacteria.  For example, penicillins, 
cephalosporins, carbapenems and bacitracin inhibit the biosynthesis of cell 
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wall peptidoglycan; tetracyclines and macrolides interfere with protein 
synthesis by binding to ribosomal subunit 30S or 50S, respectively; 
fluoroquinolones target DNA gyrase and inhibit DNA replication; 
sulphonamides act as competitive inhibitors of dihydropteroate synthase 
enzyme and thus, disrupt the folic acid synthesis; rifampicin interferes with 
bacterial RNA synthesis by inhibiting DNA-dependent RNA polymerase; and 
polymyxins disrupt the integrity of bacterial membrane (Etebu and Arikekpar, 
2016, Ullah and Ali, 2017).   
According to the WHO’s latest report (May 2017), there are currently 51 
antibiotics or combinations in clinical development trials.  However, only 33 of 
them target the ESKAPE pathogens, and only 8 of them are defined as new 
therapeutic entities, assigned to a new class of antibiotics, or exhibit a novel 
mode of action.  Although many antibiotics currently in clinical phase I trials 
are designed to target Gram-negative infections, most of them are chemical 
modifications of existing antibiotics, and target only a few bacterial 
pathogens with specific resistance mechanisms.  Currently, murepavadin is 
one of the most innovative antibiotics in the clinical development pipeline 
since it exhibits a novel mechanism of action by binding to the LPS transport 
protein D in the outer membrane of Gram-negative bacteria and interfering 
with LPS translocation to the cell surface from the periplasm, which 
ultimately leads to bacterial death (Werneburg et al., 2012).  It has been 
demonstrated that murepavadin has 8-fold more potent antimicrobial activity 
than colistin against a range of extensively drug resistant P. aeruginosa 
pathogens (Sader et al., 2018).  Recently, the United States Food and Drug 
Administration (FDA) approved two new antibiotics for systemic use (WHO, 
2017).  In June 2017, delafloxacin, a fluoroquinolone antibiotic, which acts by 
inhibiting bacterial DNA gyrase and topoisomerase IV activity, was approved 
for the treatment of acute bacterial skin and skin structure infections caused 
by methicillin-resistant Staphylococcus aureus (MRSA), streptococci or 
staphylococcal species, P. aeruginosa and Enterobacteriaceae (Pfaller et al., 
2018).  In August 2017, vabomere, a combination of meropenem (a 
carbapenem) and vaborbactam (a novel β-lactamase inhibitor), was approved 
for severe urinary tract infections caused by carbapenem and third generation 
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cephalosporin resistant Enterobacteriaceae (Castanheira et al., 2016, Cho et 
al., 2018).  Other examples of novel antibiotics in clinical development are 
summarised in Table 1.1.  However, it is important to bear in mind that only 
~14% of antibiotic candidates in Phase I clinical trials will ultimately be 
approved for clinical use (WHO, 2017). 
 
1.3 Bacterial cell wall structure 
The complex and specialised structure of the bacterial cell envelope provides 
a first line defence mechanism against hostile environments (Figure 1.2), 
allowing the cell to regulate and limit entry of small toxic molecules, including 
many antibiotics (Silhavy et al., 2010).  The bacterial cytoplasm is surrounded 
by a ~7.5 nm thick, semi-permeable inner (or cytoplasmic) membrane that is 
mainly comprised of phospholipids and proteins.  Its role is to protect the 
intracellular contents from leakage and control the passage of secreted 
proteins or small molecules between the cytoplasm, periplasm and external 
space (Strahl and Errington, 2017).  Importantly, many enzymes required for 
lipid biosynthesis, electron transport and oxidative phosphorylation are 
embedded in the inner (or cytoplasmic) membrane (Silhavy et al., 2010).  The 
outer layer of cytoplasmic membrane is surrounded by a cell wall composed 
of peptidoglycan, which provides rigidity, shape and structure.  Peptidoglycan 
is composed of crosslinked repeating units of N-acetylmuramic acid and N-
acetylglucosamine residues, which protects the bacteria from osmotic lysis by 
its elasticity (Huang et al., 2008, Vollmer, 2008).  Gram-positive bacteria are 
surrounded by many 30-100 nm thick peptidoglycan envelopes, which act as 
the main physiological defense mechanism due to lack of an outer membrane, 
while Gram-negative bacteria contain only a few relatively thin peptidoglycan 
layers (Silhavy et al., 2010).  Gram-positive bacteria also contain polymers, 
such as teichoic acids or lipoteichoic acids, covalently linked to peptidoglycan 
or the outer layer of the cytoplasmic membrane, respectively, which, contribute 
to its negative surface charge and play a significant role in bacterial adherence 
to mucosal surfaces and pathogenesis (Malanovic and Lohner, 2016).  In 
contrast, Gram-negative bacteria have an outer membrane which is non-
covalently bound to lipoproteins, which, in turn, are covalently attached to the 
 
 
 
 
Antibiotic Class Phase Mode of action Reference 
 
Lefamulin 
 
Pleuromutilin 
 
III 
 
Specifically binds to peptidyl transferase center of the 50S 
ribosome subunit and interferes with protein synthesis. 
 
 
(Veve and 
Wagner, 2018) 
 
Gepotidacin 
 
Triazaacenaphthylene 
 
II 
 
Selectively binds to GyrA and ParC subunits of bacterial 
DNA gyrase or topoisomerase IV, respectively and 
therefore, inhibits the replication of bacterial DNA.  
 
 
(Taylor et al., 
2018b) 
 
Zoliflodacin 
 
Spiropyrimidenetrione 
 
II 
 
Inhibits DNA biosynthesis through accumulation of 
double-stranded DNA cleavages and prevention of DNA 
re-ligation. 
 
 
(Taylor et al., 
2018a) 
 
Brilacidin 
 
Novel membrane 
targeting 
 
II 
 
Depolarises the bacterial cell wall and upregulates various 
regulons, chaperones and proteases, causing misfolding 
of the cytoplasmic proteins. 
 
  
(Mensa et al., 
2014) 
 
Afabicin 
 
Fabl inhibitors 
 
II 
 
Selectively targets the Fabl enzyme in the Staphylococcus 
genus and therefore, inhibits the fatty acid biosynthesis.  
 
 
(Menetrey et 
al., 2017) 
 
 
Antibiotic Class Phase Mode of action Reference 
 
Lefamulin 
 
Pleuromutilin 
 
III 
 
Specifically binds to peptidyl transferase center of the 50S 
 
(Veve and 
Table 1.1  Novel antibiotics against priority pathogens currently in the clinical development 
pipeline.  
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Figure 1.2  Schematic diagrams of the cell envelope in (a) Gram-negative 
and (b) Gram-positive bacteria. 
 
Figure 1.2  Schematic diagrams of the cell envelope in (a) Gram-negative 
and (b) Gram-positive bacteria. 
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peptidoglycan layer.  Since the peptidoglycan layer is permeable to most 
antimicrobial agents with molecular weights below ~50,000 Da, Gram-positive 
bacteria are more susceptible to antibiotic-mediated toxicity than Gram-
negative pathogens (Lambert, 2002). The main constituent of the outer 
membrane of Gram-negative bacteria is a complex lipopolysaccharide (LPS) 
composed of lipid A (a disaccharide of glucosamine with 6-7 acyl chains), a 
polysaccharide core and a specific O-antigen polysaccharide (Erridge et al., 
2002).  LPS plays a critical role in endotoxic shock and permeability of the 
outer membrane, impeding the diffusion of hydrophobic molecules, while the 
presence of outer membrane transport proteins such as porins, restrict the 
diffusion of hydrophilic molecules with molecular weights larger than ~700 Da 
(Silhavy et al., 2010).  Thus, the heterogeneity of LPS due to the structural 
diversity of O-antigen, and the effective permeability barrier of the outer 
membrane further complicate and limit the efficacy of currently available 
antibiotic options against the Gram-negative bacteria.  
 
1.4 Mechanisms of antibiotic resistance 
Many different mechanisms of resistance against antimicrobial drugs have 
been identified (Figure 1.3), including biofilm formation, expression of 
resistance genes that cause reduced uptake and increased efflux of 
antibiotics, production of enzymes that cause covalent modification of the drug 
or an altered version of the substrate, and several bacterial phenotypic states 
such as persistence and swarming, all of which result in reduced antibiotic 
activity (Brauner et al., 2016, Corona and Martinez, 2013, Levin and Rozen, 
2006,  Munita and Arias, 2016).  The rate of antimicrobial resistance depends 
on many factors including mechanism of action and efficacy of the drug, 
duration of antibiotic exposure and patient compliance. The latter is particularly 
important for antibiotics with a short plasma half-life as they require more 
frequent administration, and inadequate doses will be unable to eradicate the 
bacterial pathogen (Li et al., 2017).  
Acquisition of antibiotic resistance arises from spontaneous gene mutation or 
by horizontal gene transfer among bacterial pathogens or other species using 
 
 
Figure 1.3  Schematic representation of different mechanisms of antibiotic resistance. 
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mobile genetic elements such as plasmids, transposons, integrons and 
bacteriophages (Giedraitienė et al., 2011).  Antimicrobial resistance caused by 
spontaneous chromosomal mutations due to errors in DNA replication or faulty 
repair of damaged DNA is quite rare, usually occurring only once in a 
population of 106-108 microorganisms, yet it contributes to cross-resistance of 
structurally similar antibiotics (Hooper, 2001).  Dissemination of antimicrobial 
resistance genes between bacteria occurs via main three pathways: i) 
conjugation, via hair-like structures called pili, ii) transformation, by 
incorporation of free DNA from “dead” or degraded bacteria into the cytoplasm 
and the recipient’s own DNA, and iii) transduction, using bacteriophage 
carriers to infect a recipient bacterial cell with antimicrobial-resistant viral DNA, 
causing the bacteria to produce more copies of infecting bacteriophages or 
incorporate the viral DNA into its genome (Harbottle et al., 2006). 
Although polymyxin resistance rates are still relatively low due to their limited 
utilisation over the past 50 years, an increasing number of colistin or polymyxin 
B resistant bacterial isolates are being identified (Ko et al., 2017).  One of the 
most common strategies of polymyxin resistance in Gram-negative bacteria is 
the overexpression of efflux pumps.  There are five main families of bacterial 
antibiotic efflux pumps: i) the ATP-binding cassette (ABC) superfamily, which 
utilises energy produced from ATP hydrolysis. The other efflux pumps use 
proton or sodium gradients as an energy source and include: ii) the major 
facilitator superfamily (MFS), iii) the small multidrug resistance (SMR) family, 
iv) the resistance-nodulation-cell division (RND) family and v) the multidrug 
and toxic compound extrusion (MATE) family (Kumar and Schweizer, 2005).  
Multidrug resistant E. coli express more than nine proton-dependent efflux 
pumps which confer resistance to at least two different classes of antibiotics 
(Viveiros et al., 2007).  Highly specific efflux systems belonging to the MFS 
family, such as Tet efflux pumps, extrude only tetracyclines in several bacterial 
species, while other efflux pumps such as AcrAB-TolC and MexAB-OprM, 
belonging to the RND family, contribute to multidrug resistance in 
Enterobacteriaceae and P. aeruginosa, respectively (Li et al., 2015).  
Tolerance to colistin has been identified in P. aeruginosa biofilms as being due 
to increased expression of pmr-mediated lipopolysaccharide modification and 
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mexAB-OprM-mediated efflux (Pamp et al., 2008) whilst resistance to 
polymyxin B in Yersinia species has been shown to be mediated by the efflux 
pump/potassium antiporter system (RosAB) (Bengoechea and Skurnik, 2000).  
Furthermore, the AcrAB efflux system was shown to contribute to polymyxin B 
resistance in K. pneumoniae and E. coli (Padilla et al., 2010, Warner and Levy, 
2010). 
Degradation of antibiotics results in elimination of reactive functional groups or 
structural rearrangement of the molecule.  More recently, identification of New 
Delhi metallo-β-lactamase-1 (NDM-1) in Gram-negative Enterobacteriaceae 
has been shown to be associated with high resistance to β-lactams, 
aminoglycosides and fluoroquinolones, but not colistin or tigecycline 
(Kumarasamy et al., 2010).  Previously, a colistin-inactivating enzyme, 
colistinase, was reported in Bacillus polymyxa that caused selective hydrolysis 
of the peptide bond between the two diaminobutyric acid residues at positions 
3 and 4 (Ito-Kagawa and Koyama, 1980).  However, no recent reports have 
been published regarding colistinase activity.   
Another widespread mechanism of resistance that affects a range of different 
classes of antibiotics is alteration of the target site, which weakens antibiotic-
substrate binding.  The loss of negative surface charge due to covalent 
attachment of aminoarabinose residues to the phosphate group of the LPS 
lipid A moiety in Gram-negative bacteria, causes a lower affinity between 
positively charged polymyxins and the bacterial outer membrane and 
therefore, contributes to resistance to polypeptide antimicrobials (Gunn et al., 
1998, Kline et al., 2008).  Similarly, the incorporation of a D-alanine residue 
into teichoic acids embedded in the Gram-positive bacterial cell wall causes 
resistance to cationic antimicrobial peptides (Peschel et al., 1999).  Resistance 
of MDR A. baumannii to polymyxins was associated with modification of the 
lipid A component with phosphoethanolamine or galactosamine residues, 
causing the complete loss of LPS from the outer membrane (Cheah et al., 
2016).  In addition, overproduction of capsular polysaccharide in K. 
pneumoniae limited the interaction of polymyxin B with the bacterial cell 
surface thereby promoting emergence of resistance (Campos et al., 2004).   
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Until recently, polymyxin resistance was conferred by chromosomal mutations, 
but the discovery and dissemination of plasmid-mediated resistance genes 
(mcr) which encode phosphoethanolamine transferases (Chapter 4), has 
caused worrying concerns (Xu et al., 2018).  Since the first report of the colistin 
resistance gene mcr-1 from E. coli isolates in China (Liu et al., 2016), seven 
other mcr homologs have so far been characterised (Wang et al., 2018).  Many 
different plasmids have been identified, including IncI2 or IncFII plasmids 
harbouring colistin resistance genes mcr-7.1 and mcr-8 in K. pneumoniae, 
respectively (Wang et al., 2018, Zhang et al., 2018), IncX4 plasmids facilitating 
the dissemination of mcr-1 and mcr-2 in E.coli (Bai et al., 2018, Xavier et al., 
2016) or IncP and IncHI2 plasmids carrying mcr-1 in K. pneumoniae, and E. 
coli bacteria (Zhao et al., 2017a, Zurfluh et al., 2016).  The mcr-2 gene was 
identified with 77.3% nucleotide sequence homology to mcr-1, while mcr-3, 
with 45% and 47% nucleotide identity to mcr-1 and mcr-2 colistin resistance 
genes, respectively (Xavier et al., 2016, Yin et al., 2017).  Recently, mcr-7.1 
and mcr-8 genes were identified in K. pneumoniae of animal origin and in 
patients with respiratory tract infections, respectively (Wang et al., 2018, Yang 
et al., 2018).  This further highlights the importance of exploring the alternative 
and complementary approaches of targeted antimicrobial delivery to combat 
the potential risk of antimicrobial resistance crisis.  
 
1.4.1 Biofilms  
Biofilms are complex bacterial communities that exhibit up to 1,000 times 
higher resistance/tolerance to antimicrobial agents compared to planktonically 
growing isogenic forms and therefore, can significantly contribute to the 
severity and persistence of infections (Potera, 2010).  Bacteria within the 
biofilm are protected from accumulation and penetration of inflammatory cells, 
antibodies, disinfectants, antimicrobial drugs and environmental factors such 
as changes in pH or temperature (Vatansever and Turetgen, 2018).  
Typically, bacterial biofilms form in several distinct reversible and irreversible 
stages (Figure 1.4).  First, a conditioning layer, composed of various organic 
and organic particles, forms on solid surfaces, such as host tissue or medical
 
 
 
 
 
 
Figure 1.4  Schematic representation of biofilm formation stages.  (EPS, extracellular polymeric substance). 
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appliances including catheters, implants or contact lenses (Donlan, 2002, 
Garrett et al., 2008, Lorite et al., 2011).  This layer (film) is believed to influence 
modifications to the surface charge as well as surface tension and surface 
potential, inducing attachment and providing the nutrient source for the 
bacteria (Donlan, 2002).  The initial reversible adhesion of planktonic bacterial 
cells to the conditioning layer involves only a fraction of cells and therefore, is 
driven by gravitational and hydrodynamic forces (Kostakioti et al., 2013).  The 
availability of nutrients, ionic strength, temperature and pH are main factors 
influencing bacterial attraction or repulsion behaviour (Garrett et al., 2008).   
Flagella-mediated motility of P. aeruginosa and E. coli has been associated 
with improved adhesion to the conditioning layer as well as the ability to 
overcome repulsive and hydrodynamic forces (Pratt and Kolter, 1998, Toutain 
et al., 2007).  The physical forces that mediate bacterial attachment include 
van der Waals forces, electrostatic and steric interactions (Marshall, 1986).  A 
fraction of attached planktonic bacteria become irreversibly immobilised, 
suggesting the involvement of hydrophobic/hydrophilic interactions between 
the bacteria and the surface (Liu et al., 2004).  As the bacterial cells multiply 
and divide by binary division, cell signalling, (defined as quorum sensing), 
between the bacteria triggers changes in gene expression that initiates the 
formation of microcolonies and secretion of a protective matrix consisting of 
extracellular polymeric substance (EPS) (Chapter 6), which eventually covers 
the bacterial community (Jamal et al., 2018).  The expression of cell surface 
proteins allows for the transportation and excretion of various polysaccharides 
and therefore, along with divalent cations, induces strong cross-linking 
between the cells, conferring to mechanical stability of the biofilm (Garrett et 
al., 2008).  Eventually, the dispersal of small parts of the biofilm or the release 
of individual or groups of planktonic bacteria into host environment allows for 
bacteria to travel and re-colonise a new surface, thereby starting a whole new 
cycle of biofilm formation.  It has been suggested that bacteria dispersed from 
biofilms have a unique, transitionary phenotype and therefore might retain 
levels of virulence that can be significantly more pathogenic than their 
planktonic counterparts (Uppuluri and Lopez-Ribot, 2016).  
  
17 
 
1.5 Modification of polymyxin 
The lack of novel therapeutics to combat MDR bacterial infections has forced 
researchers to consider alternative strategies, such as modification of the 
chemical structure of existing antibiotics (Cotter et al., 2012, Fernandes, 2006).  
More recently, in an attempt to tackle MDR bacteria, polymyxins have been 
used as ‘drugs of last resort’ for the primary treatment of life-threatening 
conditions, such as lung and burn wound infections caused by A. baumannii, 
P. aeruginosa and Enterobacteriaceae (Azzopardi et al., 2013a, Falagas et al., 
2005, Hashemi et al., 2017, Nikola et al., 2015).  Nevertheless, issues of 
severe dose-limiting toxicity remain.  Thus, a number of strategies have been 
explored to reduce the nephrotoxicity and optimise the activity of polymyxins, 
mainly by focusing on structural modifications of the N-terminal fatty acyl 
moiety and Dab side chains, as summarised in Table 1.2.  However, none of 
these polymyxin derivatives, has as yet, progressed further in clinical 
development trials due to either a too narrow spectrum of antimicrobial activity 
or inconsistent cytotoxicity results and poor tolerability observed in animal 
studies (Velkov et al., 2016).   
Systemic administration of conventional low molecular weight antibiotics is 
commonly associated with an inadequate volume of distribution, short plasma 
half-life, systemic toxicity, lack of target specificity, emergence of bacterial 
resistance and therefore, requires high daily doses to reach effective 
therapeutic activity in vivo (Miao et al., 2018).  Thus, modification of the 
antibiotic to improve drug delivery may offer many potential therapeutic 
benefits over conventional small molecule antibacterial agents, including 
improved solubility, bioavailability and decreased toxicity due to controlled 
release of the antibiotic at the sites of infection or inflammation (Larson and 
Ghandehari, 2012). 
 
1.6 Nanomedicines as novel antibiotic therapies  
In recent years, nanomedicines have gained a great deal of attention in the 
field of drug delivery, mainly due to the unmet clinical need for new drugs to 
treat life-threatening conditions, such as infectious diseases.  The field of  
 
 
Polymyxin 
derivative 
Modification of 
polymyxin molecule 
Observations Reference 
 
CB-182,804 
 
Substitution of N-
terminal fatty acyl 
moiety by an aromatic 
urea 
 
Toxicity of the polymyxin B derivative (EC50 > 1000 µg/ml) was 
substantially lower compared to the parent compound (EC50 = 318 
µg/ml) in rat kidney proximal tubular cells but exhibited similar or slightly 
less potent antimicrobial activity.  
 
 
(Leese, 2010) 
5x  Substitution of (Dab) 
amino acid residue by 
diaminopropanoic acid 
(Dap) at position 3 
The compound demonstrated an improved antimicrobial activity against 
polymyxin resistant clinical isolates and reduced cytotoxicity (TC50 > 
100 µM) compared to polymyxin B (TC50 = 22 µM) in HK-2 cells.  
However, it lacked an improved therapeutic index in vivo.  
 
(Magee et al., 
2013) 
Compounds 
12 and 18 
Incorporation of an 
ester bond to link fatty 
acyl tail with the 
peptide 
Both compounds demonstrated desired antimicrobial efficacy and a 
significant reduction in cytotoxicity (IC50 > 200 µM) compared to 
polymyxin B (IC50 = 82 µM) in HK-2 cells.  A decrease in in vivo 
nephrotoxicity of both analogues was also confirmed by low levels of 
urine biomarker such as neutrophil gelatinase-associated lipocalin in a 
rat model. 
 
(Gordeev et 
al., 2016) 
CA824, 
CA900, 
CA1049 
Modification of N-
terminal fragments 
All analogues exhibited potent antimicrobial activity against Gram-
negative bacteria and were significantly less cytotoxic (IC50 = 148, 167 
and 64 µg/ml for CA824, CA900 and CA1049, respectively) compared 
to polymyxin B (IC50 = 15 µg/ml) in HK-2 cells. 
 
(Wiederhold et 
al., 2015) 
 
 
Polymyxin 
derivative 
Modification of 
polymyxin molecule 
Observations Reference 
 
CB-182,804 
 
Substitution of N-
 
Toxicity of the polymyxin B derivative (EC50 > 1000 µg/ml) was 
 
(Leese, 2010) 
EC50, 50% effective concentration; TC50, 50% of toxic concentration, CC50, concentration of the 50% cytotoxic effect; IC50, half 
maximal inhibitory concentration.  HK-2, human kidney proximal tubule cells. 
 
 
EC50, 50% effective concentration; TC50, 50% of toxic concentration, CC50, concentration of the 50% cytotoxic effect; IC50, half 
maximal inhibitory concentration.  HK-2, human kidney proximal tubule cells. 
Table 1.2  Examples of polymyxin derivatives currently in clinical development.   
 
 
 
Table 1.2  Examples of polymyxin derivatives currently in clinical development.   
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Polymyxin 
derivative 
Modification of 
polymyxin molecule 
Observations Reference 
 
NAB739 
 
Removal of 2 Dab 
amino acid residues 
 
The polymyxin B derivative containing only three cationic amine groups 
retained antimicrobial activity against E. coli but not against P. 
aeruginosa and A. baumannii.  The derivative was significantly less 
nephrotoxic than the parent drug, leading to an up to 7-fold decrease 
in binding to brush border membrane isolated from rat kidney.  
Cytotoxicity of the compound was 26-fold lower (IC50 = 337 µg/ml) 
compared to polymyxin B (IC50 = 13 µg/ml) and 7.5-fold lower 
compared to colistin (IC50 = 45 µg/ml) in HK-2 cells. 
 
 
(Vaara and 
Vaara, 2013, 
Vaara et al., 
2008) 
 
Compounds 
10, 14, 15 
and 38 
Replacement of fatty 
acyl tail with biphenyl 
or biphenyl ether 
(compounds 10, 14 
and 15) or Dab   
residue substitution 
with glycine at position 
3 (compound 38) 
All demonstrated promising antimicrobial potency.  Compounds 10 
(CC50 = 298 µM and 297 µM), 14 (CC50 = 287 µM and 296 µM), 15 
(CC50 = 316 µM and > 300 µM) and 38 (CC50 = > 300 µM) exhibited 
similar or greater cytotoxicity in human hepatocyte carcinoma cells 
(HepG2) and human embryonic kidney cells (HEK293; respectively) 
compared to polymyxin B (CC50 = >300 µM).  In vitro nephrotoxicity 
assays measuring lactate dehydrogenase and ɣ-glutamyl transferase 
release in HK-2 cells demonstrated that compounds 10, 14, 15 (CC50 
= > 128 µM/ml) and 38 (CC50 = 122 µM/ml and > 128 µM/ml) were less 
or similarly nephrotoxic compared to polymyxin B (CC50 = 23 µM/ml 
and 177 µM/ml), respectively. 
 
(Gallardo-Godoy 
et al., 2016) 
PEG-colistin  PEG-modified colistin The PEG-colistin conjugate demonstrated good antimicrobial activity in 
vitro and reduced toxicity of colistin in mice.  The latter caused 
degeneration and necrosis of renal tubular cells.  
 
(Zhu et al., 2017) 
 
 
Polymyxin 
derivative 
Modification of 
polymyxin molecule 
Observations Reference 
Table 1.2  (continued). 
 
 
 
Table 1.2  (continued). 
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‘nanomedicine’ is defined by the European Science Foundation (ESF) as ‘the 
science and technology of diagnosing, treating and preventing disease and 
traumatic injury, of relieving pain, and of preserving and improving human 
health, using molecular tools and molecular knowledge of the human body 
(ESF, 2005).  Nanomedicines have also been defined as nanometre-sized, 
complex systems composed of at least two components, one being the active 
ingredient.  They are divided into different groups based on their physico-
chemical features and size range, and include liposomes, micelles, 
dendrimers, nanoparticles, nanocrystals and polymer therapeutics (Choi and 
Han, 2018).  By 2016, fifty-one nanomedicines had been approved by the FDA 
(Choi and Han, 2018).   
 
1.6.1 Polymer therapeutics  
Duncan coined the term ‘polymer therapeutics’ to describe a class of 
nanosized therapeutic agents comprising a water-soluble polymer, which may 
be bioactive in its own right or covalently attached to an active constituent, 
such as a drug, protein, peptide or gene (Duncan, 2003).  Polymer therapeutics 
encompasses many structures, including polymeric drugs, polymer-protein 
conjugates, polymer-drug conjugates, polymeric micelles and polyplexes 
(Figure 1.5).  Polymeric drugs are natural or synthetic polymers with inherent 
biological activity.  Polymeric micelles are self-assembling polymeric structures 
with drug attached at the core via a covalent bond, while polyplexes are 
multicomponent polyelectrolyte complexes that are used for DNA transfer 
(Duncan, 2003).  Polymer-protein conjugates have protein attached to one or 
more water-soluble polymeric chains through a spacer group, and lastly, 
polymer-drug conjugates contain a water-soluble polymer and bioactive drug 
attached through a covalent bond via a spacer group.  Thus, polymer 
therapeutics are often defined as new chemical entities rather than the 
traditional drug delivery systems, which makes them very attractive to the 
pharmaceutical industry (Vicent et al., 2009). 
Polymer therapeutics are the most successful class of nanomedicines, with 
fifteen products currently in clinical use (Duncan, 2014, Duro-Castano et al., 
  
 
 
 
Figure 1.5  Schematic representation of polymer therapeutics including polymeric drugs, polymer-protein conjugates, polymer-
drug conjugates, polyplexes and polymeric micelles.  (Adapted from Duncan, 2003). 
 
Figure 1.5  Schematic representation of polymer therapeutics including polymeric drugs, polymer-protein conjugates, polymer-
drug conjugates, polyplexes and polymeric micelles.  Adapted from (Duncan, 2003). 
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2015).  The first polymer therapeutic approved by the FDA for clinical use was 
a polyethylene glycol (PEG)-adenosine deaminase (Adagen®) conjugate for 
the treatment of severe combined immunodeficiency (Levy et al., 1988).  PEG-
filgrastim (an analogue of recombinant granulocyte colony-stimulating factor) 
conjugate (Neulasta®), for the treatment of neutropenia in chemotherapy 
patients, and glatiramer acetate (Copaxone®), a random copolymer composed 
of glutamate, lysine, alanine and tyrosine residues, for patients with relapsing-
remitting multiple sclerosis, are already two of the ten most profitable drugs in 
the United States (Duncan, 2014, Lambertini et al., 2015, Scott, 2013).  
Currently, PEG-naloxegol (Movantik®) is the only polymer-drug conjugate 
approved by FDA (Duncan, 2017, Ekladious et al., 2018, Floettmann et al., 
2017).  Despite the success of polymer therapeutics, especially PEGylated 
protein conjugates, progression of polymer-drug conjugates to the market has 
been very slow, mainly due to poor rational design and lack of suitable 
polymeric carriers (Canal et al., 2011, Duro-Castano et al., 2015, Vicent et al., 
2008). 
The idea of using natural or synthetic macromolecules as drug carriers was 
first proposed by Jatzkewitz in the 1950s.  Using a dipeptide spacer to attach 
polyvinylpyrrolidone to mescaline, Ushakov and his team synthesised the first 
water-soluble polymer-drug conjugates in the following years (Givental et al., 
1965, Jatzkewitz, 1955).  The first polymer-drug conjugate designed to reduce 
toxicity and improve drug efficacy and target specificity was proposed by 
Ringsdorf in 1975 (Ringsdorf, 1975).  It contained a biocompatible polymer 
backbone, a covalently bound drug attached by a linker group, a targeting 
moiety and a solubilising agent to ensure water solubility.  The proposed model 
offered many advantageous features to the field of drug delivery compared to 
low molecular weight drugs, mainly by improving drug pharmacokinetic 
properties.  Drug plasma half-life and bioavailability can also be drastically 
improved, which is particularly important since more than 40% of drugs in 
clinical development have poor bioavailability due to low aqueous solubility 
(Lipinski, 2002).  For instance, the hydrophobicity and high systemic toxicity of 
paclitaxel was reduced by covalent conjugation to polyglutamic acid (Chipman 
et al., 2006).  What is more, drug conjugation to a water-soluble polymer can 
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significantly improve bio-distribution and targeting due to the enhanced 
permeability and retention (EPR) effect, mask immunogenicity, enhance 
cellular uptake, reduce systemic toxicity and prevent enzymatic degradation, 
especially of proteins or peptides (Xiong et al., 2014). 
 
1.6.2 Enhanced permeability and retention effect 
The EPR effect was first reported in cancer patients by Matsumura and Maeda 
in 1986 as a promising mechanism for targeted delivery of chemotherapeutic 
agents.  Accumulation of the anti-tumour protein neocarzinostatin conjugated 
to a styrene and maleic acid copolymer (SMANCS) was found to be 
significantly higher in tumours than in healthy tissues (Matsumura and Maeda, 
1986).  In the following years, evidence of the EPR phenomenon in infectious 
diseases was also proposed, although it was still not fully exploited for passive 
targeting of antibiotics (Maeda et al., 1999).  Conventional low molecular 
weight drugs distribute indiscriminately throughout the body, diffuse through 
vasculature and internalise inside both, healthy and diseased tissues, leading 
to an inadequate volume of distribution, lack of target specificity and toxicity.  
Importantly, the endothelium of healthy blood vessels is almost impermeable 
to larger macromolecules, thus restricting their entry to tissues almost 
exclusively via gaps in “leaky” veins/arteries (Markovsky et al., 2012).  The 
characteristic features of tumour tissues, which allow preferential accumulation 
of macromolecules, include a disorganised vasculature, discontinuous 
endothelium, high vascular density, angiogenesis and elevated levels of 
vascular permeability mediators, while defective lymphatic drainage enables 
conjugate retention at the target site (Maeda et al., 2000, Maeda, 2013).  A 
variety of other pathological conditions such as diabetes, thrombosis, 
atherosclerosis, asthma and infections have also been characterised by 
excessive angiogenesis since they share a similar microenvironment and 
inflammatory features with tumours (Fiedler and Augustin, 2006).  More 
recently, Azzopardi et al. (2013) described the presence of an EPR effect in 
infection, permitting passive accumulation of macromolecular conjugates at 
sites of infection due to increased vascular permeability. Ongoing 
inflammation, remodelling and angiogenesis, along with increased interstitial 
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tissue pressure and destruction, further enhance macromolecule retention at 
the infected site (Azzopardi et al., 2013b).  The principle of the EPR effect is 
shown in Figure 1.6. 
The feasibility of the EPR effect for targeted antimicrobial delivery has been 
proven in several studies.  Following intravenous injection in rats, PEGylated 
liposomes containing gold were preferentially localised in tissues infected with 
S. aureus (Laverman et al., 2001).  Additionally, 2 hours after intravenous 
administration of technetium99-labelled ubiquicidin conjugated to poly(ethylene 
glycol)-N-(N-(3-diphenylphosphinopropionyl) glycyl)-S-trityl-cysteine (PEG-
PN2S) in mice, accumulation of the conjugate was observed at the site of S. 
aureus infection (Meléndez-Alafort et al., 2009). 
 
1.7 Polymeric carrier 
The ideal polymeric carrier for antibiotic conjugation should be water-soluble, 
non-toxic, non-immunogenic, biodegradable and contain suitable functional 
groups for drug attachment.  The backbone of the polymeric carrier determines 
the pharmacodynamic and pharmacokinetic properties of the drug, while the 
structure, molecular weight, polydispersity, charge and hydrophilicity are the 
main features of the polymer which contribute to the drug loading, solubility, 
elimination, distribution and toxicity (Markovsky et al., 2012).  Many different 
polymers have been used in drug conjugation including PEG, N-(2-
hydroxypropyl) methacrylamide (HPMA) copolymer, polyglutamic acid (PGA) 
and natural polysaccharides, such as dextrin and chitosan (Gaspar and 
Duncan, 2009).  Although the most successful polymeric carriers that entered 
trials in clinical development were non-biodegradable, such as PEG and 
HPMA copolymer, increased awareness of the potential safety implications of 
chronic administration and high doses is required (Duncan, 2009, Schütz et 
al., 2013, Swierczewska et al., 2015). Toxic accumulation of non-
biodegradable polymers may occur if their molecular weight exceeds the renal 
threshold, which may result in lysosomal storage disease or intracellular 
vacuolation (Duncan, 2017, Markovsky et al., 2012). Consequently, 
researchers are increasingly turning to biodegradable polymers for conjugation 
 
 
 
 
 
 
Figure 1.6  Schematic representation of localisation of the polymer-antibiotic conjugates. 
 
Figure 1.6  Schematic representation of localisation of the polymer-antibiotic conjugates. 
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of bioactive molecules.  Due to its biodegradability and high primary amine 
content, low molecular weight chitosan has been used to enhance the delivery 
of orally administered insulin, leading to increased bioavailability and intestinal 
absorption of the peptide (Lee et al., 2010).  In addition, thanks to the presence 
of α-amylase in plasma and in extracellular fluids, dextrin is also commonly 
exploited for controlled release of protein and peptide drugs due to its 
biocompatibility and biodegradability (Gaspar and Duncan, 2009).  Since 
dextrin lacks a convenient amino or carboxyl groups, functionalisation is 
required to couple it with bioactive substances.  However, increasing the 
degree of chemical modification of dextran was found to decrease the rate of 
biodegradability of the polymer, so this must be carefully controlled 
(Vercauteren et al., 1990).  
 
1.7.1 Alginates 
This study proposed that alginates may also be successfully and safely 
exploited for drug delivery, as they possess many favourable features.  
Alginates are naturally-occurring polysaccharides, non-toxic and non-
immunogenic, whose physical and biological properties can be controlled by 
tailoring their size and composition.  Alginates are linear copolymers 
composed of β-D-mannuronic acid (M) and α-L-guluronic acid (G) residues 
that are linked by 1-4 glycosidic bonds and exhibit a stereochemical difference 
at the C-5 position (Draget and Taylor, 2011).  The monomers are arranged 
into various lengths and distributions of polymeric blocks of repeating M, G or 
mixed MG residues which define the physicochemical characteristics of the 
polysaccharide.  In this way, β-(1-4) linkages formed by mannuronic acid 
residues lead to a more flexible, linear conformation of M-blocks, whereas 
guluronic acid forms an α-(1-4) bond, which results in the folded, more rigid 
and stiff G-block structure (Yang et al., 2011).  The distribution and quantity of 
M and G residues in the resulting alginate can vary significantly between the 
species of brown algae used, which part of the plant is used (leaves or stems) 
and is highly dependent on the growth conditions of the seaweed.  
Most commercially produced alginates are extracted from brown seaweed 
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such as Macrocystis, Laminaria and Ascophyllum species (Qin, 2008).  
Naturally, alginate exists as calcium, sodium, magnesium or even potassium 
salts which can be converted into water-soluble sodium alginate when treated 
with alkali solutions such as sodium hydroxide followed by further filtration and 
precipitation by calcium chloride (Qin, 2008).  Bacterial sources also exist, with 
Pseudomonas and Azotobacter spp. able to produce the exopolysaccharide 
alginates during their normal growth cycles.  Typically, the molecular weight of 
alginate is between 105-106 Da, equivalent to 500-5000 residues per chain. 
However, alginates isolated from bacteria are often larger (Andersen et al., 
2012).  The physical properties of alginates, such as viscosity, are highly 
dependent on molecular size.  Since alginates are polydisperse and their 
chains vary in size and composition, low molecular weight alginates are 
typically prepared by hydrolysis using a weak acid, such as hydrochloric acid 
(Andersen et al., 2012).  
While polysaccharides are generally considered to be biodegradable, not all of 
them are broken down by mammalian enzymes.  For example, alginate is 
readily degraded by alginate lyases, which are secreted by many species 
including marine algae, marine molluscs, and a wide range of microorganisms.  
However, alginate is inherently non-degradable in mammals since they do not 
produce the enzyme to digest the polymer chains (Wong et al., 2000).  Since 
commercially available alginates have a molecular weight above the renal 
threshold, they may not be completely removed from the body following 
systemic administration (Al-Shamkhani and Duncan, 1995), which could be 
problematic for alginate-protein conjugates designed to treat chronic 
conditions.  Studies have shown that mouse and human phagocytic cells were 
unable to degrade bacterial alginate due to inadequate enzymatic and free 
radical capacities (Simpson et al., 1993).  These findings suggest that, after 
endocytosis of alginate conjugates, lysosomal glucosidases, esterases and 
proteases may not be capable of degrading the polymer.  Therefore, Yang et 
al. (2011) developed sulfation, oxidation, amidation and esterification methods 
to modify the free hydroxyl and carboxyl groups of alginates, thereby rendering 
the polymer degradable.  For example, oxidation of the hydroxyl groups of 
alginate with sodium periodate led to complete polymer degradation at 
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physiological conditions after 100 h (He et al., 2005).  The optimal stability of 
alginate chains is around pH 6.  Thus, depolymerisation of alginate 
biomaterials occurs in vivo under physiological conditions at pH 7.4 by 
spontaneous β-elimination (Andersen et al., 2012).  At sites of infection, 
alginates can be degraded by reactive oxygen species, especially hydroxyl 
radicals, or by bacterial alginate lyase that catalyses the β-elimination reaction.  
The ability of alginate lyase, produced by K. pneumoniae, to cleave linkages 
of GM and GG blocks has already been shown (Sutherland, 1995). 
Alginates are recognised as a safe material by the FDA (Sosnik, 2014) and 
are widely used in medicine and biotechnology due to their stabilising, 
viscosifying and gelling properties (Andersen et al., 2012, Laurienzo, 2010).  
Not only are alginates extensively used in the food industry, but they are have 
also been widely used for various medical applications including drug delivery, 
wound dressings, dental impression materials and in tablet formulations for 
gastric reflux, such as Gaviscon (Chatfieid, 1999, Draget and Taylor, 2011).  
One of the most important features of alginate is its ability to selectively bind 
to divalent cations such as Ca2+, leading to gel formation (Draget and Taylor, 
2011).  Increasing the G-block content of the alginate actually augments its 
ability to bind to divalent cations.   
 
1.7.2 OligoG CF-5/20 
Although alginates are known to be biodegradable, hydrophilic and non-toxic, 
until recently, few investigations had used alginates for protein and peptide 
conjugation, due to the lack of alginate-degrading mammalian enzymes and 
their relatively large size.  OligoG CF-5/20 is a G-block oligosaccharide with > 
85% G residues and a narrow molecular weight distribution (mean molecular 
weight ~3,200 g/mol; equivalent to ~16 monomer units) that is produced from 
the stem of brown seaweed (Laminaria hyperbora) (Hengzhuang et al., 2016).  
OligoG is an anionic, highly water-soluble oligomer, although in practice, its 
high viscosity at concentrations > 15% limits its solubility (Khan et al., 2012).  
The chemical structure of OligoG is presented in Figure 1.7.  OligoG powder 
is prepared by purification using charcoal filters, followed by “spray-drying”.  
 
 
Figure 1.7  Chemical structure of OligoG, including α-L-guluronate (G) and β-D-manuronate (M) blocks. 
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Quality control of the final product is carried out using H1-nuclear magnetic 
resonance and high-performance anion-exchange chromatography with 
pulsed amperometric detection (Khan et al., 2012).  The intrinsic antimicrobial 
activity of the prototypical OligoG CF-5/20 product is discussed in Chapter 3. 
 
1.8 Examples of polysaccharide-antibiotic conjugates 
Polysaccharides, such as alginates, possess many favourable features for 
targeted delivery of antimicrobial drugs including biodegradability, 
hydrophilicity and a lack of toxicity.  Various studies have demonstrated the 
potential value of polysaccharides as antibiotic carriers for targeted drug 
delivery.  For example, colistin has been conjugated to dextrin (Mw 7500 g/mol 
with 1 mol % succinoylation) using EDC and sulfo-NHS carbodiimide linking 
agents (~10% colistin loading).  The resulting dextrin-colistin conjugates 
maintained potent antimicrobial activity against a panel of MDR Gram-negative 
bacteria whilst exhibiting markedly decreased in vitro cytotoxicity compared to 
the unmodified antibiotic in HK-2 cells, leading to a 4-5-fold improved IC50 
concentration (Azzopardi et al., 2015, Ferguson et al., 2014).  In addition, in 
vivo studies also demonstrated improved pharmacokinetics of the dextrin-
colistin conjugates, leading to a considerably prolonged plasma half-life of the 
drug (Ferguson et al., 2014). 
In another example, the antibiotic norfloxacin has also been coupled to dextran 
(Mw 64000 g/mol) bearing mannose (2.3 mol %) through a tetrapeptide Gly-
Phe-Gly-Gly linker (8.2% w/w norfloxacin loading) to facilitate targeted drug 
delivery to macrophages (Balazuc et al., 2005, Roseeuw et al., 2003).  While 
unconjugated norfloxacin lacked antimicrobial activity against intracellular 
Mycobacteria in vivo due to rapid renal clearance, antibiotic efficacy was 
restored following conjugation to dextran.   
Additionally, the conjugation of chitosan (Mw 13000 g/mol) to streptomycin 
(22% w/w streptomycin loading) has also been shown and was linked by 
reduction of the resulting Schiff base, which significantly improved the 
internalisation of antibiotic into macrophages and improved its antimicrobial 
activity 100-fold more in comparison to a mixture of the individual components 
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(Mu et al., 2016).  The chitosan-streptomycin conjugate showed significant 
bactericidal activity against multiple intracellular bacterial pathogens, including 
Listeria monocytogenes, S. aureus and Salmonella typhimurium in infected 
human umbilical vein endothelial cells (HUVEC), epithelial cells (HaCaT) and 
macrophages, however, cytotoxicity was observed when RAW264.7 cells were 
treated at concentrations > 300 µg/ml.  
 
1.9 Aims of the project 
The aim of this project was to develop a bi-functional antibiotic delivery system 
using the alginate oligosaccharide, OligoG CF-5/20, to reduce the toxicity and 
optimise the antimicrobial efficacy of antibiotics of last resort against MDR 
Gram-negative bacterial pathogens.  This project hypothesised that passive 
targeting of OligoG-polymyxin conjugates to sites of infection by the EPR 
effect, followed by separation of the parent molecules via intrinsic, 
complementary antimicrobial enzyme activities at the target site, would 
significantly enhance the efficacy of the antibiotics and reduce their toxicity. 
 
The specific aims of the study were: 
• To generate a library of OligoG-polymyxin conjugates and characterise 
their physicochemical and toxicological properties. 
• To evaluate the antimicrobial efficacy of OligoG-polymyxin conjugates 
against a panel of MDR Gram-negative bacteria. 
• To investigate the in vitro pharmacokinetic/pharmacodynamic profile of 
OligoG-colistin conjugates, in respect to antibiotic release and 
effectiveness.  
• To assess the activity of OligoG to disrupt the physical structure and 
architecture of biofilms of MDR Gram-negative bacteria and to study its 
localisation within the biofilm polymeric network. 
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Chapter 2 
 
General Materials and Methods 
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2.1 Chemicals 
2.1.1 General chemicals 
Aprotinin from bovine lung, cytochrome c from equine heart, carbonic 
anhydrase from bovine erythrocytes, albumin from bovine serum, blue dextran, 
bicinchoninic acid (BCA) solution, copper (II) sulfate pentahydrate (4% w/v), 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), sodium 
hydroxide, sodium chloride, potassium chloride, disodium hydrogen 
phosphate, potassium dihydrogen phosphate and Tween® 20 were from 
Thermo Fisher Scientific (Loughborough, UK).  Ninhydrin, hydrindantin, lithium 
acetate dihydrate, ethanolamine, acetic acid (glacial), acetonitrile, anhydrous 
dimethyl sulfoxide (DMSO), ethanol, chloroform, 4-dimethylaminopyridine 
(DMAP), N,N'-dicyclohexyl carbodiimide (DCC), N-hydroxysulfosuccinimide 
(sulfo-NHS) and sucrose were from Sigma Aldrich (Poole, UK).  Pullulan gel 
filtration standards were obtained from Polymer Laboratories (Church Stretton, 
UK).  All chemicals were of analytical grade, except for DMSO used in cell 
culture. 
 
2.1.2 Alginates 
OligoG CF-5/20 (Lot: BU-1211-35; ≥ 85% guluronic acid and Mn of 3,200 
g/mol) and high molecular weight alginate PRONOVA UP MVG (Batch: FP-
505-01) medium viscosity, > 60% guluronic acid and Mw of 200,000 g/mol) 
were provided by Algipharma AS (Sandvika, Norway).   
 
2.1.3 Antibiotics 
Colistin sulfate, polymyxin B, bacitracin, azithromycin, vancomycin 
hydrochloride, spiramycin, spectinomycin and rifampicin were from Sigma 
Aldrich (Poole, UK).   
 
2.1.4 Fluorescent probes  
Oregon Green 488 cadaverine 5-isomer (OrGr), LIVE/DEAD® BaclightTM 
Bacterial Viability kit, SYTO 9TM and Concanavalin A Alexa FluorTM 633 
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conjugate (ConA) were from Invitrogen Molecular Probes (Paisley, UK).  
Sulforhodamine 101 (Texas Red) cadaverine (TxRd) was from Chemometec 
(Allerod, Denmark).  Rhodamine 6G was from Sigma Aldrich (Poole, UK).   
 
2.1.5 Chemicals for bacterial culture 
Tryptone soy (TS) broth, tryptone soy agar (TSA), blood agar (BA) base and 
Mueller-Hinton (MH) broth were purchased from LabM (Bury, UK).  
Defibrinated horse blood was from TCS Biosciences (Botolph Claydon, UK).  
Resazurin sodium salt, mucin (II) from porcine stomach, deoxyribonucleic acid 
(DNA) from salmon fish sperm, RPMI 1640 amino acid solution, 
diethylenetriaminepentaacetic acid (DTPA), egg yolk emulsion and 
ethylenediaminetetraacetic acid (EDTA) were from Sigma Aldrich (Poole, UK).  
MaxSignal® colistin enzyme-linked immunosorbent assay (ELISA) test kit was 
from Bioo Scientific Corp. (Austin, USA).   
 
2.1.6 Chemicals for cell culture 
Keratinocyte serum-free (K-SFM) medium (with L-glutamine), bovine pituitary 
extract (BPE, 0.05 mg/ml), human recombinant epidermal growth factor (EGF, 
5 ng/ml), 0.05% w/v trypsin-0.53 mM EDTA were from Invitrogen Life 
Technologies (Paisley, UK).  Trypan blue, DMSO (cell culture grade) and 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were from 
Sigma Aldrich (Poole, UK).  Human tumour necrosis factor alpha (TNFα) 
ELISA kit was from Thermo Fisher Scientific (Loughborough, UK).   
 
2.2 Cell line 
Human kidney proximal tubule cell line (HK-2, CRL-2190) was purchased from 
American Type Culture Collection (ATCC) (Manassas, USA).  HK-2 cells were 
confirmed to be free of mycoplasma contamination.  Typical morphology of the 
cells is shown in Figure 2.1. 
 
2.3 Bacterial isolates 
Clinical bacterial isolates and Escherichia coli ATCC 25922 were provided by 
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 250 µm 
Figure 2.1  Morphology of the HK-2 cells.  Picture was taken using the 
Nikon Eclipse TS100 inverted microscope equipped with Moticam® digital 
camera (magnification x10). 
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Prof Tim Walsh (Department of Medical Microbiology and Infectious Disease, 
Cardiff University, UK), except for MDR Acinetobacter baumannii 7789, 
Pseudomonas aeruginosa PAO1 ATCC 15692, Pseudomonas aeruginosa 
National Collection of Type Culture (NCTC) 10662 and Escherichia coli NCTC 
10418 which were donated by Dr Robin Howe (Public Health Wales 
Microbiology Department, University Hospital of Wales, Cardiff, UK).  Multiple 
drug resistance was confirmed by the referring laboratories.  The origin of 
pathogens and resistance genotypes are provided in Table 4.1.  
 
2.4. Equipment 
2.4.1 General equipment for bacterial and cell culture 
Sterile general consumables: flat-bottom 96-well plates, universal containers, 
centrifuge tubes (15 and 50 ml), 7 ml bijou containers, petri dishes, tissue 
culture flasks (25 and 75 cm2), pipettes (5, 10 and 25 ml) and cryovials were 
purchased from Starstedt (Leicester, UK).  Low protein binding sterile 
polyvinylidene fluoride (PVDF) syringe filters (0.22 µm) were purchased from 
Merck Millipore (Watford, UK).  Sterile needles were purchased from BD 
Microlance (Fraga, Spain) and sterile syringes were from BD Plastipak 
(Madrid, Spain).  Spectra/Por® 7 regenerated cellulose dialysis tubing was 
from Spectrum Laboratories Inc. (California, USA).  Slide-A-Lyzer sterile 
dialysis cassettes were from Thermo Fisher Scientific (Loughborough, UK).  
Microbank vials were from Pro-Lab (Birkenhead, UK).  Sterile Transwell (0.4 
μm pore polycarbonate membrane) plates and sterile flat-bottom black 96-well 
plates were from Corning Inc. (New York, USA).  Sterile 96-well flat glass 
bottom black plates were from Greiner Bio-One (Stonehouse, UK) and sterile 
surgical thread was from Ethicon Inc. (Somerville, USA).   
 
2.4.2 Analytical equipment 
2.4.2.1 Gel permeation chromatography (GPC) 
An aqueous GPC system comprised of JASCO pump (PU-4180), two TSK gel 
columns (5000 PWXL followed by 3000 PWXL), a guard column (Progel PWXL) 
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and PL Datastream monitor was from Polymer Laboratories (Church Stretton, 
UK).  A Gilson 133 differential refractometer (Middleton, USA) was used to 
study the elution profile.  The Cirrus GPC software (version 3.2) from Polymer 
Laboratories (Church Stretton, UK) was used for data collection and analysis. 
 
2.4.2.2 Fast protein liquid chromatography (FPLC) 
An ÄKTA Purifier FPLC system connected to a prepacked Superdex 75 
(10/300 or 16/600) GL size exclusion column and a fraction collector (Frac-
950) was from GE Healthcare (Amersham, UK).  The Unicorn software 
(version 5.31) from GE Healthcare (Amersham, UK) was used for UV 
absorbance data collection and analysis.   
 
2.4.2.3 Spectrophotometry: Ultraviolet/visible (UV/vis) 
A Fluostar Optima microplate reader with Optima software (version 3.00 R2) 
from BMG Labtech (Aylesbury, UK) was used for UV/vis absorbance and 
fluorescence intensity measurements.  A Du 800 UV/Vis Spectrophotometer 
and Du 800 software (version 2.0.83) were from Beckman Coulter (High 
Wycombe, UK).  
 
2.4.2.4 Confocal laser scanning microscopy (CLSM) 
A Leica TCS SP5 system equipped with Leica DMI6000B microscope and 
Leica Application Suite Advanced Fluorescence (LAS AF) software (version 
1.6.2) was from Leica Microsystems (Milton Keynes, UK).  CLSM images were 
processed using image analysis software Imaris (version 8.1.2) from Bitplane 
(Concord, USA).  Biofilm structural changes were quantified using COMSTAT 
image analysis software (Heydorn et al., 2000). 
 
2.4.2.5 Miscellaneous equipment 
A Hanna HI2210 pH meter was from Hanna Instruments (Leighton Buzzard, 
UK).  A Scanvac freeze-dryer was from Thistle Scientific (Uddingston, UK) 
connected to a high vacuum pump from Vacuubrand (Brackley, UK).  PD-10 
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desalting columns (Sephadex G-25) were purchased from GE Healthcare 
(Amersham, UK).   
 
2.5 Sterilisation 
To ensure workspace sterility and avoid contamination of the samples, for 
microbiological experiments, working surfaces were sprayed with 1% w/v 
VirkonTM disinfectant solution and the experiments were performed under a 
Bunsen burner flame or in a laminar flow cabinet.  Except for centrifugation 
steps, all cell culture was performed in a Microflow Class II laminar flow 
cabinet.  For tissue culture experiments, materials and equipment placed in 
the safety cabinets and incubators were sprayed with a 70% v/v ethanol 
solution.  Those items not supplied pre-sterilised were sterilised by (a) 
autoclaving (120°C, 15 lb/m2, 15 min) for glassware, certain plastics, 
phosphate buffered saline (PBS) and distilled water (dH2O) or (b) 
microfiltration (0.22 µm) for solutions. 
 
2.6 General methods 
This section gives a detailed description of the general methods used in these 
studies.  Those specific methods used in each chapter are described in full 
there.  Methods used for conjugate synthesis are described in detail in Chapter 
3 (Section 3.3.1) and the methods used for conjugate characterisation are 
described below. 
 
2.6.1 Purification of OligoG-antibiotic conjugates 
FPLC was used to purify the reaction mixture of OligoG-antibiotic conjugate by 
removal of unreacted protein and crosslinking agents.  To begin with, a 
prepacked Superdex 75 (16/600) column was washed with one column volume 
(~120 ml) of filtered (0.22 µm) and degassed dH2O at a flow rate of 0.3 ml/min.  
The column was then equilibrated with two column volumes of filtered and 
degassed PBS (pH 7.4) at a flow rate of 0.5 ml/min and calibrated (1 ml/min 
flow rate) using standardised proteins of various molecular weights: aprotinin 
(6,500 g/mol), cytochrome C (12,400 g/mol), carbonic anhydrase (29,000 
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g/mol), albumin (66,000 g/mol) and alcohol dehydrogenase (150,000 g/mol) (3 
mg/ml in PBS, pH 7.4) by injection of 200 µl of sample into a 100 µl loop.  Blue 
dextran (10 mg/ml in PBS, pH 7.4) was used as a void volume marker.  The 
calibration curve is shown in Figure 2.2.  Then, samples of the conjugation 
reaction mixture (2 ml) were injected into a 2 ml loop using PBS buffer (pH 7.4) 
as eluent at a flow rate of 1 ml/min.  Fractions corresponding to OligoG-
antibiotic conjugates were collected, pooled (~40-45 ml in total) and 
lyophilised.  The resultant products were redissolved in a minimal volume of 
dH2O, then dialysed using the dialysis membrane of 1,000 g/mol molecular 
weight cut-off against 1 L of dH2O to remove PBS salts.  Dialysis was carried 
out for 5 h, changing the water hourly, before the desalted conjugates were 
lyophilised and stored at -20°C.  
 
2.6.2 Characterisation of OligoG-antibiotic conjugates  
After purification, physicochemical characterisation of OligoG-antibiotic 
conjugates was performed by GPC, FPLC, BCA assay and ninhydrin assay.  
 
2.6.2.1 Characterisation by GPC 
The approximate molecular weight and polydispersity of the OligoG-antibiotic 
conjugates was determined according to their hydrodynamic radius using an 
aqueous GPC system.  First, TSK gel columns were equilibrated using filtered 
(0.22 µm) and degassed PBS (pH 7.4) at a flow rate of 1 ml/min.  Then, 
polysaccharide (pullulan) molecular weight standards (molecular weight from 
180 to 788,000 g/mol) were used to produce a calibration curve, as shown in 
Figure 2.3.  Samples were prepared at 3 mg/ml in PBS (pH 7.4) and 
approximately 80 µl was injected into the system (20 µl loop at a flow rate of 1 
ml/min).  
 
2.6.2.2 Characterisation by FPLC 
FPLC (as previously described) was also used to estimate proportion (%) of 
free and bound antibiotic.  Equilibration and calibration of a Superdex 75 
column (10/300 GL) was performed as previously described in Section 2.6.1. 
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(a)  
 
 
 
 
 
 
 
 
 
 
 
 
 
(b)  
 
 
Figure 2.2  Typical FPLC calibration using Superdex 75 (16/600) column.  
(a) Chromatogram of various protein molecular weight standards.  (b) 
Calibration curve for estimation of molecular weight.  V0 (void volume) = 
45 ml, Vb (bed volume) = 120 ml. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.3  Typical GPC calibration using pullulan molecular weight 
standards.  (a) Chromatogram of various pullulan standards.  (b) 
Calibration curve for estimation of molecular weight.  V0 (void volume) = 
13 ml, Vb (bed volume) = 20 ml. 
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A typical calibration curve can be seen in Figure 2.4.  Purified OligoG-antibiotic 
conjugates were dissolved in PBS (pH 7.4) (3 mg/ml) and 200 µl of the sample 
was injected into a 100 µl loop using PBS (pH 7.4) as the mobile phase at a 
flow rate of 0.5 ml/min.  The area under the curve corresponding to free and 
conjugated antibiotic was calculated and used to estimate the percentage of 
free drug in the conjugate.  
 
2.6.2.3 Characterisation by BCA 
The BCA assay was used to determine the total protein content in the OligoG-
antibiotic conjugates (Smith et al., 1985).  Colorimetric detection of proteins is 
achieved when the peptide bonds in the protein reduce cupric ion (Cu2+) to 
cuprous ion (Cu+) by the biuret reaction, which then chelates with two BCA 
molecules.  This complex formation produces a purple coloured solution, 
whereby the intensity of the colour is proportional to the protein concentration 
in the sample.  
The BCA assay was carried out in a 96-well microtitre plate.  Calibration curves 
were produced using colistin sulfate, polymyxin B or bacitracin (20 µl, 0-1 
mg/ml in PBS, n = 3) and used to determine the protein content of the 
corresponding conjugate.  Typical calibration curves are shown in Figure 2.5.  
Sample wells contained OligoG-antibiotic conjugate (20 µl, 1 and 3 mg/ml in 
PBS, n = 8).  BCA reagent (1 ml of BCA: 20 µl Cu (II) sulfate) was added to 
each well (200 µl), then, the microtitre plate was gently agitated and incubated 
in the dark at 37°C for 20 min.  The absorbance values were then read 
spectrophotometrically at 550 nm and used to calculate the protein content in 
the OligoG-antibiotic conjugates (% w/w). 
 
2.6.2.4 Characterisation by ninhydrin assay 
Prior to conjugation to OligoG, it was considered important to determine the 
number of available primary amine groups on the antibiotic molecules using 
the ninhydrin assay.  Ninhydrin is a powerful oxidising agent, which reacts with 
the primary amine groups at pH 4-8, resulting in a Ruhemann's purple product 
(Friedman, 2004).   
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 2.4  Typical FPLC calibration using Superdex  75 column (10/300 
GL) column.  (a) Chromatogram of various protein molecular weight 
standards.  (b) Calibration curve for estimation of molecular weight.  V0 
(void volume) = 7.7 ml, Vb (bed volume) = 24 ml. 
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Figure 2.5  Typical BCA assay calibration curves using colistin sulfate, 
polymyxin B and bacitracin as protein standards.  Data is expressed as 
mean ± SD (n = 3).  
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First, a lithium acetate buffer (4 M) was prepared by dissolving lithium acetate 
dihydrate (40.81 g) in 60 ml of dH2O.  The pH of the buffer was adjusted to 5.2 
with the addition of acetic acid (glacial) and made up to a final volume of 100 
ml with dH2O.  Then, ninhydrin reagent was prepared by dissolving ninhydrin 
(0.2 g) and hydrindantin (0.03 g) in 7.5 ml of DMSO and 2.5 ml of lithium 
acetate buffer.  Ethanolamine calibration standards (0.0165-0.1158 mM in 
PBS, pH 7.4) and of test compounds (86 µl) were diluted with an equal volume 
of ninhydrin reagent and heated in a water bath (100°C) for 15 min.  The 
solutions were cooled to room temperature then 50% v/v ethanol solution (130 
µl) was added to each tube.  Aliquots (200 µl) were transferred into the wells 
of a 96-well microtitre plate and analysed spectrophotometrically at 570 nm.  A 
typical calibration curve is shown in Figure 2.6. 
 
2.6.3 Biological characterisation of OligoG-antibiotic conjugates 
2.6.3.1 Cell maintenance 
HK-2 cells were grown in K-SFM, containing 0.05 mg/ml BPE and 5 ng/ml 
human recombinant EGF in a humidified 37°C/5% CO2 incubator.  Cell culture 
medium was changed on alternate days. 
 
2.6.3.2 Defrosting cells 
Cells were grown from frozen stocks (1 ml of cell suspension/vial).  First, cells 
were rapidly thawed in a water bath (37°C), transferred into a universal tube 
containing 9 ml of K-SFM and centrifuged at 226 g (20°C) for 5 min.  The 
supernatant was then removed by aspiration and the cell pellet was 
resuspended in K-SFM (5 ml).  The cell suspension was then transferred into 
a 25 cm2 flask and placed in an incubator.  After 24 h, the culture medium was 
replaced with fresh K-SFM and cells were grown until ~80% of confluency was 
reached. 
 
2.6.3.3 Cell passaging 
Once ~80% of confluency was reached, the HK-2 cells were passaged at a 
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Figure 2.6  Typical ninhydrin assay calibration curve using ethanolamine 
standards.  Data is expressed as mean ± SD (n = 3).  
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Viable cell count (cells/ml) = Mean cell count x dilution factor x 104 
 
ratio of 1 to 4 and transferred to a 75 cm2 flask.  The old medium was aspirated 
and the cells were washed with sterile PBS (10 ml) to remove dead cells before 
addition of trypsin-EDTA solution (1 ml).  Flasks were then incubated at 37°C 
for approximately 3 min or until the cells were detached from the surface.  Next, 
9 ml of K-SFM was added to the flask and the cell suspension was transferred 
into a universal tube and centrifuged at 226 g (20°C) for 5 min.  The 
supernatant was removed and the cells were resuspended in fresh K-SFM (10 
ml).  This suspension was used to prepare new flasks after appropriate dilution.  
 
2.6.3.4 Cell counting 
Cells were washed with PBS, trypsinised and resuspended as described 
previously.  To produce a homogenous single cell suspension, cells were first 
passed through a needle (23G).  Then, an aliquot of cell suspension (100 µl) 
was mixed with an equal volume of trypan blue (0.2% in PBS) and transferred 
into a haemocytometer.  Cells from ten 0.1 mm3 squares (five taken from the 
top chamber, 5 taken from the bottom chamber) were counted.  Viable cells 
were counted within a square and on the left and top boundary grid lines.  Non-
viable cells (stained dark blue) were not included in the cell count.  Cell number 
was calculated using the following formula: 
 
 
where mean was the arithmetic mean of the 10 squares, the dilution factor was 
2 (to account for dilution with trypan blue) and 104 accounted for conversion 
from 0.1 mm3 to 1 ml).  The cell suspension was subsequently diluted with K-
SFM to achieve a cell density of 1 x 105 cells/ml. 
 
2.6.3.5 Characterisation by MTT 
An MTT assay was used to measure viability and proliferation of cells in the 
presence of OligoG-antibiotic conjugates.  The yellow tetrazolium MTT reagent 
is reduced to purple insoluble formazan in metabolically active cells by 
mitochondrial dehydrogenase enzymes, resulting in the production of insoluble 
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formazan crystals which correlates with the number of viable cells (Mosmann, 
1983).  
HK-2 cells were seeded (100 µl/well) in a sterile 96-well microtitre plate at 1 x 
105 cells/ml and allowed to adhere for 24 h at 37°C.  Subsequently, the old 
medium was removed and replaced with fresh medium containing test 
compounds dissolved in K-SFM (0.22 µm filter-sterilised) and serially diluted 
across the plate.  The plate was then incubated for 67 h at 37°C.  Next, MTT 
solution (20 µl, 5 mg/ml in PBS and 0.22 µm filter-sterilised) was added to each 
well and incubated for a further 5 h at 37°C.  Finally, medium from each well 
was carefully removed and the formazan crystals were solubilised in DMSO 
(100 µl) for 30 min, before measuring absorbance at 550 nm using a plate 
reader.  The results were expressed as a percentage of the cell viability 
compared to untreated control cells (± SEM, n = 18). 
 
2.6.3.6 Characterisation by TNFα ELISA 
Release of the cytokine, TNFα, by HK-2 cells after exposure to free- and 
OligoG-conjugated antibiotic (72 h) was assessed using an ELISA kit, 
according to the manufacturer’s instructions (Section 3.3.4).  Plates were 
analysed spectrophotometrically at 450 nm.  A typical calibration curve is 
shown in Figure 2.7.  
 
2.6.4 Microbiological characterisation of OligoG-antibiotic conjugates 
2.6.4.1 Preparation of microbiological growth media and agar 
Agars (BA and TSA) and broths (MH and TS) were prepared according to the 
manufacturer’s instructions.  BA was supplemented with 5% v/v defibrinated 
horse blood.  The prepared agar plates were then stored at 4°C until required. 
 
2.6.4.2 Bacterial cultures maintenance  
Bacterial isolates were grown from -80°C frozen stocks (on Microbank beads).  
One bead of each bacterial strain was used to streak the isolate on BA plates. 
The plates were incubated overnight at 37°C then stored at 4°C until required. 
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Figure 2.7  Typical ELISA assay calibration curve using TNFα standards.  
Data is expressed as mean ± SD (n = 6).  
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Bacterial cultures were re-plated every 4 weeks. 
 
2.6.4.3 Preparation of overnight bacterial culture  
A single bacterial colony was picked with a sterile loop, inoculated in TS broth 
(10 ml) and incubated overnight (37°C) in shaking incubator (120 rpm). 
 
2.6.4.4 Minimum inhibitory concentration (MIC) assay 
The susceptibility of a panel of Gram-negative bacteria to OligoG-antibiotic 
conjugates was tested using serial microdilutions in MH broth (100 μl/well) 
across a sterile 96-well microtitre plate (EUCAST, 2003).  Overnight bacterial 
cultures were standardised in sterile PBS to achieve an optical density (OD625) 
between 0.08 and 0.10 (0.5 McFarland standard) and then further diluted in 
MH broth at a ratio of 1 to 10 and 5 μl was added to all wells containing test 
compound.  Sterility (MH broth), growth (no antibiotic) and quality control 
strains were used in every study.  Plates were wrapped in parafilm and 
incubated at 37°C for 20 h.  The sterility control was accepted if no visible 
bacterial growth was noted, the growth control was considered acceptable if 
visible cloudiness and turbidity was observed.  The MIC value was reported as 
the lowest concentration where no visible bacterial growth was observed.  The 
results were expressed as median values (n = 3).  MIC values were accepted 
if those of the quality control strains were within one serial dilution from 
published values (EUCAST, 2003). A significant difference between two MIC 
values was accepted if they differed by at least a two-fold dilution.  A typical 
plate layout for MIC determination is shown in Figure 2.8. 
 
2.6.4.5 Colistin quantification  
The concentration of colistin in MH broth was measured using an ELISA kit. 
To extract colistin, 50 µl of the sample was mixed with 240 µl of 20% v/v 
acetonitrile solution in colistin extraction buffer, followed by 16 µl of clean up 
buffer I (vortexed for 10 s) and 16 µl of clean up buffer II (vortexed for 3 min 
and then centrifuged for 10 min, 4000 g, 21°C).  Aliquots of extracted solution 
(75 µl) were assayed using the ELISA kit according to the manufacturer’s  
  
 
Figure 2.8  Typical plate layout for susceptibility testing of OligoG-antibiotic conjugates using the MIC assay. 
 
5
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instructions.  Plates were analysed spectrophotometrically at 450 nm.  A 
calibration curve was constructed by plotting the mean relative absorbance of 
the calibration standards (%) against the corresponding colistin concentration 
(ng/ml).  Data was expressed as mean ± SD (n = 2).  A typical calibration curve 
is shown in Figure 2.9.  
 
2.7 Statistical analysis  
Data were presented as mean ± standard deviation (SD, when n ≤ 3) or 
standard error of the mean (SEM, when n > 3).  GraphPad Prism (version 6.01, 
San Diego, USA) was used for statistical analysis.  Statistical significance was 
indicated by *, where *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.  
The coefficient of determination (R2) was used to analyse the fit of the 
regression models.  To evaluate the significance between the two independent 
groups, Student’s t-test was used.  Analysis of variance (ANOVA) was used to 
evaluate multiple group comparisons (n > 2) followed by Dunnett’s (compares 
every sample mean to the control mean) or Tukey’s (compares every sample 
mean to every other mean) post hoc tests to account for multiple comparisons. 
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Figure 2.9  Typical ELISA assay calibration curve using colistin 
standards.  Data is expressed as mean ± SD (n = 2).  
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Chapter 3 
 
Synthesis and Characterisation of OligoG-
Polymyxin Conjugates 
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3.1 Introduction 
To develop the polymer-antibiotic conjugate as a successful candidate to treat 
multidrug-resistant (MDR) bacterial infections, it was important to select not 
only the most appropriate polymeric carrier, but also the best bioactive 
compound and conjugation chemistry.  It was essential for the covalent linker 
between the polymeric backbone and the drug to be inert and stable in the 
bloodstream, without inhibiting antibiotic activity.  This can be achieved by 
enzymatic biodegradation of the polymer or by selecting a linker that is 
enzymatically cleavable or sensitive to changes in pH, to facilitate liberation of 
the drug at the target site (Duncan, 2003).  Conjugation of low molecular weight 
antibiotics to a water-soluble polymer can significantly improve efficacy and 
reduce immunogenicity and toxicity of the drug.  The increased molecular 
weight of the conjugated drug can also reduce the renal clearance and 
enhance antibiotic bioavailability leading in improved biodistribution through 
the EPR effect (Vicent et al., 2008).  Factors such as “batch-to-batch” 
reproducibility, toxicity and stability of the polymer-drug conjugate were also 
considered. 
 
3.1.1 Choice of polymer 
Polysaccharides, such as hyaluronan, dextran and polysialic acid, have been 
widely used in drug delivery and other biomedical applications.  They are 
comprised of long chains of saccharide units (typically > 10 monomers) bound 
together by glycosidic linkages to form polymeric carbohydrate molecules, 
which, on hydrolysis, yield the constituent mono- or oligosaccharides.  
Polysaccharides have the additional benefit of being able to adhere to mucosal 
surfaces via non-covalent interactions known as ‘mucoadhesion’ (Basu et al., 
2015, Lee et al., 2000).  This further supports the potential application of 
polysaccharides in drug delivery for chronic respiratory diseases.  This chapter 
aimed to investigate whether alginates can also be successfully exploited in 
drug delivery as they possess many favourable features as discussed in 
Chapter 1.  Numerous alginate conjugates have been described in the 
literature; these are summarised in Table 3.1. 
 
 
 
Alginate conjugate Indication Linker Reference 
 
Alginate-graphene  
oxide 
 
Novel non-toxic carrier for targeted/controlled drug-release.  Alginate-
graphene oxide polymer was used to encapsulate anticancer drug 
doxorubicin, showing high drug loading capacity and fast drug 
release in acidic conditions with high cytotoxicity towards HeLa cells. 
 
 
Amide 
 
(Fan et al., 
2016) 
 
Alginate-curcumin 
 
 
As a potential treatment for various inflammatory diseases including 
cancer and Alzheimer’s disease, curcumin conjugation to alginate 
(alginate mean molecular weight; 4 × 105 g/mol) increased water 
solubility, enhanced stability and improved bioavailability of the drug. 
 
 
Ester 
 
(Dey and 
Sreenivasan, 
2014) 
 
 
Alginate-rhodamine  
 
 
Rhodamine attachment to alginate backbone facilitated the specific 
recognition and scavenging of biologically active and toxic metal ions 
such as Cr3+ or Hg2+. 
 
 
Amide 
 
(Saha et al., 
2012) 
 
 
Alginate-cisplatin 
 
Low water solubility and high systemic toxicity of cisplatin was 
overcome by conjugation to alginate.  Further incorporation into 
epidermal growth factor modified liposomes significantly improved 
cisplatin targeting and efficacy at the site of ovarian tumours in mice. 
 
 
Pt-O 
 
(Wang et al., 
2014) 
 
Table 3.1  Examples of alginate conjugates in clinical development. 
 Pt-O, platinum-oxygen bond. 
5
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OligoG is a low molecular weight alginate oligosaccharide, which is extracted 
as a sodium salt from the stem of brown seaweed (Laminaria hyperbora).  It is 
composed of α-L-guluronic acid (> 85%) and β-D-mannuronic acid (< 15%) 
residues, which contain suitable hydroxyl and carboxyl functional groups for 
drug attachment (Khan et al., 2012).  
To date, it has been shown that OligoG inhibits bacterial growth and 
potentiates the efficacy of commonly used antibiotics against MDR Gram-
negative pathogens (Khan et al., 2012).  Inhibition of biofilm formation and 
physical disruption, or “clumping”, of established Gram-negative biofilms in the 
presence of OligoG has been reported (Khan et al., 2012).  Previous studies 
have demonstrated that OligoG interacts with and modifies the cell surface of 
P. aeruginosa and effectively inhibits the motility and swarming of important 
CF pathogens such as Burkholderia spp., causing not only bacterial 
aggregation and reduction in virulence, but also weakening of the mechanical 
robustness of treated biofilms (Powell et al., 2013, Powell et al., 2014).  In 
addition, OligoG interferes with, and alters, mucin hydrogel networks in 
sputum, thus allowing it to be used as a potential treatment in pathological 
respiratory diseases (Pritchard et al., 2016).  Importantly, preliminary 
resistance studies indicated that daily sub-culturing of P. aeruginosa PAO1 
with escalating concentrations of OligoG had no effect on antibiotic 
susceptibility (tested by MIC assay), indicating that resistance did not develop 
over a prolonged period of time (Khan et al., 2012).  
Preclinical trials in rats have demonstrated that 82.6% of orally administered 
OligoG was eliminated by the gastrointestinal tract within the first 24 h 
(Pritchard et al., 2016).  Additional studies revealed that after 24 h of 
intravenous administration of 3H-radio-labelled OligoG, 80.3% of the dose had 
been excreted via urine (Pritchard et al., 2016).  Results from Phase I 
(Identifier: NCT00970346) and Phase IIa (Identifier: NCT01465529) clinical 
trials revealed that OligoG is safe and well-tolerated in healthy humans 
(demonstrated by inhalation studies using up to 540 mg/day over 3 days) and 
cystic fibrosis (CF) patients with no abnormal clinical signs or significant 
changes in respiratory, biochemical and hematological properties (Pritchard et 
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al., 2016).  OligoG is currently undergoing Phase IIb clinical studies in patients 
with CF as an inhalation therapy.  
 
3.1.2 Selection of bioactive compound  
Polymyxins, such as polymyxin B and colistin (also known as polymyxin E), 
are a class of polypeptide antibiotics that have poor oral absorption and, like 
other small molecule drugs, a lack of disease specific targeting.  In addition, 
polymyxins have limited clinical use due to relatively high toxicity, thereby 
making polymyxins very promising candidates for polymer conjugation.  It was 
hypothesised that polymer conjugation could significantly alter the 
biodistribution, reduce the toxicity and increase the efficacy of these antibiotics 
at the infected site.  
Polymyxins are composed of a hydrophilic heptapeptide ring which is attached 
to a hydrophobic acyl tail through a tripeptide link, resulting in an amphiphilic 
structure (Azzopardi et al., 2013a).  Under physiological conditions (pKa = 
~10), five amino groups per polymyxin molecule are positively charged and 
accessible for conjugation (Kwa et al., 2008).  The only structural difference 
between polymyxin B and colistin molecules is a change in a single amino acid.  
Colistin contains a D-leucine residue at position 6, which is replaced by D-
phenylalanine in polymyxin B, as shown in Figures 3.1 and 3.2 (Kwa et al., 
2008).  Ordinarily, polymyxins are not homogenous compounds, but rather 
mixtures of closely related molecules.  For example, colistin is composed of at 
least 30 different constituents.  Colistin A and B (also known as polymyxin E1 
and polymyxin E2, respectively) are the main components, although only 
polymyxin E1 is considered an active therapeutic ingredient (Kadar et al., 2013, 
Kline et al., 2001).  Similarly, polymyxin B1 and polymyxin B2 are the main 
components in polymyxin B, accounting for more than 80% of the drug (Velkov 
et al., 2013).  The major difference between the constituents is in the fatty acyl 
tail, which is composed of 6-methyloctanoic acid in polymyxin B1 and E1 or 6-
methylheptanoic acid in polymyxin B2 and E2 (Kadar et al., 2013).  
After administration to patients, more than 50% of the polymyxin dose 
becomes bound to human plasma proteins (Li et al., 2003a).  Free amino acid  
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(a) 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
Figure 3.1  (a) Graphic and (b) chemical structure of colistin.  Amino acid 
components: Dab, diaminobutyric acid; Thr, threonine; Leu, leucine; Phe, 
phenylalanine.  
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(a) 
 
 
(b) 
 
 
 
 
 
 
 
 
 
Figure 3.2  (a) Graphic and (b) chemical structure of polymyxin B.  Amino 
acid components: Dab, diaminobutyric acid; Thr, threonine; Leu, leucine; 
Phe, phenylalanine.  
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groups of polymyxins strongly interact with negatively charged membrane 
lipids of various tissues, including heart, brain, liver, lung, kidney or muscles 
cells (Kadar et al., 2013).  Therefore, the release of tissue-bound polymyxin is 
relatively slow and the drug can persist in the body for over five days (Martin 
et al., 1999).  Following IV administration of colistin to rats, only small amounts 
of unchanged drug was recovered in the urine (Li et al., 2003b).  This suggests 
that extensive reabsorption of polymyxins occurs, from renal tubular cells into 
the blood.  Likewise, after IV injection of polymyxin B in critically ill patients, up 
to 95% of the drug was reabsorbed by renal tubular cells (Sandri et al., 2013).  
Given that less than 1% of unchanged polymyxin B was recovered in urine, it 
is believed that polymyxin B is excreted by a non-renal clearance pathway 
(Abdelraouf et al., 2012).   
The five positively charged amino groups of colistin or polymyxin B have been 
implicated in causing side-effects, such as neurotoxicity and nephrotoxicity.  At 
the cellular level, accumulated polymyxins bind to acidic phospholipids and the 
glycoprotein, megalin, located on the apical membrane of renal proximal tubule 
cells to increase membrane permeability (Azzopardi et al., 2012).  This causes 
an increased influx of water, anions and cations, which ultimately leads to cell 
swelling and lysis (Kadar et al., 2013).  Acute tubular necrosis has been also 
reported due to increased levels of creatinine and urea, which are also 
associated with polymyxin-induced toxicity (Azad et al., 2013).  Respiratory 
paralysis induced by neuromuscular blockade has also been observed in 
patients treated with polymyxins, which was attributed to them binding to the 
lipids of the nerve fibre membrane, resulting in impaired acetylcholine release 
from presynaptic neurons into the synaptic gap (McQuillen et al., 1968, Myint 
et al., 2016).  Insufficient release of acetylcholine prevents sodium ion influx 
into postsynaptic muscle fibres, leading to inhibition of muscle contraction.  
Most of the cases described in the literature suggested an increased risk of 
neuromuscular blockade in patients with renal dysfunction (Lindesmith et al., 
1968, Myint et al., 2016). 
As a consequence of these toxicity issues, sulfomethylation of colistin free 
amino groups has been used to produce a less toxic pro-drug, colistimethate 
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sodium (CMS; Colomycin®), which hydrolyses in the body into active colistin 
(Beveridge and Martin, 1967).  Although sulfomethylation decreases the 
efficacy of the drug (as well as its membrane-binding capacity), it is the only 
form of colistin currently used clinically for systemic administration.  Unlike 
colistin, when CMS is administered IV to critically ill patients, ~60% is 
eliminated unchanged in the urine by glomerular filtration (Michalopoulos and 
Falagas, 2011).  Prior to administration, lyophilised CMS is reconstituted in 
sterile water and hydrolysis occurs rapidly in human plasma at 37°C.  Due to 
the unpredictable rate and extent of hydrolysis, reconstitution should be 
performed no more than 24 h prior to administration, since premature 
hydrolysis and formation of active drug may occur if the solution is made up in 
advance (Le et al., 2010).  Indeed, in 2007, the FDA issued an alert after a 
patient died following inhalation of a pre-mixed Colomycin solution that was 
believed to have hydrolysed in vitro (FDA, 2007). 
 
3.1.3 Selection of appropriate linker 
Selection of an appropriate linker for the attachment of the polymer to its 
payload is fundamental to being able to reproducibly generate a stable 
conjugate in high yields.  The ability to achieve triggered drug release and 
reinstatement of its activity at the target site is also advantageous.  Many linker 
groups have been used for polymer-drug conjugation including carbonate, 
urethane, anhydride, ester or amide bonds (Elvira et al., 2005).  To improve 
the therapeutic index and decrease the systemic toxicity of antibiotics, amide, 
ester and urethane linkers have been used to attach the peptide and polyene 
antibiotics to PEG (Cal et al., 2017).  PEGylated amphotericin B, linked via a 
stable amide bond, not only retained antifungal activity in a range of clinical 
isolates, but also exhibited significantly higher water solubility and markedly 
reduced toxicity (Halperin et al., 2016).  Due to the lability of the ester bond, 
PEGylated colistin prodrug reverted back into its active form within the first 24 
h in vitro and demonstrated a similar antimicrobial activity to CMS against 
several MDR bacterial pathogens and displayed no nephrotoxicity, as 
confirmed by histological analysis of mice kidneys (Zhu et al., 2017). 
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Carbodiimide compounds are so-called ‘zero-length’ cross-linking 
reagents that are used to facilitate direct conjugation of the bioactive 
molecule without becoming part of the final linker structure (Xu et al., 2003).  
Indeed, the majority of previously reported alginate conjugates were 
synthesised using EDC/NHS crosslinkers to form an amide bond, while 
DCC/DMAP coupling agents have been used for ester bond formation (Basu 
et al., 2015, Yang et al., 2011).  In this study, amide and ester linkers were 
chosen for antibiotic conjugation to OligoG.   
Amide linkage is a very common means of conjugating a polysaccharide to a 
protein drug and was previously used in dextrin-colistin conjugates (Ferguson 
et al., 2014).  These conjugates are very stable and rely on degradation of the 
polymer’s backbone by the enzyme alginate lyase.  This leaves both sugar 
residues and the linker group still attached to the antibiotic, which may impact 
on its antimicrobial activity.  Endolytic alginate lyase cleaves the glycosidic 
bonds using a β-elimination reaction, leading to depolymerisation of alginate 
into oligomers (Kim et al., 2011).  Subsequently, exolytic oligoalginate lyase 
further degrades oligomers into unsaturated monosaccharides.  To date, 
however, no enzymatic pathways capable of degrading alginates have been 
discovered in humans.  However, some bacterial pathogens such as P. 
aeruginosa or A. vinelandii are able to synthesise, degrade and metabolise 
alginates.  To form a stable amide bond, water-soluble EDC activates the 
carboxyl groups of OligoG polymer backbone forming an O-acylisourea 
intermediate, which then reacts with the primary amino groups of the 
polymyxin.  In aqueous solutions, however, O-acylisourea is unstable and 
prone to hydrolysis, which results in regeneration of carboxyl groups and the 
liberation of unsubstituted urea (Hermanson, 2013).  Therefore, to increase 
the efficacy of the reaction, sulfo-NHS is commonly combined with EDC to 
convert the O-acylisourea intermediate into a stable amine-reactive sulfo-NHS 
ester, which then rapidly reacts with amino groups on the target molecule.  The 
reaction scheme can be seen in Figure 3.3. 
In contrast to the amide linker, incorporation of an ester bond between the 
alginate oligomer and antibiotic would allow separation of the parent molecules 
 
 
 
 
OligoG
EDC
+
O-Acylisourea
OligoG N-unsubstituted urea
+
+
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sulfo-NHS ester 
Colistin sulfate
OligoG-amide-colistin
Hydrolysis
Figure 3.3  Schematic diagram showing synthesis of the OligoG-amide-polymyxin conjugate. 
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by esterase enzymes and hydrolysis at sites of bacterial infection.  Ongoing 
inflammation, overproduction of reactive oxygen and nitrogen species and an 
acidic pH would accelerate ester bond degradation (Liang and Liu, 2016, Pu 
et al., 2014).  Additionally, hydrolytic enzymes such as esterases, catalyse the 
cleavage of the ester bond, forming alcohol and acid metabolites (Montella et 
al., 2012).  The advantage of this approach is that conjugated antibiotics may 
benefit from passive targeting to sites of infection by the EPR effect (Section 
1.6.2), and that full antibiotic activity of each component could be reinstated 
after separation.  Hence, the potential “bifunctionality” of the conjugate (i.e.  the 
antibiotic potentiation effect of OligoG alongside polymyxin efficacy) could also 
be exploited by this co-localisation of the antibiotic and intact alginate oligomer 
at the site of infection.  Ester bond formation using DCC and DMAP was first 
reported by Neises and Steglich (Neises and Steglich, 1978).  Here, DCC 
reacts with the carboxyl groups of OligoG to form an O-acylisourea 
intermediate, which then reacts with the hydroxyl groups of the polymyxins.  
However, since hydroxyl groups are much weaker nucleophiles than amines, 
potential side reactions can occur causing spontaneous rearrangement of the 
O-acylisourea intermediate into undesirable N-acylurea, which is unable to 
further react with hydroxyl groups (Tsakos et al., 2015).  Therefore, to 
accelerate the DCC-mediated coupling and suppress the side product 
formation, DMAP is commonly used as a catalyst.  The DMAP rapidly interacts 
with O-acylisourea forming acyl pyridinium species, which further react with 
hydroxyl groups of the target molecule to form the ester bond (Tsakos et al., 
2015).  This reaction scheme can be seen in Figure 3.4.  
The main principle of conjugate synthesis and drug release can be seen in 
Figure 3.5. 
 
3.2 Experimental aims and objectives 
The specific aims of this study were: 
• To synthesise a library of polymer-polymyxin conjugates using the 
antimicrobial alginate OligoG.  
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DDC
+
O-Acylisourea
+
Dicyclohexylurea by-productOligoG-ester-colistinColistin sulfate
DMAP
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Figure 3.4  Schematic diagram showing synthesis of the OligoG-ester-polymyxin conjugate. 
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Figure 3.5  Schematic diagram showing alginate antibiotic conjugation and 
drug release from the polymer of (a) the OligoG-AMIDE-colistin conjugate 
and (b) the OligoG-ESTER-colistin conjugate. 
 
(a) 
(b) 
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• To characterise polymer-drug conjugates in respect of their total protein 
content (drug loading), molecular weight and molecular weight 
distribution (polydispersity), purity (free protein content of the conjugate) 
and the number of amino groups in the polymyxins used for OligoG 
binding.  
• To assess the in vitro cytotoxicity of the OligoG-antibiotic conjugates in 
human kidney (HK-2) cells. 
 
3.3 Methods 
Many general methods were used for physicochemical characterisation of 
OligoG-polymyxin conjugates including the BCA assay (Section 2.6.2.3), 
FPLC (Section 2.6.2.2), GPC (Section 2.6.2.1) and the ninhydrin assay 
(Section 2.6.2.4).  Biological characterisation of OligoG-antibiotic conjugates 
was performed using a TNFα ELISA (Section 2.6.3.6) and the MTT assay 
(Section 2.6.3.5) as described in Chapter 2. 
 
3.3.1 Synthesis of OligoG-antibiotic conjugates 
OligoG-polymyxin conjugates were synthesised using the zero-length cross-
linking agents, EDC (with sulfo-NHS) or DCC (with DMAP), to create stable 
amide or ester bond formation, respectively.  The reactions are described in 
detail below.  In addition, OligoG-amide-bacitracin conjugate has been 
synthesised and characterised using the methods described below but due to 
relatively low drug loading, the results are provided as supplementary 
information (Appendices 5.1-5.5).  
a) Synthesis of OligoG-polymyxin conjugates using an amide (A) linker  
OligoG (1000 mg, 0.3 mmol), EDC (96.8 mg, 0.5 mmol) and sulfo-NHS (109.6 
mg, 0.5 mmol) were dissolved in dH2O (10 ml) in a round-bottomed flask and 
stirred for 15 min at 21°C.  To this mixture, colistin sulfate (146.7 mg, 0.1 mmol) 
or polymyxin B (144.4 mg, 0.1 mmol) was added followed by dropwise addition 
of NaOH (0.5 M) until pH 8 was reached.  The reaction mixture was stirred for 
2 h at 21°C, then stored at -20°C prior to purification by FPLC.  
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b) Synthesis of OligoG-polymyxin conjugates using an ester (E) linker  
OligoG (1000 mg, 0.3 mmol), DCC (64.5 mg, 0.3 mmol), DMAP (6.4 mg, 0.05 
mmol) and colistin sulfate (146.7 mg, 0.1 mmol) or polymyxin B (144.4 mg, 0.1 
mmol) were dissolved under stirring in anhydrous DMSO (10 ml) in a round-
bottomed flask.  The reaction mixture was left to stir overnight at 21°C.  The 
reaction was stopped by pouring the mixture into excess chloroform (~50 ml).  
Formed precipitates were collected by filtration and dissolved in dH2O (10 ml), 
then stored at -20°C prior to purification by FPLC.  
 
3.3.2 Purification and characterisation of OligoG-polymyxin conjugates 
FPLC was used to purify OligoG-polymyxin conjugates by removing unreacted 
linking agents and drug, as already described in Chapter 2 (Section 2.6.1).  
Collected fractions were desalted, lyophilised and stored at -20°C prior use.  
The final product was characterised by BCA assay to determine total protein 
content (Section 2.6.2.3); by GPC to define molecular weight and molecular 
weight distribution (Section 2.6.2.1); by FPLC to quantify the percentage of 
unconjugated drug (Section 2.6.2.2) and by ninhydrin assay to calculate the 
number of primary amines used for OligoG conjugation (Section 2.6.2.4).  
 
3.3.3 Cytotoxicity of OligoG-antibiotic conjugates  
An MTT assay (Section 2.6.3.5) was used to measure HK-2 cell viability and 
proliferation after 72 h incubation with OligoG, OligoG-polymyxin conjugates 
or polymyxin alone.  Cytotoxicity of OligoG-E-colistin and OligoG-E-polymyxin 
B conjugates had previously been assessed by E. L. Ferguson (for inclusion 
in a patent application).  The concentration range of 0.004-1 mg/ml (polymyxin 
equivalent) was used to calculate the IC50 (half maximal inhibitory 
concentration) values of the compounds (n = 18).  
 
3.3.4 TNFα ELISA assay 
The release of the proinflammatory cytokine, TNFα, from HK-2 cells was 
assessed using an ELISA kit.  Cells were treated with a range of 
concentrations of OligoG-polymyxin conjugates or polymyxin alone as 
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described in Chapter 2 (Section 2.6.3.5).  After 72 h incubation, the 96-well 
microtitre plates were centrifuged (226 g, 3 min), the supernatant was 
transferred into a clean 96-well plate, then diluted in equal parts with reagent 
diluent and analysed with the TNFα ELISA according to the manufacturer’s 
instructions.  In parallel, 100 μl of K-SFM was added to centrifuged cells and 
MTT assays were performed as described previously (Section 2.6.3.5).  A 
standard curve was constructed by plotting the mean absorbance obtained 
from each standard solution versus the corresponding TNFα concentration 
(pg/ml).  This curve was used to calculate the TNFα concentrations of the test 
samples, which were then multiplied by the dilution factor (x 2) and divided by 
cell viability for each drug concentration (from the MTT assay results).  Data 
was expressed as mean ± SEM (n = 6). 
 
3.4 Results 
3.4.1 Synthesis and purification of OligoG-polymyxin conjugates 
FPLC confirmed successful OligoG-polymyxin conjugate synthesis, with 
conjugates typically eluting between 40-95 ml.  Polymyxins, which exhibited 
strong absorbance at 210 nm, eluted at ~100 ml.  Since OligoG had no 
absorbance signal, unconjugated OligoG was not visible by FPLC.  Fractions 
containing conjugates were collected, pooled and lyophilised.  A typical elution 
profile of the conjugate reaction mixture can be seen in Figure 3.6a (OligoG-
A-polymyxin conjugate) and Figure 3.6b (OligoG-E-polymyxin conjugate).  
 
3.4.2 Characterisation of OligoG-polymyxin conjugates 
GPC analysis revealed a shorter retention time, indicative of an increase in 
molecular weight and polydispersity of the OligoG-drug conjugates, compared 
with the free drugs (Figure 3.7).  Typically, OligoG-polymyxin conjugates had 
an apparent molecular weight 2-3 times higher than that of the free drug, 
resulting in a range of 22,500-27,000 g/mol for amide-linked conjugates and 
slightly lower (15,500-20,000 g/mol) for ester-linked conjugates.  The 
polydispersity index indicated a broad molecular weight distribution, which 
varied from 2.2-2.7 for amide-linked and 2.1-3.1 for ester-linked conjugates.   
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6  Typical elution profile of conjugate reaction mixture before 
purification using a Superdex 75 (16/600) size exclusion column.  (a) 
Chromatogram of the OligoG-A-polymyxin conjugate, (b) chromatogram of 
the OligoG-E-polymyxin conjugate.  V0 (void volume) = 45 ml, Vb (bed 
volume) = 120 ml.  
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Figure 3.7  Typical elution profile of OligoG-polymyxin conjugates using 
GPC analysis.  V0 (void volume) = 13 ml, Vb (bed volume) = 20 ml.  
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A summary of the relative molecular weight average and polydispersity of each 
OligoG-polymyxin batch is presented in Table 3.2. 
The presence of the high molecular weight conjugate with an elution peak at 
~8-14 ml was verified by FPLC analysis.  Free antibiotic eluted at ~17 ml, while 
a peak corresponding to unreacted cross-linking agents was observed at ~18-
19 ml.  The typical elution profile of OligoG-polymyxin conjugate and its 
unreacted components can be seen in Figure 3.8a.  The chromatograms of 
purified conjugates are shown in Figure 3.8b, where the first peak shows the 
OligoG-antibiotic conjugate with an almost undetectable amount of free drug 
(circled peak).  Analysis of the area under the curves indicated that the free 
drug content in the conjugates was always < 6% (Table 3.2).  The drug loading, 
calculated by BCA assay, of OligoG-A-polymyxin conjugates varied from 6.1-
12.5% (w/w), while OligoG-E-polymyxin conjugates contained 7-12.9 % (w/w) 
of the drug (Table 3.2).  After conjugation, the ninhydrin assay revealed that 
OligoG-A-colistin conjugates used ~3-4 primary amino groups on the colistin 
molecule, while OligoG-A-polymyxin B conjugates used ~2 of these groups, as 
indicated in Table 3.2. 
 
3.4.3 Biological characterisation of OligoG-antibiotic conjugates 
The concentration-dependent cytotoxicity of free antibiotics, OligoG and 
OligoG-polymyxin conjugates in HK-2 cells is shown in Figure 3.9.  Table 3.3 
summarises the IC50 values derived from these plots.  As expected, no 
cytotoxicity was observed when cells were treated with OligoG alone up to 10 
mg/ml.  While colistin and polymyxin B were cytotoxic to HK-2 cells in a dose-
dependent manner (IC50 = 0.026 ± 0.002 mg/ml and 0.011 ± 0.001 mg/ml, 
respectively), conjugation of OligoG markedly reduced their toxicity.  
Conjugates containing an amide linker increased colistin’s IC50 by 9.3-fold (IC50 
= 0.242 ± 0.066 mg/ml) whereas ester-linked conjugates reduced toxicity by 
2.2-fold (IC50 = 0.057 ± 0.014 mg/ml).  Similarly, OligoG conjugation 
significantly reduced the toxicity of polymyxin B by 27.2-fold for OligoG-A-
polymyxin B (IC50 = 0.299 ± 0.033 mg/ml) and 2.9-fold for OligoG-E-polymyxin 
B (IC50 = 0.032 ± 0.003 mg/ml) conjugates.  There was a significant difference  
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Figure 3.8  Characterisation of OligoG-polymyxin conjugates using FPLC.  
(a) Typical analysis profile of OligoG-A-colistin conjugate.  (b) Elution 
profiles of purified OligoG-drug conjugates.  Elution peak of the free drug 
has been circled.  V0 (void volume) = 7.7 ml, Vb (bed volume) = 24 ml.  
 
 
 
 
 
 
 
 
Tested 
compound 
Mw (g/mol)  
(PDI) by  
GPC 
Mw (g/mol) 
(PDI) by  
SEC-MALLS 
Protein 
content 
(% w/w) 
Molar ratio  
(per colistin) 
Conjugated 
NH2 per 
molecule 
Free protein 
(%) 
OligoG-A-colistin 25,500 (2.6) 12,300 (1.4) 8.7 4.6 2.8 5.7 
OligoG-A-colistin 22,500 (2.3) 9,100 (1.3) 8.8 4.6 2.7 1.5 
OligoG-A-colistin 24,500 (2.3) - 9.1 4.4 3.6 2.5 
OligoG-A-colistin 27,000 (2.5) - 12.5 3.1 3.3 2.4 
OligoG-A-colistin 24,500 (2.2) - 8.1 5.0 4.6 4.0 
OligoG-E-colistin 14,500 (2.3) 5,900 (1.2) 12.9 3.0 - 2.0 
OligoG-E-colistin 16,500 (2.2) - 11.5 3.4 - 3.5 
OligoG-E-colistin 20,000 (3.1) - 8.3 4.9 - 2.7 
OligoG-A-polymyxin B 23,000 (2.7) 12,800 (1.5) 8.0 5.1 1.9 1.6 
OligoG-A-polymyxin B 23,500 (2.2) 9,100 (1.3) 6.1 6.8 2.0 1.6 
OligoG-E-polymyxin B 15,500 (2.1) 6,200 (1.2) 7.0 5.9 - 2.7 
 
Table 3.2  Characterisation summary of OligoG-polymyxin conjugates. 
Molecular weight was estimated by GPC relative to pullulan standards or by size exclusion chromatography with multi-angle 
laser light scattering (SEC-MALLS).  Mw, molecular weight average of the weight; PDI, polydispersity index. 
7
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9  In vitro cytotoxicity of OligoG-polymyxin conjugates in HK-2 
cells.  Cell viability after incubation with a range of (a) colistin and (b) 
polymyxin B concentrations.  Data is presented as % of normal growth 
compared with the untreated control cells ± SEM (n = 18).  Significant 
difference is indicated by *, where *p < 0.05, **p < 0.01, ***p < 0.001, ****p 
< 0.0001 compared to colistin sulfate or polymyxin B.  (Two-way ANOVA 
and Dunnett’s multiple comparisons tests).  
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Compound IC50 (mg/ml) Fold-change 
OligoG-A-colistin 0.242 ± 0.066 9.3 
OligoG-E-colistin 0.057 ± 0.014 2.2 
Colistin sulfate 0.026 ± 0.002 - 
OligoG-A-polymyxin B 0.299 ± 0.033 27.2 
OligoG-E-polymyxin B 0.032 ± 0.003 2.9 
Polymyxin B 0.011 ± 0.001 - 
OligoG > 10 - 
 
Table 3.3  IC50 values (± SEM) and fold-change of OligoG-polymyxin 
conjugates derived from MTT assay in HK-2 cells.   
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between cytotoxicity of the treatment combinations tested (p < 0.05). 
Concentration-dependent release of TNFα is presented in Figure 3.10a.  
However, as the previous MTT assays had shown that the different treatments 
used had different effects on cell viability, the TNFα release data was adjusted 
to account for cell viability of each drug concentration as shown in Figure 
3.10b.  The outliers were identified and removed using Robust regression and 
Outlier removal (ROUT) method (Q coefficient was set to 0.2%) specified by 
GraphPad Prism software.  Both Polymyxin B and colistin alone induced 
greater TNFα release compared to the conjugates, where TNFα release was 
very low or undetectable, except for OligoG-E-polymyxin B, although this was 
still lower than free polymyxin B.  At the highest drug concentration, significant 
differences were observed between free and OligoG-conjugated antibiotics at 
equivalent drug concentrations (p < 0.05). 
 
3.5 Discussion  
The limited therapeutic options available to treat MDR infections, particularly 
those caused by Gram-negative pathogens, has forced the clinical use of last 
resort antibiotics, such as polymyxins in humans.  However, the misuse and 
overuse of polymyxins (especially in animal husbandry) has greatly contributed 
to antimicrobial resistance.  Therefore, this Chapter aimed to synthesise a 
library of OligoG-polymyxin conjugates to (i) select the best linker for use in 
polymer conjugate chemistry, and (ii) characterise their in vitro toxicity and 
antimicrobial activity (addressed in subsequent chapters). 
The fate of alginates after systemic administration has been studied in mice by 
covalent incorporation of tyrosinamide into the polymer chains and subsequent 
radioiodination (Al-Shamkhani and Duncan, 1995).  After IV administration of 
the polymer conjugate for 24 h, larger fractions (> 48,000 g/mol) remained in 
the circulation without any tissue accumulation, while low molecular weight 
fractions (< 48,000 g/mol) were excreted in the urine.  After systemic 
administration, many polysaccharides, such as hyaluronan and dextrin are 
degraded by physiological enzymes, which can be harnessed to release the 
drug payload at the target site using polymer-masked unmasked protein   
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(a)  
 
 
 
 
 
 
 
 
 
 
 
 
(b)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 TNFα release in HK-2 cells after incubation with OligoG-
polymyxin conjugates for 72 h.  (a) TNFα release for a range of polymyxin 
concentrations (± SEM; n = 6).  (b) TNFα release adjusted to cell viability for 
each drug concentration (± SEM; n = 6).  Significant difference is indicated 
by *, where *p < 0.05, ****p < 0.0001 compared to the colistin or polymyxin 
B controls.  (Two-way ANOVA and Dunnett’s multiple comparisons tests). 
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therapy (PUMPT).  Unfortunately, alginate conjugates are not suitable for 
PUMPT, since alginates such as OligoG are not degraded by mammalian 
enzymes.  Instead, it is necessary to rely on bacterial alginate lyase, secreted 
by certain bacteria, to break down the polymer.  
Preliminary experiments, using GPC to analyse the change in molecular 
weight of OligoG in the presence of alginate lyase isolated from 
Sphingobacterium multivorum (1-1000 U/ml) had revealed a concentration-
dependent reduction in molecular weight (Ferguson et al., 2016).  Similarly, 
incubation of OligoG-polymyxin conjugates with bacterial alginate lyase (1 
U/ml) had effectively decreased apparent molecular weight of the conjugate, 
triggering ~30% of colistin and ~90% of polymyxin B release within 24 h.  
Interestingly, no notable difference between amide or ester-linked conjugates 
was observed.  While amide-linked conjugates rely on degradation of the 
polymer backbone, incorporation of an ester bond would render the conjugates 
susceptible to degradation and drug release due to acidic pH, esterase 
enzymes and overproduction of reactive oxygen species in the infected 
tissues, as well as secreted alginate lyase from bacterial infection.  It is widely 
accepted that non-biodegradable polymers with a molecular weight lower than 
the renal threshold (< 40,000 g/mol) can be excreted without accumulating in 
the body (Greco and Vicent, 2008), so the conjugates synthesised here would 
be readily excreted by the kidney, regardless. 
P. aeruginosa is one of the leading pathogens responsible for high morbidity 
and mortality in patients with cystic fibrosis due to overproduction of 
exopolysaccharide composed of guluronic and mannuronic acids, by 
predominantly mucoid isoforms.  Co-administration of bacterial alginate lyase 
with antibiotics has been shown to significantly improve biofilm eradication in 
patients colonised with alginate-producing, mucoid bacteria (Alkawash et al., 
2006).  When mucoid P. aeruginosa biofilms were treated with gentamicin at 
64 mg/ml (2-fold higher than its minimum bactericidal concentration) for 1 
week, eradication was not achieved.  However, when alginate lyase (20 U/ml) 
was co-administered with gentamicin, significant elimination of the mucoid 
biofilm was accomplished.  These results validate the future potential of 
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developing a “two-step therapy”, whereby OligoG-antibiotic conjugates and 
alginate lyase are administered sequentially to target sites of infection by the 
EPR effect, thereby triggering localised drug release by polymer degradation. 
Unlike well-defined conventional small molecule drugs, polysaccharide-protein 
and -peptide conjugates are complex mixtures that are not easily separated, 
identified or characterised.  Indeed, many potential polymeric carriers, 
especially polysaccharides, lack structural uniformity. It has been 
demonstrated that molecular weight, chemical structure or morphological 
differences in the polymer, may have a profound effect on the physicochemical 
and biological properties of the whole polymer-drug conjugate (Ali and 
Brocchini, 2006, Godwin et al., 2001).  While the lack of polymer uniformity 
may not be an issue for oral and topical formulations, its influence on 
biodistribution, metabolism and elimination of the conjugate after systemic 
administration is expected to be more significant.  Polymer non-uniformity 
could also potentially impede batch-to-batch reproducibility for pharmaceutical 
development.  What is more, previous reports have indicated the propensity 
for polysaccharides to become non-biodegradable and immunogenic after 
chemical modification such as drug conjugation (Vercauteren et al., 1990).  It 
was therefore extremely important to fully characterise the OligoG-polymyxin 
conjugates used in these studies. 
A major disadvantage of SEC methods employing a single concentration 
detector, is that they provide only comparative measurements derived from a 
calibration curve of molecular weight markers, as a function of time.  While this 
method can provide accurate molecular weights for samples with the same 
chemistry as the calibration standards, when the chemical structure of the 
sample and standards are different, (as is the case with polysaccharide-
peptide conjugates which are neither a protein or polymer), the results are only 
comparative.  Also, since alginate molecular weight standards are not 
available for GPC calibration, pullulan molecular weight standards had to be 
used to produce the calibration curve.  Pullulan is a polysaccharide that forms 
random coils in aqueous solution (Shingel, 2004), whereas alginates exhibit 
an expanded macromolecular structure due to repulsion between the negative 
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charges along its chain.  Due to the effect on hydrodynamic volume, pullulan 
standards are known to overestimate alginate molecular weight by up to 6 
times (Andersen et al., 2012).  Nevertheless, GPC showed that the conjugates 
were a polydisperse mixture of species, it being well-known that 
polysaccharides are highly polydisperse (PDI > 2), which presents a particular 
challenge for pharmaceutical development (Duncan, 2003).  Ideally, drugs 
developed for pharmaceutical applications should have a narrow 
polydispersity, since high polydispersity can affect biological activity of the drug 
and hinder conjugate characterisation.  Consequently, SEC with multi-angle 
laser light scattering (SEC-MALLS) detection is used as an international 
standard method for determining molecular weight and molecular weight 
distribution of alginates (American Society for Testing and Materials; ASTM, 
2016).  The principle of the technique is based on the Rayleigh theory, which 
shows that the intensity of the scattered light by a molecule is proportional to 
its molecular weight (Andersson et al., 2003).  Therefore, multiple light 
scattering measurements can be made (at a range of different angles) to 
calculate absolute molecular mass.  To validate the results obtained in these 
studies, OligoG-polymyxin conjugates developed in this chapter were also 
analysed using SEC-MALLS (carried out by Dr Olav Aarstad at the Norwegian 
University of Science and Technology, NTNU, Trondheim, Norway).  As 
expected, notably lower molecular weights and molecular weight distributions 
of the OligoG-polymyxin conjugates were measured using this technique. 
FPLC could not be used to determine the molecular weight of purified 
conjugates because OligoG-polymyxin conjugates eluted in the void volume of 
the column.  It is also important to note that FPLC was not capable of 
distinguishing between free OligoG and the OligoG-polymyxin conjugate, since 
they both elute at the same point.  Although it is not ideal to include free OligoG 
in the product, clinical trials have shown the polymer to be safe and non-
immunogenic (at concentrations up to 60 mg/ml) and its inherent biological 
activity may yield additional clinical benefit.  In the longer term, to facilitate 
thorough characterisation of the active species, this issue will ultimately need 
to be addressed.  Nevertheless, FPLC showed that only a small fraction of the 
free drug was present in the conjugate suggesting that OligoG-polymyxin 
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conjugates would have a beneficial therapeutic index in vivo. 
OligoG-polymyxin conjugates were reproducibly synthesised to contain 6.1-
12.9% (w/w) protein with < 6% free drug.  The choice of linker did not appear 
to significantly affect drug loading, although the OligoG-polymyxin B 
conjugates typically contained less drug than the colistin conjugates.  The 
ninhydrin assay indicated a decrease in available primary amines in the 
OligoG-conjugated amide-linked polymyxins, suggesting that 2-4 amino 
groups were used for binding to the polymer.  Although colistin and polymyxin 
B are known to contain 5 primary amines, the ninhydrin assay only detected 
~4 of them.  This may be due to one of the amines being inaccessible.  It has 
also been shown that some amines react with ninhydrin at a much slower rate, 
affecting Ruhemann’s purple colour yield formation (Friedman, 2004), which 
could also help explain the difference between the actual and measured amine 
groups seen here.  
Since polymyxins have been reported to cause severe nephrotoxicity in up to 
53.5% of patients (Spapen et al., 2011), it was important to determine the in 
vitro toxicity of the conjugates in kidney cells.  As previously shown in the 
literature, polymyxin B was 2-3 times more nephrotoxic than colistin sulfate in 
HK-2 cells (Vaara and Vaara, 2013).  Importantly here, OligoG conjugation 
significantly decreased the cytotoxicity of both colistin and polymyxin B in 
human kidney cells.  Previous studies reported an IC50 value for dextrin-colistin 
conjugates to be 0.06 mg/ml (Ferguson et al., 2014), while in this study, the 
OligoG-colistin conjugates had IC50 values of 0.24 mg/ml and 0.06 mg/ml (for 
amide- and ester-linked conjugates, respectively), suggesting that OligoG 
conjugates may be better tolerated in vivo.  As expected, OligoG-E-polymyxin 
conjugates exhibited higher toxicity towards HK-2 cells compared with the 
amide-linked conjugates.  Since 2-4 of the polymyxin’s primary amines were 
used for irreversible amide bond formation with OligoG, and these groups 
being known to mediate polymyxin toxicity, it was not surprising that the amide-
linked conjugates were less toxic than ester-bound conjugates.  Previous 
studies have investigated structure of the polymyxin molecule with the major 
colistin and polymyxin B components shown to exhibit similar antimicrobial 
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activity in a range of clinical Gram-negative pathogens (Roberts et al., 2015).  
However, polymyxin B1 and colistin A induced 3-fold higher apoptotic effects 
in HK-2 cells compared to polymyxin B2 and colistin B, suggesting that 
individual lipopeptide components might be reabsorbed differently by HK-2 
cells.  This further highlights the need to standardise the composition of 
commercially available colistin and polymyxin B products, to improve the 
safety profile of OligoG-polymyxin conjugates. 
Immunogenicity of the polymer-drug conjugates can cause severe clinical 
issues, affecting both the biodistribution and efficacy of the drug in vivo.  It has 
been suggested that polymers might induce B cell activation leading to 
antibody production (Jiskoot et al., 2009).  For example, previous studies have 
shown the presence of anti-PEG antibodies in patients treated with PEG-
asparaginase, which led to rapid clearance of the conjugate from the 
bloodstream (Armstrong et al., 2007).  It is known that drug delivery systems 
(including polymer-drug conjugates) can be immunogenic, causing recognition 
and binding of the drug by opsonin proteins (Owens and Peppas, 2006).  
Opsonins can be components of the blood serum, such as albumin or 
fibrinogen, as well as complement proteins and immunoglobulins (Markovsky 
et al., 2012).  As a result, macrophages of the mononuclear phagocytic system, 
can recognise opsonin proteins bound to foreign material, leading to fast 
conjugate clearance from the bloodstream and its accumulation, mainly in the 
spleen and liver (Markovsky et al., 2012).  As previously highlighted nano-
sized agents with hydrodynamic diameters larger than 20 nm, might not be 
able to avoid recognition by mononuclear phagocytic system (Duncan and 
Vicent, 2010).  In addition, activated macrophages produce pro-inflammatory 
mediators such as TNFα or interleukin-1 (IL-1) that play a crucial role in 
inflammation (Parameswaran and Patial, 2010).  In this study, OligoG 
conjugation was shown to markedly reduce the release of inflammatory 
cytokines in HK-2 cells at concentrations higher than > 0.5 mg/ml.  A previous 
study had already shown a significant and dose-dependent reduction in 
systemic inflammatory responses in mice infected with P. aeruginosa 
NH57388A following OligoG treatment, with levels of IL-1α dropping from 30.8 
pg/ml (in untreated mice) to 4.5 pg/ml after receiving 5% OligoG (Hengzhuang 
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et al., 2016).  Mild alveolar macrophage accumulation has been observed in 
rats after 28 days of daily administration of 6% nebulised OligoG, but this was 
not considered a toxicological effect, but rather, a normal adaptive response 
to inhaled material (Myrvold et al., 2010).  Detailed immunological analysis of 
alginates and their components (G-blocks, M-blocks and MG-blocks) revealed 
that high G (64%) content alginates were ~10 times less immunogenic 
compared to low G (46%) alginates, indicating that M- and MG-, but not the G-
blocks were potent cytokine stimulators, inducing human monocytes to 
produce high levels of IL-1, IL-6 and TNFα (Otterlei et al., 1991).  All the data 
provided from the studies above suggests that OligoG (G > 85%) conjugation 
to antibiotics might be advantageous in vivo by reducing the inflammatory 
responses provoked by cytotoxic antibiotics. 
 
3.6 Conclusions  
Here, successful conjugation of OligoG to polymyxin antibiotics was achieved 
via amide and ester linkage.  OligoG-polymyxin conjugates containing 6.1-
12.9% (w/w) antibiotic and possessing a molecular weight between 14,500-
27,000 g/mol were reproducibly synthesised.  Conjugation of OligoG to 
polymyxins was also shown to significantly reduce in vitro toxicity and 
immunogenicity in a kidney cell line.  These preliminary studies confirmed the 
potential of these OligoG-polymyxin conjugates as an antibacterial therapy and 
a library of OligoG-polymyxin conjugates was developed for further analysis.  
The following studies assessed in vitro antimicrobial activity of the conjugates 
in a range of bacterial pathogens (Chapter 4).  
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Chapter 4 
 
Antimicrobial Activity of OligoG-Polymyxin  
Conjugates 
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4.1 Introduction 
Promisingly, as described in Chapter 3, OligoG conjugation was shown to 
significantly reduce the cytotoxicity of the antibiotics colistin and polymyxin B.  
Hence, to show clinical utility to these conjugates, it was necessary to 
demonstrate that they still retained antimicrobial activity towards multidrug-
resistant (MDR) Gram-negative bacteria. It was also important to characterise 
the ability of alginate oligomers to potentiate antibiotic treatment and impede 
biofilm development when conjugated to the antibiotic, both important 
properties of OligoG (Khan et al., 2012). Therefore, in these studies, the 
antibacterial efficacy of OligoG-polymyxin conjugates was assessed against a 
range of pathogens to ensure clinical efficacy.  
In addition, this study was designed to investigate how the conjugates might 
behave when used clinically.  For example, colistin is known to bind strongly 
to mucin and plasma proteins, leading to reduced activity (Huang et al., 2015, 
Sivanesan et al., 2017), but polymer-protein conjugation has been previously 
shown to prevent this interaction due to steric hindrance (Gao and He, 2014, 
Verhoef and Anchordoquy, 2013).  
 
4.1.1 Mechanism of action of polymyxin antibiotics 
As relatively “old” drugs, polymyxin antibiotics were not subjected to the rigours 
of contemporary drug development and regulatory procedures.  As a result, 
their mode of action of interacting with the lipid A moiety of lipopolysaccharide 
(LPS) in the outer membrane of Gram-negative bacteria has only recently 
been elucidated (Hancock, 1997).  Electrostatic interactions between the 
anionic phosphate groups of lipid A and cationic amino groups of polymyxin 
has been shown to displace divalent cations, such as magnesium and calcium, 
which are required for bacterial outer membrane stabilisation (Velkov et al., 
2010).  Following this, the incorporation of N-terminal fatty acyl chain and 
hydrophobic regions, such as D-Phe6-L-Leu7 of polymyxin B or D-Leu6-L-Leu7 
of colistin, into the bacterial outer membrane then causes further expansion 
and distortion of the membrane (Yu et al., 2015).  Eventually, polymyxins cross 
the outer membrane by self-mediated uptake and straddle the hydrophilic 
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heads and hydrophobic fatty acyl tails of the phospholipid inner membrane 
bilayer, disrupting the physical integrity of the membrane (Velkov et al., 2010).  
A secondary target for the bactericidal activity of polymyxin suggested by Deris 
et al., (2014) showed that polymyxin B and colistin inhibit the efficacy of a 
respiratory enzyme called NADH-quinone oxidoreductase (NDH-2) in the 
inner membrane of Gram-negative bacteria.  As a result, enhanced membrane 
permeability and leakage of intracellular contents facilitates cell lysis and death 
(Evans et al., 1999).  
It has also been proposed that polymyxins in the periplasmic space could form 
molecular contacts between the outer and inner membranes of Gram-negative 
bacteria (Cajal et al., 1995, Cajal et al., 1996).  The binding of polymyxins to 
the negatively-charged phospholipid layer of outer and inner membranes 
triggers lipid exchange, thus disturbing their phospholipid composition, which 
results in osmotic imbalance and cell lysis (Clausell et al., 2007, Velkov et al., 
2010, Yu et al., 2015). 
The bactericidal antibiotics such as aminoglycosides, β-lactams and 
quinolones have been shown to induce hydroxyl radical production in both 
Gram-positive and Gram-negative bacteria, which contributes to rapid cell 
death (Kohanski et al., 2007).  Rapid polymyxin B and colistin-induced killing 
of MDR A. baumannii has also been associated with hydroxyl radical 
production and accumulation via the Fenton reaction, which could be delayed 
by radical quenching (Sampson et al., 2012).  It is believed that when 
polymyxins cross the outer and inner bacterial membranes, an increase in 
NADH consumption and hyper-stimulation of the electron transport chain 
induces superoxide generation, which is converted into hydrogen peroxide by 
superoxide dismutase located in the cells (Yu et al., 2017).  As a result, both 
superoxide and hydrogen peroxide radicals inactivate the iron-sulphur (Fe-S) 
clusters, leading to ferrous iron (Fe2+) conversion into ferric iron (Fe3+) along 
with hydroxyl radical production from hydrogen peroxide by the Fenton 
reaction (Yu et al., 2017, Yu et al., 2015).  Eventually, overproduction of 
reactive oxygen species triggers oxidative damage to proteins, lipids and DNA 
leading to rapid cell death (Yu et al., 2017).  A summary of the antibacterial  
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mechanisms mediated by polymyxin antibiotics is shown in Figure 4.1.  
Given the key role of charged groups on the polymyxin molecule to its 
antimicrobial activity, it was extremely important to establish whether 
reversible (ester-linked) or irreversible (amide-linked) conjugation of OligoG to 
polymyxin B and colistin would affect its ability to kill bacteria.  
 
4.1.2 Antimicrobial susceptibility testing  
A significant increase in polymyxin use in hospitalised and critically ill patients 
has necessitated the development of a reliable method to determine the 
susceptibility of bacteria to polymyxin B and colistin in these patients.  
Recently, the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) and Clinical and Laboratory Standards Institute (CLSI) 
recommended the use of broth micro-dilution as a standard method for 
minimum inhibitory concentration (MIC) determination of polymyxins 
(EUCAST, 2016, Vasoo, 2017).  An MIC assay defines the lowest 
concentration required to inhibit visible growth of a bacterial pathogen after 
overnight incubation (EUCAST, 2003).  However, several technical issues 
regarding accuracy of susceptibility testing for colistin and polymyxin B have 
been reported.  Firstly, due to the cationic nature of polymyxins, their 
adherence and binding to negatively-charged surfaces of commonly-used 
laboratory tools made of glass, polystyrene or polypropylene has been widely 
observed (Vasoo, 2017).  Even though the joint CLSI-EUCAST group suggests 
performing MIC assays in microtitre plates made of plain polystyrene, a recent 
report by Karvanen et al. (2017) highlighted a significant loss of colistin from 
solutions prepared in polystyrene test tubes, compared with other materials, 
such as polypropylene or glass.  Previously, addition of the surfactant, 
polysorbate 80, had been recommended by CLSI to prevent lipoglycopeptide 
adherence to plastics (CLSI, 2012).  However, susceptibility testing of E. coli, 
K. pneumoniae, P. aeruginosa and Acinetobacter species to polymyxins 
subsequently showed a decrease in MIC values (by up to 8-fold) in the 
presence of polysorbate 80 (Sader et al., 2012). Synergy between polysorbate 
80 and polymyxin B has also been reported in P. aeruginosa, showing that the
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(a) 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
Figure 4.1  Antibacterial mechanisms mediated by polymyxins.  Panel (a) shows membrane lysis death pathway.  Panel (b) 
indicates vesicle-vesicle contact pathway.  Panel (c) represents hydroxyl radical death pathway.  (Adapted from Yu et al., 2015). 
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surfactant modified the outer membrane lipid structure to facilitate entry of 
polymyxin (Brown et al., 1971).  Furthermore, polysorbate 80 itself was shown 
to possess weak antimicrobial activity (Brown et al., 1979).  As a result, CLSI 
and EUCAST no longer recommend polysorbate 80 for use in susceptibility 
testing of polymyxins (EUCAST, 2016).  Additionally, heterogeneity in the 
composition of polymyxin B and colistin formulations, as well as variation in 
the calcium and magnesium content of Mueller-Hinton broth, have also led to 
misleading MIC results (Bakthavatchalam et al., 2018, Vasoo, 2017).  
Alternative susceptibility testing methods have been reported in the literature, 
but due to their relatively high molecular weight, polymyxins diffuse poorly in 
agar, which compromises the reliability of the Etest and disk diffusion 
techniques (Chew et al., 2017, Humphries, 2015, Lo-Ten-Foe et al., 2007).  
The agar dilution method has been suggested as a means of overcoming the 
adsorption of polymyxins to the surface of plastic (Humphries, 2015).  Studies 
by Hogardt et al. (2004) demonstrated that agar dilution produced higher MIC 
values compared to those obtained using the broth microdilution method, 
suggesting higher resistance frequency to polymyxins in agar.  Likewise, while 
automated systems such as VITEK 2 employ turbidimetric analysis of bacterial 
growth, they exhibit low sensitivity towards heteroresistant subpopulations of 
bacteria (Lo-Ten-Foe et al., 2007, Vasoo, 2017).  Consequently, susceptibility 
of a range of laboratory and clinical strains of bacteria to OligoG-polymyxin 
conjugates was determined using the broth microdilution method according to 
the instructions provided by the joint CLSI-EUCAST group (EUCAST, 2016).  
Additionally, given that drug-resistant E. coli is predicted to kill an extra 40,000 
people a year by 2026 (O’Neill, 2016), the effectiveness of the OligoG-
polymyxin conjugates against colistin resistant E. coli (plasmid-encoded mcr-
1 colistin resistance) was also studied to determine whether polymyxin 
conjugation to OligoG could overcome antibiotic resistance.  Plasmids (IncHI2, 
IncI2, IncX4 and IncP) carrying mcr-1 has been identified in 
Enterobacteriaceae and is the first polymyxin resistance gene known to be 
capable of spreading between bacterial strains and species by horizontal gene 
transfer (Liu et al., 2016, Zhao et al., 2017b).  The mcr-1 gene encodes an 
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intramembrane enzyme (phosphatidylethanolamine transferase) that is 
responsible for phosphoethanolamine residue transfer to the lipid A moiety in 
the Gram-negative bacterial cell membrane.  This structural modification of 
lipid A leads to a lower affinity for polymyxins and reduced ability to activate 
the innate immune response, culminating in reduced antimicrobial efficacy (Xu 
et al., 2018, Yang et al., 2017).  
Since the OligoG-polymyxin conjugates were expected to display different 
pharmacokinetics to the unmodified antibiotic, in addition to using conventional 
MIC tests, bacterial growth patterns in the presence of prolonged exposure to 
antibiotic treatments were also studied.  One of the main advantages of the 
growth curve is the ability to demonstrate bacterial regrowth which is 
commonly associated with the presence of resistant (persister) sub-
populations (Yourassowsky et al., 1985).  
Additionally, as a third model of bacterial susceptibility testing, confocal laser 
scanning microscopy (CLSM) was employed to evaluate biofilm formation in 
the presence of OligoG-polymyxin conjugates or polymyxin alone, to 
specifically determine biofilm thickness, roughness coefficients and biomass.  
CLSM is a commonly used tool for generating high resolution images of the 
three-dimensional structure of biofilms (Lawrence and Neu, 1999).  
 
4.1.3 Combination therapy for Gram-negative infections 
Since many bacterial infections are commonly treated with combination 
therapies, the antimicrobial efficacy of OligoG-polymyxin conjugates was also 
tested in combination with azithromycin using a two-directional checkerboard 
assay.  Checkerboard assays are commonly used to assess the interaction of 
different antimicrobial agents and the efficacy of drug combinations at clinically 
relevant concentrations (Saiman, 2007). The fractional inhibitory concentration 
index (FICI) is derived by comparing the MIC values of the individual agents 
with the MIC value of the combined treatments (Hsieh et al., 1993).  
Azithromycin was selected for these studies since it had been previously 
shown that azithromycin can exhibit synergistic activity with polymyxin 
derivatives against E. coli, Enterobacter cloacae, K. pneumoniae and A. 
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baumannii strains (Vaara et al., 2010) and P. aeruginosa (Landman et al., 
2005).  Synergism has also been demonstrated between polymyxin B and 
imipenem or rifampicin in polymyxin-resistant P. aeruginosa isolates 
(Landman et al., 2005).  Azithromycin acts by interfering with protein synthesis 
inside the cell, therefore it must cross the cell wall to exert its antimicrobial 
effect (Parnham et al., 2014).  It has been proposed that co-administered 
polymyxins could permeabilise the bacterial outer membrane, thereby 
enhancing internalisation of azithromycin and allowing the use of lower 
antibiotic doses, which would cause less side effects.  Indeed, it has further 
been shown that colistin facilitated and synergistically enhanced the efficacy 
and entry of azithromycin into P. aeruginosa, K. pneumoniae and A. baumannii 
(Lin et al., 2015). 
 
4.1.4 Environmental factors affecting Minimum Inhibitory Concentration  
In contrast to standard in vitro models of antimicrobial susceptibility which 
routinely employ Mueller-Hinton (MH) medium to optimise bacterial growth, 
when antibiotics are administered to patients, they are exposed to a wide range 
of proteins and destructive environments.  For example, mucins are high 
molecular weight glycoproteins that regulate the rheological properties of the 
airway mucus and thus, contribute to mucociliary clearance of foreign particles 
and pathogens (Lillehoj and Kim, 2002, Ma et al., 2017).  However, 
hypersecretion and overproduction of mucin in sputum, along with bacterial 
debris and inflammatory cells, is commonly seen in chronic respiratory 
infections and pathological airway conditions, including cystic fibrosis and 
chronic obstructive pulmonary disease (Ma et al., 2017, Voynow and Rubin, 
2009).  Colistin is commonly used in patients with chronic airway infections 
caused by P. aeruginosa.  Huang et al. (2015) demonstrated that colistin binds 
strongly to mucin, causing > 100-fold increase in colistin MIC in a range of 
Gram-negative bacteria. The authors proposed that binding of colistin to 
secretory mucin in sputum or airway epithelium, would lead to reduced in vivo 
free colistin concentrations and hence reduced antibacterial efficacy.  In 
addition, these sub-MIC concentrations of antibiotic may also lead to increased 
development of antibiotic resistance.  Consequently, it was deemed pertinent 
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to establish whether attachment of OligoG to the antibiotic could inhibit these 
mucin-polymyxin interactions and improve antibacterial efficacy.  
Given its potential therapeutic use, it was also considered interesting to study 
the microbiological activity of OligoG-polymyxin antibiotics in CF sputum itself.  
However, its high heterogeneity, high variability between patients, excessive 
therapeutic use of antibiotics, an abundance of resistant yeasts and changes 
in consistency during sterilisation, make CF sputum unreliable and impractical 
for the susceptibility testing (Fung et al., 2010).  Consequently, an alternative 
medium to mimic the nutritional composition of the CF lung was sought.  
Palmer et al. (2007) had previously developed a defined, synthetic CF sputum 
medium (SCFM) to mimic the composition of CF sputum.  However, it did not 
contain important components, such as the mucin, lipids, nucleotides or intact 
proteins, that are usually present in CF sputum (Palmer et al., 2007).  More 
applicable to these studies, Sriramulu et al. (2005) established an artificial 
sputum (AS) medium that closely resembles the unique composition of CF 
sputum, containing, not only amino acids and salt ions, but also DNA, mucin, 
lecithin and surfactants.  Adaptations of this AS medium have since been used 
in several studies (Fung et al., 2010, Kirchner et al., 2012, Pritchard et al., 
2017), supporting the decision to use this medium to study the antimicrobial 
efficacy of OligoG-polymyxin conjugates in a more clinical relevant model of 
the lung environment. 
 
4.2 Experimental aims and objectives 
The specific aims of this study were: 
• To investigate the antimicrobial activity of OligoG-polymyxin conjugates 
and polymyxin antibiotics in a range of MDR Gram-negative pathogens, 
including colistin-resistant E. coli strains, in conventional MH as well as
mucin-supplemented and AS medium.  
• To characterise the in vitro pharmacokinetic profiles of bacteria grown 
in the presence of OligoG-colistin conjugates or colistin sulfate using 
bacterial growth curves.  
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• To visually assess how the presence of OligoG-colistin conjugates or 
colistin sulfate altered the development of P. aeruginosa (24 h) biofilms. 
• To compare the antimicrobial activity of azithromycin in the presence of 
OligoG-polymyxin conjugates and polymyxins alone as a possible 
combination treatment for Gram-negative infections. 
 
4.3 Methods 
Various general methods including preparation of agars, broths and bacterial 
cultures were used as reported in Chapter 2 (Sections 2.6.4.1 and 2.6.4.3).  
OligoG-polymyxin conjugates were synthesised and prepared as detailed in 
Section 3.3.1. OligoG-polymyxin conjugates used in this Chapter were 
synthesised by myself as described previously in Chapter 3 while conjugates 
containing acid hydrolysed high molecular weight alginate (Pronova) (2.5k 
AHG-A-colistin and 2.5k AHG-E-colistin) were synthesised by E. L. Ferguson. 
 
4.3.1 Bacterial strains  
The Gram-negative bacterial isolates used for susceptibility testing included 
reference bacterial strains and clinical isolates.  The origin and relevant 
resistance genotypes are listed in Table 4.1 (Khan et al., 2012, Yang et al., 
2017).  
 
4.3.2 Susceptibility testing using MIC assays  
Susceptibility testing of OligoG-polymyxin conjugates, colistin and polymyxin 
B was performed using conventional broth microdilution MIC assays as 
described in Chapter 2 (Section 2.6.4.4).  The MIC susceptibility breakpoints 
defined by CLSI and EUCAST for colistin and polymyxin B are summarised in 
Table 4.2. 
 
4.3.3 Susceptibility testing using MIC assays modified with mucin  
In addition, to study the antimicrobial activity of antibiotic treatments and 
OligoG (0.2% and 2% w/v) in the presence of mucin, MH broth was also  
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Strain code Bacterial isolate Genotype        Origin 
V1 Pseudomonas aeruginosa R22    VIM-2 China 
V2 Pseudomonas aeruginosa MDR 301    VIM-2 Poland 
X11 Pseudomonas aeruginosa NH57388A        - Denmark 
V13 Pseudomonas aeruginosa PAO1, ATCC 15692        - Reference strain 
E69 Pseudomonas aeruginosa NCTC 10662        - Reference strain 
V3 Klebsiella pneumoniae KP05 506    NDM-1 India 
V6 Klebsiella pneumoniae IR25    NDM-1 India 
V4 Acinetobacter baumannii MDR ACB    MDR Libya 
V19 Acinetobacter baumannii 7789    MDR United Kingdom 
V5 Escherichia coli    AIM-1 Australia 
V7 Escherichia coli IR57    NDM-1 India 
V11 Escherichia coli 5702        - United Kingdom 
V24 Escherichia coli 7273        - United Kingdom 
E70 Escherichia coli NCTC 10418        - Reference strain 
THAI 21 Escherichia coli PN21    mcr-1 Thailand 
THAI 25 Escherichia coli PN25    mcr-1 Thailand 
THAI 26 Escherichia coli PN26        - Thailand 
 Escherichia coli ATCC 25922        - Reference strain 
E68 Staphylococcus aureus NCTC 6571        - Reference strain 
E75 Staphylococcus aureus NCTC 12493        - Reference strain 
 
Table 4.1  Bacterial isolates used for characterisation of OligoG-antibiotic conjugates. 
Resistance genotype: VIM-2, carbapenem-hydrolyzing metallo-β-lactamase; NDM-1, New Delhi metallo-β-lactamase; 
MDR, multidrug resistant; AIM-1, metallo-β-lactamase; mcr-1, plasmid-encoded colistin resistance. 
9
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Polymyxin 
MIC breakpoints (µg/ml) 
 
Pseudomonas 
spp. 
 
Acinetobacter 
spp. 
Enterobacteriaceae 
CLSI EUCAST CLSI EUCAST CLSI EUCAST 
S I R S I R S I R S I R S I R S I R 
Colistin sulfate ≤ 2 - ≥ 4 ≤ 2 - > 2 ≤ 2 - ≥ 4 ≤ 2 - > 2 - - - ≤ 2 - > 2 
Polymyxin B ≤ 2 4 ≥ 8 - - - ≤ 2 - ≥ 4 - - - - - - - - - 
 
Table 4.2  MIC breakpoints (µg/ml) for colistin sulfate and polymyxin B recommended by the Clinical and Laboratory Standards 
Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) in 2018. 
Interpretative indices: S, susceptible; I, intermediate; R, resistant. 
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supplemented with 0.2% and 2% w/v porcine stomach (type II) mucin.  A stock 
solution of mucin was prepared (12.5% w/v in MH broth) and used to set up 
the 96-well plates according to the standard MIC protocol.  It was noted that 
addition of mucin to the MH medium produced a cloudy solution, which made 
it impossible to distinguish differences between bacterial growth or no growth 
after the overnight incubation step.  Therefore, at the end of the incubation 
period, 30 µl of resazurin, an oxidation-reduction agent, was added to the wells 
of the plate (stock solution prepared at 0.01% w/v in sterile dH2O) and 
incubated for a further 3 h at 37°C.  The results were then determined visually; 
blue colouration indicating no bacterial growth and a pink colour signifying live 
cells or bacterial growth.  A typical plate set-up using resazurin for MIC assay 
determination can be seen in Figure 4.2. 
 
4.3.4 Susceptibility testing using MIC assays modified with artificial 
sputum medium 
To study the antimicrobial efficacy of antibiotic treatments under more clinically 
relevant conditions, the standard MIC assay was employed using AS medium 
instead of MH medium.  
RPMI 1640 medium was made up in dH2O according to the manufacturer’s 
instructions consisting of (10.4 g/L) and 3-(N-morpholino) propanesulfonic acid 
(MOPS) (0.165 M final concentration) and the pH adjusted to 7.0 with 0.5 M 
NaOH.  The solution was filter sterilised, then stored at 4°C prior to use.  
AS medium was prepared by dissolving deoxyribonucleic acid (DNA) from 
salmon fish sperm (4 g/L) and porcine stomach (type II) mucin (5 g/L) in sterile 
dH2O by stirring overnight at 4°C.  The remaining components of the AS 
medium were then subsequently added to the DNA/mucin solution including, 
RPMI 1640 medium (2% v/v), diethylenetriaminepentaacetic acid (DTPA) (5.9 
mg/L), egg-yolk emulsion (0.5% v/v), NaCl (5.0 g/L) and KCl (2.2 g/L).  After 
mixing, the pH was adjusted to 7.0 by the addition of NaOH (0.5 M) and the 
medium made up to a final volume of 1 L.  Finally, the AS medium was filter-
sterilised using a barrel filter (0.22 μm pore size), stored at 4°C in the dark and 
used within 4 weeks.  
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(a) 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
(c) 
 
 
 
 
 
 
 
 
 
SC 
Figure 4.2  Typical MIC plate set up. (a) The MIC plate after 20 h incubation 
with tested compounds and mucin. (b) Plate after addition of resazurin 
indicator (pink, bacterial growth; blue, no bacterial growth). (c) Plate after 3 h 
incubation with resazurin. Row F, positive growth control (GC); Row G, 
sterility control (SC). Rows A-E tested compounds. 
Tested 
compounds 
GC 
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4.3.5 Bacterial growth curves 
To study the pharmacokinetic profiles of bacteria during antibiotic treatment, 
96-well microtitre growth curve plates were set up according to methods 
previously described in Section 2.6.4.4 (used at concentrations ranging from 
16 x MIC to MIC/16).  Plates were then wrapped in parafilm and placed in a 
microtitre plate reader at 37°C, and absorbance at 600 nm was measured 
hourly for 48 h.  For comparison, bacterial growth in the presence of i) OligoG, 
ii) PRONOVA (high molecular weight alginate) and iii) OligoG plus colistin, at 
equivalent concentrations to those used in the corresponding conjugates, was 
measured. Experiments were conducted in triplicate and results were 
presented as mean values (n = 3). 
 
4.3.6 Checkerboard assay 
Following MIC determinations against the various test bacteria, checker board 
MIC assays were performed to test the interaction and potency of two 
antimicrobials concurrently i.e. OligoG-colistin conjugates and colistin sulfate 
against azithromycin.  For this, stock solutions of OligoG-colistin conjugates 
and colistin (used at 8 x the MIC value) and serial two-fold dilutions of 
azithromycin (used at concentrations ranging from 16 x MIC to MIC/16) were 
freshly prepared in MH medium.  MH medium (50 µl) was placed in each well 
of rows B-H (columns 1-10) of a 96-well microtitre plate.  Solutions of OligoG-
colistin conjugate or colistin (100 µl) were placed in row A (columns 1-10) of 
the plate and serially diluted down the plate by transfer of 50 µl, stopping at 
row G so that row H contained MH medium only.  Serially diluted azithromycin 
solutions (50 µl) were added in decreasing concentrations across the plate 
(rows A-H), stopping at column 9, so that column 10 contained conjugate or 
colistin solution only.  Columns 11 (growth control) and 12 (sterility control) 
contained MH medium only (100 µl).  Each microtitre well (except column 12) 
was inoculated with bacteria as previously described (Section 2.6.4.4), then 
the plate was wrapped in parafilm and incubated at 37°C for 20 h.  A typical 
plate set up for checkerboard assay can be seen in Figure 4.3.  Assays were 
performed in triplicate and results were expressed as median values.  Then,  
 
 
 
Figure 4.3  Typical plate layout for checkerboard MIC assay using OligoG-A-colistin and azithromycin in combination against 
P. aeruginosa MDR 301 (MIC = 1 and 8 µg/ml, respectively).  
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the FICI was calculated by using the concentration of the first non-turbid well 
in each row along the turbid/non-turbid interface as follows: 
 
 
 
The combined therapy was considered synergistic when the mean FICI was ≤ 
0.5, additive when the FICI was between 0.5-2,  indifferent when the FICI was 
between 2-4, and antagonistic when the FICI was ≥ 4 (Bonapace et al., 2002).  
 
4.3.7 Biofilm formation assay 
The effect of antibiotic and conjugate treatments on biofilm formation was then 
determined. For this, serially diluted antibiotic solutions (ranging from 2 x MIC 
[of antibiotic/conjugate] to MIC/4) in MH broth were added to the wells of a 
Greiner glass-bottomed optical 96-well plate (90 μl per well).  Pseudomonal 
cultures (P. aeruginosa R22) from overnight inoculums were standardised to 
107 CFU/ml and added to the wells of 96-well plate (10 μl per well).  The plate 
was wrapped in parafilm and incubated for 24 h on a rocker (20 rpm) at 37°C.  
Sterility (MH only) and growth (no antibiotic) controls were included in each 
plate.  After 24 h, the supernatant was carefully removed and 5 μl of 
LIVE/DEAD stain (LIVE/DEAD Bacterial Viability kit; prepared by mixing 5 μM 
of SYTO 9 [LIVE] and 30 μM of propidium iodide [DEAD] in PBS) was added.  
The plate was wrapped in foil and kept in the dark for 10 min, then PBS (45 μl) 
was added to the wells and CLSM was performed immediately using objective 
magnification of x63 under oil, resolution of 512 x 512, line averaging of 1 and 
a step size of 0.79 µm.  The excitation/emission ranges used in this study were 
480/500 nm for SYTO 9 and 490/635 for propidium iodide.  Experiments were 
performed in triplicate and biofilm stack images (n = 15) were quantified by 
Comstat image analysis programme that applies a fixed binary thresholding to 
distinguish the biofilm biomass from the background (Heydorn et al., 2000).  
Thus, the changes in biofilm thickness, roughness coefficient and biomass 
were reliably assessed. 
FIC index A/B = 
MIC (A combination)
MIC (A alone)
+  
MIC (B combination)
MIC (B alone)
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4.4 Results 
4.4.1 Microbiological characterisation of OligoG-polymyxin conjugates 
Conjugation of OligoG slightly reduced the antimicrobial activity of colistin and 
polymyxin B against a panel of Gram-negative bacteria, typically increasing 
the MIC to 1-2-fold compared to that of the free drug (Table 4.3).  OligoG-
ester-polymyxin conjugates showed the best equivalence to the free drug’s 
activity, while an increase in the antibiotic’s MIC of 2-fold or more was most 
commonly seen for amide-linked conjugates, especially those containing 
polymyxin B.  Nevertheless, the OligoG-A-colistin conjugates had significantly 
higher antimicrobial activity compared to previously published dextrin-A-
colistin conjugates as indicated in Table 4.4.  Minimal batch-to-batch variability 
in the antimicrobial activity of the OligoG-colistin conjugates was observed in 
several Gram-negative strains (Table 4.5). 
When antimicrobial activity was tested in colistin-resistant strains, it was 
observed that OligoG alone had no antibacterial activity (MIC > 1280 µg/ml) 
and that conjugation did not improve the bactericidal efficacy of colistin (Table 
4.3).  As observed in the other (colistin-sensitive) strains, ester-linked antibiotic 
conjugates exhibited slightly better antimicrobial activity compared to amide-
linked ones and displayed similar MIC values to those of the free drug.   
When the antimicrobial activity of OligoG-polymyxin conjugates was tested in 
the presence of 0.2% or 2% mucin, MIC values increased in a dose-
dependent manner, with increasing concentration of mucin, and there was a 
clear decrease in antimicrobial efficacy (Table 4.6).  The inhibitory effect of 
mucin was greatest for K. pneumoniae, where MIC values increased > 10-
fold in the presence of mucin.  Also, when bacteria were treated with OligoG 
(0.2% or 2%) with colistin or polymyxin B without conjugation antibiotic activity 
was similar to that of equivalent concentrations of the free drug.  
Similarly, the antimicrobial activity of the antibiotics in AS medium was also 
reduced compared to in MH medium (Table 4.7).  Typically, MIC values were 
around 2-4-fold higher in the AS medium.  Interestingly, OligoG-colistin 
conjugates retained their efficacy towards the E. coli IR57 isolate in AS  
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OligoG-A-colistin 2 1 0.5 1 0.125 1 1 0.125 0.008 0.125 0.063 0.25 32 32 0.5 1 
OligoG-E-colistin 1 0.5 0.25 0.25 0.125 0.125 0.25 0.125 0.008 0.25 0.031 0.5 16 8 0.25 1 
Colistin sulfate 0.5 0.5 0.25 0.125 0.125 0.063 0.5 0.25 < 0.008 0.125 0.031 0.125 8 8 0.125 0.25 
                 
OligoG-A-polymyxin B 4 2 1 4 0.5 4 2 0.5 0.063 2 0.25 4 32 32 0.5 16 
OligoG-E-polymyxin B 0.25 0.5 0.25 0.25 0.25 0.125 0.063 0.5 0.016 0.5 0.063 0.25 8 4 0.25 0.5 
Polymyxin B 0.25 0.5 0.25 0.063 0.125 0.125 0.125 0.125 < 0.004 0.5 0.063 0.25 8 4 0.125 0.5 
 
Table 4.3  MIC determinations of OligoG-polymyxin conjugates against a range of Gram-negative bacterial pathogens.  
Decreased antimicrobial activity of conjugated polymyxin, where the MIC was at least 2-fold higher compared to colistin sulfate or 
polymyxin B controls, is shown in red. 
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OligoG-A-colistin 2 1 0.125 1 1 0.125 0.008 0.125 0.063 
Dextrin-A-colistin 128 512 4 8 8 8 1 4 8 
          
Fold-change 6 9 5 3 3 6 7 5 7 
 
Table 4.4  Comparison of the antimicrobial activity MIC (µg/ml) of OligoG-A-colistin and dextrin-A-colistin conjugates. 
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Drug 
MIC (µg/ml) 
Batch 
number 
P. aeruginosa 
MDR 301 
K. pneumoniae 
KP05 506 
E. coli 
IR57 
A. baumannii 
7789 
OligoG-A-colistin 
1 1 0.25 0.5 0.5 
2 1 0.125 0.125 0.125 
3 2 0.125 0.125 0.063 
4 2 0.125 0.125 0.063 
5 2 0.125 0.25 0.125 
      
OligoG-E-colistin 
1 0.5 0.125 0.25 0.125 
2 0.5 0.063 0.125 0.063 
Colistin sulfate - 0.5 0.125 0.125 0.25 
 
 
Table 4.5  Batch-to-batch reproducibility of MIC determinations of OligoG-colistin conjugates against a range of Gram-negative 
bacterial pathogens. 
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ND, not determined. 
 
 
 
 
 
Drug            Mucin (%) → 
MIC (µg/ml) 
P. aeruginosa 
R22 
A. baumannii 
MDR ACB 
K. pneumoniae 
IR25 
E. coli 
IR57 
0 0.2 2 0 0.2 2 0 0.2 2 0 0.2 2 
OligoG-A-colistin 4 4 64 0.125 4 64 0.125 8 > 128 0.063 2 8 
OligoG-E-colistin 1 16 64 1 16 64 0.063 32 > 128 0.063 4 64 
2.5k AHG-A-colistin 2 4 64 1 16 64 0.125 16 > 128 0.25 2 4 
2.5k AHG-E-colistin 1 4 64 1 4 32 0.063 4 128 0.25 2 4 
0.2% OligoG + colistin 0.25 2 32 ND ND ND ND ND ND < 0.063 2 4 
2% OligoG + colistin 1 4 32 ND ND ND ND ND ND 0.25 0.5 2 
Colistin sulfate 0.5 2 16 0.5 1 16 0.063 1 64 0.125 1 2 
             
OligoG-A-polymyxin B 2 64 > 128 4 16 128 2 16 > 128 2 16 32 
OligoG-E-polymyxin B 0.5 2 32 0.25 1 16 0.125 2 128 0.125 0.5 1 
0.2% OligoG + polymyxin B 0.5 4 64 ND ND ND ND ND ND 0.125 2 4 
2% OligoG + polymyxin B 1 4 32 ND ND ND ND ND ND < 0.063 0.5 2 
Polymyxin B 0.25 4 64 0.125 1 16 0.125 4 64 0.5 1 4 
 
1
0
8
 
Table 4.6  Microbiological efficacy (MICs) of antibiotics in the absence and presence of mucin against Gram-negative 
bacterial pathogens. 
. 
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MIC (µg/ml) 
P. aeruginosa 
MDR 301 
P. aeruginosa 
NH57388A 
K. pneumoniae 
KP05 506 
E. coli 
 IR57 
E. coli  
5702 
A. baumannii 
7789 
Drug        Medium → AS MH AS MH AS MH AS MH AS MH AS MH 
OligoG-A-colistin 4 1 2 0.5 2 0.125 0.125 0.125 0.25 0.063 2 0.125 
OligoG-E-colistin 4 0.5 1 0.25 1 0.125 0.063 0.25 0.125 0.031 1 0.125 
Colistin sulfate 2 0.5 1 0.25 1 0.125 0.125 0.125 0.125 0.031 1 0.25 
             
OligoG-A-polymyxin B 16 2 4 1 8 0.5 0.5 2 1 0.25 4 0.5 
OligoG-E-polymyxin B 8 0.5 2 0.25 2 0.25 0.125 0.5 0.25 0.063 1 0.5 
Polymyxin B 4 0.5 1 0.25 1 0.125 0.125 0.5 0.25 0.063 0.5 0.125 
 
Table 4.7  Comparison of the effect of growth medium (AS medium and MH broth) on antimicrobial activity (MIC determinations) 
of antibiotics. 
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medium, showing equivalent or lower MICs than in MH broth.  
 
4.4.2 Characterisation of bacterial growth curves 
Bacterial growth curves (Figure 4.4) showed that the OligoG-colistin 
conjugates delayed bacterial growth in a concentration-dependent manner 
and slowed the rate of regrowth compared to untreated bacteria.  On the other 
hand, colistin sulfate alone showed more rapid bacterial regrowth. Overall, at 
the median of previously determined MIC values across all batches, OligoG-
colistin conjugates typically showed the longest inhibition of bacterial 
regrowth, while colistin sulfate showed the shortest inhibition of bacterial 
regrowth (indeed, equivalent to the no antibiotic control for K. pneumoniae 
KP05 506 and A. baumannii 7789 (Appendices 2.1 and 2.3).  OligoG-colistin 
conjugates inhibited bacterial regrowth for up to 48 h at ≥ 2 x MIC, while 
colistin sulfate inhibited bacterial regrowth for up to 48 h at ≥ 8 x MIC (i.e. 
higher equivalent concentrations of colistin alone were required to achieve 
the equivalent growth inhibition obtained for the OligoG-colistin conjugates).  
There was no difference in time to onset of bacterial regrowth between the 
amide- and ester-linked conjugates.  The combination of OligoG plus colistin 
at equivalent concentrations to the OligoG and colistin in the corresponding 
conjugates showed concentration-dependent growth inhibition.  Typically, 
colistin that was covalently conjugated to OligoG showed equivalent activity 
to unconjugated colistin plus OligoG at equivalent concentrations.  
Furthermore, OligoG or Pronova, at an equivalent concentration to the OligoG 
in the OligoG-colistin conjugates (amide- and ester-linked), had no significant 
effect in reducing bacterial growth.  
 
4.4.3 Checkerboard assays with azithromycin 
MIC values for OligoG-colistin conjugates, colistin and azithromycin are 
summarised in Table 4.8.  In most cases, combining azithromycin with 
OligoG- colistin or colistin sulfate resulted in an indifferent or additive effect 
on the organisms tested here.  Generally, OligoG conjugation did not alter the 
efficacy of the antibiotic combination, except in A. baumannii 7789, where the  
 
 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.4  Bacterial growth curves for P. aeruginosa MDR 301 (48 h) in the presence of (a) colistin sulfate, (b and f) OligoG-
colistin conjugates (amide and ester linked). Controls used included (c and g) unconjugated colistin plus OligoG, (d and h) 
OligoG and (e and i) the high molecular weight alginate, PRONOVA, all at equivalent concentrations used in corresponding 
conjugates (n = 3).   
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(d)          (e) 
 
 
 
 
 
 
 
Figure 4.4  (continued). 
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(f)          (g) 
 
 
 
 
 
 
 
(h)          (i) 
 
 
 
 
 
 
 
Figure 4.4  (continued). 
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Drug 
 
P. aeruginosa 
MDR 301 
K. pneumoniae 
KP05 506 
A. baumannii 
7789 
E. coli 
NCTC 10418 
M
IC
 (
µ
g
/m
l)
 OligoG-A-colistin 1 0.125 0.125 0.25 
OligoG-E-colistin 0.5 0.125 0.125 0.125 
Colistin sulfate 0.5 0.125 0.25 0.125 
Azithromycin 8 32 32 4 
      
F
IC
I 
OligoG-A-colistin + Azithromycin 1.35 (Additive) 3.15 (Indifferent) 3.40 (Indifferent) 0.64 (Additive) 
OligoG-E-colistin+ Azithromycin 1.45 (Additive) 2.43 (Indifferent) 2.53 (Indifferent) 0.46 (Synergy) 
Colistin sulfate + Azithromycin 1.51 (Additive) 2.20 (Indifferent) 1.14 (Additive) 0.83 (Additive) 
 
Table 4.8  MIC and FICI values of OligoG-colistin conjugates, colistin and azithromycin, alone and in combination. 
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combination with colistin resulted in an additive effect (FICI = 1.14) but the 
conjugates’ effect was indifferent (FICI > 2.5).  Synergy was only observed 
when azithromycin was combined with OligoG-E-colistin in the E. coli NCTC 
10418 isolate (FICI = 0.46). 
 
4.4.4 The effect of OligoG-colistin conjugates on biofilm formation  
In the biofilm formation assay, CLSM images of LIVE/DEAD stained 
Pseudomonal biofilms demonstrated homogeneous growth in the untreated 
control.  However, addition of OligoG-colistin conjugates or colistin sulfate 
markedly disrupted biofilm formation and induced bacterial death at ≥ MIC, as 
shown in Figure 4.5.  At the MIC (1 µg/ml), the OligoG-E-colistin conjugate 
caused bacterial clumping, disruption of biofilm structure, and cell death.  In all 
cases, Comstat analysis of the images revealed a significant reduction in 
biofilm thickness at ≥ MIC (p < 0.05; Figure 4.6).  Also, OligoG-A-colistin and 
OligoG-E-colistin conjugates at ≥ MIC, and colistin sulfate at MIC, significantly 
increased the biofilm roughness (p < 0.05).  In addition, both the OligoG-A-
colistin and OligoG-E-colistin conjugates at 2 x MIC markedly reduced the 
biofilm biomass compared to untreated control (p < 0.05), although no 
significant activity was observed with colistin sulfate alone at up to 2 x MIC 
(Figure 4.6).  In all cases, the ratio of dead to live bacterial cells was 
significantly higher at MIC compared to the untreated control (p < 0.05).  On 
the other hand, a substantially larger biofilm biomass and thickness, as well as 
lower biofilm roughness and the ratio of dead to live cells was observed for all 
tested compounds at ≤ MIC/2 which was more evident with OligoG-A-colistin 
conjugate and colistin sulfate. 
 
4.5 Discussion  
Here, the antimicrobial activity of OligoG-polymyxin conjugates was assessed 
in a range of Gram-negative MDR pathogens.  Susceptibility testing using MIC 
assays is an extensively used technique allowing the determination of the 
lowest effective dose of an antimicrobial agent and identification of resistant 
bacterial pathogens based on clinical breakpoints.  Indeed, suboptimal doses  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5  Biofilm formation assay showing LIVE (green)/DEAD (red) stained CLSM (aerial and cross-sectional views) of P. 
aeruginosa R22 biofilms grown for 24 h in the presence of free- and OligoG-conjugated colistin.  
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Figure 4.6  Comstat image analysis of P. aeruginosa R22 biofilms grown for 24 h in the presence of free- and OligoG-conjugated 
colistin.  (a) Bio-volume (µm3/ µm2); (b) mean thickness (µm); (c) roughness coefficient and (d) DEAD/LIVE bacteria ratio (± 
SEM; n = 15).  Significant difference is indicated by *, where *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared to 
untreated control.  (One-way ANOVA and Dunnett’s multiple comparisons tests).  
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Figure 4.6  (continued).  
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of antibiotic, poor absorption and extensive clearance of the drug from the 
body, as well as high MIC values are associated with narrow 
pharmacodynamic index and poor clinical outcome (Macgowan, 2008).  
Conflicting recommendations for polymyxin MIC susceptibility breakpoints 
between the Clinical and Laboratory Standards Institute (CLSI) and the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST), have 
been reported.  While the CLSI guidelines (CLSI, 2018) state MIC breakpoints 
for colistin and polymyxin B against P. aeruginosa and Acinetobacter spp., but 
not for the Enterobacteriaceae family, susceptibility breakpoints for polymyxin 
B are not identified at all in the EUCAST report (EUCAST, 2018).  
Consequently, interpretation of breakpoints using CLSI and EUCAST 
guidelines may cause difficulties in identifying resistant bacterial pathogens.  
Then again, there are no current susceptibility breakpoints defined for polymer-
antibiotic conjugates, so the cut-off guidelines for polymyxins were used for 
comparison/guidance. 
Although the polymyxins had already been shown to exhibit significantly higher 
in vitro cytotoxicity, compared to the OligoG-polymyxin conjugates, colistin and 
polymyxin B demonstrated potent antimicrobial activity against a range of MDR 
Gram-negative pathogens.  In this study, OligoG-polymyxin conjugates 
retained equivalent antimicrobial efficacy to the unconjugated antibiotic.  
Typically, OligoG-polymyxin conjugates were below the susceptibility 
breakpoints, except for OligoG-A-polymyxin B, which had MIC values of 4 
µg/ml against four P. aeruginosa, K. pneumoniae and E. coli isolates.   
Since alginates are degraded by bacterial alginate lyase and reinstatement of 
protein bioactivity following enzymatic degradation has already been 
described.  Ferguson et al. (2016) assessed the antimicrobial activity of 
OligoG-polymyxin conjugates in the presence of alginate lyase.  They 
observed no significant change with either amide- or ester-linked conjugates, 
suggesting that, either OligoG degradation was not necessary for antibiotic 
activity, or that the alginate oligomers were degraded by bacterial enzymes or 
those contained within the MH medium.  As polymyxins exhibit their 
antimicrobial activity using cationic amino groups, this might explain why ester-
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linked conjugates are more biologically active compared to amide-linked ones.  
A reduction in the overall cationic charge of polymyxins following conjugation 
of two to four positively charged amino groups to OligoG through amide 
linkage, might contribute to the slightly reduced activity of OligoG-A-polymyxin 
conjugates compared to free drug.  In addition, enhanced vascular 
permeability at sites of infection is expected to promote the accumulation of 
macromolecular conjugates at higher local concentration than in plasma 
(Azzopardi et al., 2013b), suggesting that the stable and controlled release of 
drug from the polymer might achieve better therapeutic activity at a lower dose, 
contributing to reduced toxicity and emergence of resistant bacteria. 
The unique tripartite structure of polymyxin antibiotics is crucial for their 
interaction with bacterial LPS and their antimicrobial efficacy.  Previous studies 
have shown that modification of the cyclic ring or N-terminal fatty acyl chain, 
as well as masking of the cationic amino groups, resulted in complete or partial 
loss of antibacterial activity (Velkov et al., 2010).  For example, 
sulfomethylation of the free polymyxin amino groups yielded less toxic colistin 
and polymyxin B derivatives, but with significant loss of activity (Barnett et al., 
1964).  Furthermore, administration of a dextran 70-polymyxin B conjugate 
with imipenem was effective in reducing lethality in mice modelling E. coli or 
P. aeruginosa septic shock but retained minimal antimicrobial activity by itself 
that might be caused by steric hindrance due to high molecular weight polymer 
binding and blocking of the active sites of the drug (Bucklin et al., 1995, Fuchs 
et al., 1998).  In addition, covalent conjugation of colistin to dextrin was shown 
to significantly reduce the antimicrobial activity of the antibiotic, even after 
amylase triggered release of the drug, in a range of Gram-negative bacteria 
(Ferguson et al., 2014).  It has also been demonstrated that by increasing the 
molecular weight and degree of succinoylation to incorporate carboxyl groups 
in dextrin, the antimicrobial efficacy of dextrin-colistin conjugates markedly 
decreased (Ferguson et al., 2014).  OligoG is a low molecular weight and an 
inherently bioactive polymer, which might explain the substantially improved 
antimicrobial activity of the OligoG-polymyxin conjugates.  Indeed, comparison 
of the MIC values of the OligoG-A-colistin conjugate with previously published 
values for dextrin-A-colistin conjugates (Ferguson et al., 2014), showed that 
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the OligoG-A-colistin conjugates were significantly more active than the 
dextrin-A-colistin conjugates, resulting in 3 to 9-fold lower MIC values. 
The emergence of plasmid-mediated resistance to the polymyxin antibiotics 
may limit the treatment options available to tackle severe clinical infections, 
especially those caused by Enterobacteriaceae, and therefore, may contribute 
to the spread of pan-drug-resistant bacteria (Jeannot et al., 2017).  To date, 
twelve variants of the colistin resistance gene mcr-1 have been identified in 
Enterobacteriaceae from over forty different countries (Wang et al., 2018).  
Particularly disquieting is their spread to IncP plasmids, as IncP plasmids are 
self-transferable and broad host range, so could transfer colistin to many other 
genera outside Enterobacteriaceae including Pseudomonas (Liu et al., 2017, 
Lu et al., 2017).  Unfortunately, OligoG conjugation did not improve the 
antimicrobial activity of colistin and polymyxin B in colistin-resistant E. coli 
strains.  Since polymyxins exert their antimicrobial activity by interacting with 
the lipid A component of LPS located in the outer membrane of Gram-negative 
bacteria, it is not surprising that modifying the structure of the lipid A moiety 
decreased the initial binding between the OligoG-polymyxin conjugates and 
bacteria.  Yang et al. (2017) demonstrated that overexpression of the mcr-1 
gene in E. coli not only had a detrimental effect on the growth rate and viability 
of the host bacteria, but also induced significant morphological changes and 
compromised the structural integrity of the outer membrane (Yang et al., 
2017).  This suggests that these mcr-1 positive E. coli were evidently 
challenged in terms of fitness to find a balance between overcoming colistin 
mediated toxicity and cell survival (MIC = 4-8 µg/ml).  Therefore, other studies 
have explored alternative combination treatment possibilities.  Bulman et al. 
(2017) assessed the antimicrobial activity of commercially available antibiotics 
combined with polymyxin B against an E. coli isolate carrying mcr-1 and NDM-
5 resistance in time-kill studies.  The combination of polymyxin B, amikacin 
and aztreonam completely eradicated the polymyxin and carbapenem 
resistant E. coli pathogen after 26 h, with undetectable bacterial counts for up 
to 240 h.  An alternative approach against Enterobacteriaceae pathogens 
expressing mcr-1 resistance by MacNair et al., (2018) demonstrated that 
colistin could potentiate the activity of conventionally used antibiotics against 
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Gram-positive bacteria, thereby inhibiting bacterial (Gram-negative) growth 
below the clinical susceptibility breakpoints.  In this way, the administration of 
OligoG-polymyxin conjugates might disrupt the bacterial outer membrane 
sufficiently to induce antibiotic uptake and increase the susceptibility to e.g. 
Gram-positive antibiotics such as macrolides, and thus, prevent the 
emergence of resistance due to the absence of selective pressure. 
It was initially hypothesised that conjugation of OligoG to polymyxin would 
prevent the interaction of mucin with the antibiotic.  However, when MIC 
assays were performed in the presence of mucin, the MIC values for OligoG-
polymyxin conjugates and unconjugated OligoG plus polymyxin increased 
significantly showing that OligoG conjugation was unable to prevent mucin 
from binding to and neutralising the polymyxin antibiotics.  These results 
correlated with those of Huang et al., (2015) who showed that addition of mucin 
to the culture medium increased the MIC values of colistin and polymyxin B by 
over 100-fold.  They also demonstrated that antibiotics with a high primary 
amine content and overall polybasic positive charge such as colistin sulfate, 
polymyxin B and tobramycin, had the strongest interaction with mucin 
compared to less basic antibiotics such as ciprofloxacin and daptomycin.  It 
was, therefore, surprising that OligoG conjugation to the polymyxin amine 
groups did not inhibit this interaction.  Previous studies have shown that OligoG 
binds and significantly increases the negative surface charge of respiratory 
mucins via hydrogen bonding (Pritchard et al., 2016) which might contribute to 
the increased attraction of polymyxins to mucins and thus, reduced efficacy.  
While colistin is active against MDR Gram-negative bacteria, mucin binding in 
the airways might reduce its antimicrobial activity and availability, while 
exposure to suboptimal doses of antibiotic could contribute to the development 
of colistin resistance.  Previous studies have shown that high molecular weight 
DNA is highly abundant in sputum constituting up to 10% of its dry weight and 
that it can also interact with antibiotics such as tobramycin, which could lead 
in further reduction of antibiotic potency (Hunt et al., 1995).  Polymer 
conjugation has previously been shown to prevent binding of drugs to plasma 
proteins (Banerjee et al., 2012), therefore it remains to be determined whether 
OligoG might enhance drug efficacy in more complex in vivo systems.  
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OligoG-polymyxin conjugates exhibited a 4-fold decrease in antimicrobial 
activity in AS medium compared to MH broth.  Previous studies have also 
reported 4-fold greater MIC values for colistin in AS medium compared to MH 
broth that has been attributed to altered growth of bacteria, modification of LPS 
structure or direct colistin-mucin interactions (Pritchard et al., 2017).  Recently, 
Schneider-Futschik et al. (2018) investigated the antimicrobial efficacy of a 
series of polymyxin lipopeptides against P. aeruginosa CF isolates grown in 
AS medium and their interaction with sputum biomolecules, including DNA, 
mucin, surfactant, F-actin, LPS and phospholipids.  This study indicated the 
propensity of sputum biomolecules to diminish the antimicrobial activity of 
natural and synthetic polymyxin lipopeptides, but also highlighted the potential 
antibacterial efficacy of an octapeptin A3 lipopeptide carrying four positively 
charged amino groups against P. aeruginosa isolates.  Since two to four 
primary polymyxin amino groups were used for binding to OligoG and stable 
amide bond formation, this might explain the reduced antimicrobial activity 
observed in AS medium of the OligoG-A-polymyxin conjugates. Both, OligoG-
ester-colistin and OligoG-ester-polymyxin B conjugates exhibited 2-fold 
improved efficacy in AS medium compared to MH broth against the E. coli IR57 
isolate, suggesting that ester-linked colistin would have a better therapeutic 
index in vivo.  Other studies have also looked at colistin and LPS interactions.  
It is known that polymyxins bind to and neutralise bacterial LPS (Davies and 
Cohen, 2011).  Even though Roberts et al. demonstrated ~50% reduction in 
the interaction of LPS with dextrin-colistin conjugates compared to colistin 
alone, concentration-dependent inhibition of LPS-induced TNFα secretion by 
human kidney cells and reduced hemolysis of rat erythrocytes was observed 
(Roberts et al., 2016).  The interaction between LPS and OligoG-polymyxin 
conjugates still needs to be explored for their potential use in the treatment of 
systemic sepsis.  Overall, the antimicrobial activity of inhaled colistin is highly 
affected by sputum binding in the airways, but it remains unclear whether 
intravenously administered OligoG-polymyxin conjugates, exhibiting sustained 
and controlled release of antibiotic at the site of infection, could be more 
effective in reducing sputum binding than a rapid and high concentration of 
colistin achieved via inhalation. 
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Studies of the bacterial growth kinetics indicated a dose-dependent response 
to OligoG-colistin conjugates (amide- and ester-linked) and a decreased rate 
of bacterial regrowth.  These results might suggest that the conjugates 
produced a more stable and controlled release of colistin, thereby maintaining 
its concentration within the therapeutic window and prolonging its activity at 
the site of infection.  The sustained release of colistin from PEG due to labile 
ester bonding, lead to similar or improved antimicrobial activity against P. 
aeruginosa and A. baumannii isolates (Zhu et al., 2017).  In this study, higher 
concentrations of free colistin, compared to OligoG-colistin conjugates, were 
required to inhibit bacterial regrowth for up to 48 h.  At the previously 
determined MIC, both OligoG-colistin conjugates showed the longest inhibition 
of bacterial regrowth compared to colistin.  However, the ester-linked 
conjugate delayed the onset of bacterial regrowth for a much longer time 
compared to amide-linked conjugates.  Previous studies have analysed the 
growth pattern of several P. aeruginosa isolates from CF patients in the 
presence of sub-MIC concentrations of individual components or combined 
mixtures of antimicrobial lipopeptide and colistin (De Gier et al., 2016).  They 
revealed that lipopeptide alone (at 4 µg/ml) was ineffective in reducing the 
growth of colistin sensitive and resistant P. aeruginosa, whereas colistin (at 
concentrations of 0.25 and 2 µg/ml respectively), prolonged the lag growth 
phase for up to 4 hours.  The successful synergistic inhibition of bacterial 
growth for > 18 h was achieved when both components were used at the 
individually tested concentrations.  Similarly, OligoG-amide-colistin (1 µg/ml, 
colistin equivalent) and OligoG-ester-colistin (0.5 µg/ml, colistin equivalent) 
conjugates used at their MIC concentrations, delayed the lag phase of P. 
aeruginosa MDR 301 for > 24 h and > 18 h, respectively and changed the rate 
of bacterial growth, suggesting that OligoG-colistin conjugates would have 
better and prolonged therapeutic activity in vivo. 
The combination therapy of two synergistic antimicrobial agents can 
simultaneously enhance the efficacy of each compound and thus, reduce the 
required dosage and toxicity or even broaden the antimicrobial spectrum 
(Riahifard et al., 2017).  Even though OligoG conjugation did not enhance the 
efficacy of colistin in combination with azithromycin, synergistic activity was 
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observed for the OligoG-E-colistin conjugates with azithromycin in an E. coli 
isolate.  It is proposed that colistin may increase the permeability of the 
bacterial outer membrane to azithromycin, which may explain the synergy 
observed between the OligoG-E-colistin conjugate and azithromycin in this E. 
coli pathogen.  Importantly, colistin conjugation to OligoG did not induce an 
antagonistic activity with azithromycin, suggesting that OligoG-colistin 
conjugates and azithromycin could be used clinically in combination with no 
deleterious effects.  Previous studies have demonstrated the ability of OligoG 
to potentiate the antimicrobial efficacy of colistin against the mucoid P. 
aeruginosa NH57388A CF isolate (Hengzhuang et al., 2016).  In this case, 
OligoG alone was also able to enhance the efficacy of azithromycin.  However, 
since it has no MIC value, the FICI cannot be calculated.  Similarly, low 
molecular weight (Mw < 10 kDa) oligosaccharides of alginate and chitosan 
have previously been combined with azithromycin, demonstrating additive and 
synergistic effects against P. aeruginosa, respectively (He et al., 2014). This 
correlates with the results obtained in this study with the OligoG-colistin 
conjugates which also demonstrated additive activity between OligoG-colistin 
conjugates and azithromycin against the P. aeruginosa MDR 301 isolate.  
Importantly, the therapeutic benefits of OligoG-colistin conjugates, in 
combination with azithromycin, might have been underestimated by the 
checkerboard assay, as passive accumulation of conjugates at the site of 
infection due to the EPR effect, and controlled release of the drug from the 
polymer, might enhance the efficacy of azithromycin and thus, reduce the 
doses required to eradicate the pathogen. 
Both amide- and ester-linked OligoG-colistin conjugates markedly disrupted 
the formation of P. aeruginosa biofilms, although, only the OligoG-E-colistin 
conjugate caused actual bacterial clumping (at MIC concentrations and 
above).  Comstat analysis of z-stack images revealed that both OligoG-colistin 
conjugates and colistin sulfate at concentrations below or equal to the MIC, 
were unable to inhibit biofilm growth, leading to a marked increase in biofilm 
biomass and thickness and a decrease in roughness coefficient.  The 
presence of persister cells within the biofilm due to exposure of sub-MIC 
concentrations of antibiotics might explain this phenomenon (Lewis, 2006).  
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Alternatively, OligoG might be broken down by bacterial enzymes and used as 
a carbon source to increase bacterial respiration rate and efficiency of growth 
(Passalacqua et al., 2016).  In addition, Powell et al. (2018) have previously 
shown that OligoG, at concentrations ≥ 0.5% induced bacterial aggregation, 
and at ≥ 2% significantly disrupted P. aeruginosa biofilm formation and growth 
as confirmed by decreased biofilm biomass and thickness, and increased 
roughness coefficient.  
In this Chapter, the antimicrobial efficacy of OligoG-polymyxin conjugates has 
been characterised in vitro, highlighting a potential new clinical therapy for the 
treatment of multidrug resistant bacterial infections.  
 
4.6 Conclusions  
Multi-drug resistance is one of the leading causes of morbidity and mortality 
worldwide.  The recent emergence of resistance to colistin, encoded by mobile 
genetic elements, highlights an urgent need for improved antimicrobials that 
can be delivered to sites of infection.  OligoG-polymyxin conjugates exhibited 
substantial or full retention of antimicrobial activity and controlled release of 
the antibiotic from OligoG resulting in sustained inhibition of bacterial growth.  
OligoG conjugation was unable to inhibit the deleterious effects of mucin 
binding or nutrient-deficient media, nor could it overcome mcr-1 colistin 
resistance.  However, targeted delivery of the antibiotic to sites of infection 
through the EPR effect would potentially maximise its local bioavailability and 
efficacy, while at the same time, minimising any side effects and drug 
resistance.  To investigate further the controlled release of antibiotic, an in vitro 
pharmacokinetic-pharmacodynamic model was developed to compare the 
activity of free- and OligoG-conjugated colistin (Chapter 5).  
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Chapter 5 
 
In vitro  
Pharmacokinetic-Pharmacodynamic 
Model 
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5.1 Introduction  
Characterisation of the pharmacokinetic-pharmacodynamic (PK-PD) profile of 
a drug is an essential step in optimising dosing and predicting its behaviour in 
vivo.  Since polymer conjugation substantially alters the PK-PD properties of 
the attached antibiotic, this chapter aimed to develop an in vitro two-
compartment PK-PD model to characterise drug release from the conjugate 
and compare the antimicrobial efficacy of free- and OligoG-conjugated colistin 
against the MDR A. baumannii 7789 clinical isolate.  A. baumannii is an 
opportunistic pathogen that causes a broad range of clinical infections that are 
associated with significant antibiotic resistance and mortality rates of 8.4-
36.5% (Falagas and Rafailidis, 2007).  Thus, it provided a clinically relevant 
organism to characterise the antimicrobial profile of the OligoG-colistin 
conjugates.  
 
5.1.1 PK-PD models described in the literature 
While MIC susceptibility testing is an important and useful tool for defining the 
potential therapeutic activity of new antimicrobial agents, the static 
concentrations of antibiotic used do not always correlate with the efficacy of 
the drug in vivo.  MIC values are also unable to distinguish between 
bacteriostatic and bactericidal activity, nor can they tell us whether bactericidal 
activity is concentration- or time-dependent or if it has a post-antibiotic effect 
when drug concentrations fall below MIC (Lister, 2006).  Additionally, MIC 
assays are unable to quantify the rate of bacterial killing or identify the 
pharmacodynamic target.  Although animal models have been widely used to 
imitate the characteristics of infection in humans and determine the 
relationships between antibiotic concentrations found in tissue, plasma or 
serum, the differences in animal and human metabolisms and the impact of 
the immune system, complicate the evaluation of antibiotic interactions with 
bacteria (Andes and Craig, 2002).  These limitations have led researchers to 
develop in vitro PK-PD models to predict concentration-time profiles and 
correlate them to antibiotic efficacy at the site of infection.  One of the main 
advantages of employing in vitro PK-PD models is that they simulate human 
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pharmacokinetic properties, allowing the effect of various antibiotic 
concentrations on the rate and extent of bacterial eradication to be determined 
using time-to-kill (TTK) assays (Budha et al., 2009).  Typically, the change in 
viable bacterial counts is monitored over time and quantified at different time 
intervals by various methods (summarised in Table 5.1), thus enabling 
analysis of bacterial growth patterns during drug exposure.  Most in vitro PK-
PD models described in the literature can be classified into one of two models: 
static models (constant antibiotic exposure) that simulate the drug 
concentration at a steady state, or single/multiple compartment models 
(changing antibiotic concentrations) attained by diffusion or dilution to simulate 
multiple dosing (Gloede et al., 2010).   
Conventional static TTK models have been extensively used to study the effect 
of fixed antibiotic concentrations on bacterial growth.  However, these 
approaches are not clinically relevant, as the antibiotic concentration remains 
unchanged throughout the experiment (Owen et al., 2007).  To reflect the 
situation in vivo, and to mimic the elimination half-life of a drug, single 
compartment PK-PD models have been developed, where the systematic loss 
and dilution of the antibiotic is achieved by the continuous pumping of sterile 
media into a central reservoir containing bacteria and the antimicrobial agent 
(Grasso et al., 1978).  Filter membranes and magnetic stirrers have been 
incorporated into these one-compartment models to maintain homogenous 
mixing and prevent bacterial loss from the system, which can cause 
experimental bias (Budha et al., 2009).  Unfortunately, filter membrane 
blockage is common in these modified models, especially when antibiotics with 
short elimination half-lives were analysed (Vaddady et al., 2010).  To 
overcome the loss of viable bacteria from the system, two-compartment PK-
PD models have been constructed, whereby the antibiotic contained in the 
central compartment is physically separated from the bacterial pathogen in the 
peripheral compartment (usually by dialysis membrane) and distributed 
through the compartments using peristaltic pumps (White, 2001).  The 
concentration gradient between the central and peripheral compartments 
induces passive diffusion of the antibiotic across the dialysis membrane, 
exposing the bacteria to fluctuating drug concentrations over time (Ba et al.,  
 
 
Method Description Limitations Reference 
 
Viable bacterial 
counts 
 
Incubation of bacterial samples on agar 
plates by spiral plating or the Miles-Misra 
method followed by bacterial colony 
counting. 
 
 
Caution must be taken to 
avoid an antibiotic carry-over 
effect. 
 
(Jönsson et al., 
2018, Tam et al., 
2005) 
Turbidimetric 
measurements 
Determination of turbidity or cloudiness 
(optical density) of bacterial samples 
spectrophotometrically.  Measurements 
can be directly correlated to bacterial 
concentration. 
 
Not reliable if bacteria form 
clumps in the liquid medium.  
Cannot distinguish between 
live and dead bacteria. 
 
(Li et al., 1993) 
Microscopic counts Determination of bacterial cell numbers 
using Petroff-Hausser counting chambers 
by phase-contrast microscopy.  Trypan 
blue can be used to distinguish between 
live and dead bacteria. 
 
Small cells might be missed 
or miscounted. Labour 
intensive. 
(Dever et al., 1992) 
Bioluminescence 
assays 
Quantification of bacterial intracellular 
ATP content (as a measure of bacterial 
respiration) and correlation to bacterial 
concentration. 
 
Difficult to differentiate the 
intracellular and extracellular 
bacterial ATP. 
 
(Hanberger et al., 
1993) 
 
Table 5.1  Examples of bacterial quantification methods used in time-to-kill assays. 
1
3
0
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2001).  The main drawback of the multi-compartment model has been that they 
can be technically challenging to set up, since they require special equipment 
and software to interpret the results.  
Selecting the most appropriate PK-PD model to characterise the antimicrobial 
profile and controlled release properties of antibiotics contained in complex 
drug delivery systems such as polymer-drug conjugates has been challenging.  
Due to the limitations of conventional PK-PD systems, Azzopardi et al. (2015) 
developed a novel two-compartment dialysis bag model to investigate the 
antimicrobial properties, (including degradation and antibiotic release patterns 
of the dextrin-colistin conjugates), whose content of unmasked colistin 
changed with time.  This model offered a simple and effective way of analysing 
and modifying the composition of the individual compartments.  For example, 
to mimic the pathological conditions of infected tissue, infected wound fluid or 
physiological concentrations of amylase was placed in the outer compartment, 
enabling the pharmacokinetics of enzyme-triggered activation of the dextrin-
colistin conjugate to be studied.  
This study, therefore, aimed to develop a similar in vitro PK-PD model for the 
characterisation of OligoG-colistin conjugates, that allowed differentiation of 
free- and OligoG-conjugated colistin.  Separation of the species was achieved 
by diffusion through a dialysis membrane, using either a Slide-a-lyzer dialysis 
cassette or a dialysis membrane bag, as previously used to study the PK-PD 
parameters of dextrin-colistin conjugates (Azzopardi et al., 2015).  The two-
compartment dialysis bag model was employed to assess the TTK profile of a 
single OligoG-colistin (amide- and ester-linked) conjugate dose.  As previously 
discussed, the concentration gradient between the two compartments was 
used as a driving force to achieve the required fluctuations in drug 
concentrations (Gloede et al., 2010).  
 
5.2 Experimental aims and objectives  
The specific aims of this study were: 
• To determine whether complete release of the antibiotic from OligoG 
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was required for full re-instatement of the antibacterial activity of the 
individual components of the alginate-conjugate. 
• To develop an in vitro two-compartment PK-PD model to compare the 
diffusion profiles of colistin sulfate, OligoG-A-colistin and OligoG-E-
colistin conjugates. 
• To compare the antimicrobial activity and TTK profile of colistin sulfate, 
OligoG-A-colistin and OligoG-E-colistin conjugates against MDR A. 
baumannii 7789.  
 
5.3 Methods 
OligoG-A-colistin (8.8% w/w colistin content, Mw ~22,500 g/mol) and OligoG-
E-colistin (12.9% w/w colistin content, Mw ~14,500 g/mol) conjugates tested 
in this chapter were synthesised and characterised as previously described in 
Chapter 3. For details of bacterial strain used in this study refer to Table 4.1. 
 
5.3.1 Development of the two-compartment PK-PD model using the Slide-
a-lyzer dialysis cassettes 
Initially, sterile Slide-a-lyzer dialysis cassettes (molecular weight cut-off; 
MWCO: 2,000 and 10,000 g/mol) were used to compare the PK-PD profile of 
free- and OligoG-conjugated colistin.  The model consisted of a sealable 
sampling port, an inner compartment (IC; 3 ml) and an outer compartment (OC; 
200 ml) separated by regenerated cellulose membrane as shown in Figure 
5.1.  All model systems were prepared and maintained under aseptic 
conditions.  A summary of the model development is presented in Table 5.2. 
 
5.3.1.1 Phase 1: Method validation using the dialysis cassettes 
A dialysis cassette was filled with PBS containing either the OligoG-colistin 
conjugate or colistin sulfate (10 mg/ml colistin equivalent). The cassette was 
then suspended in sterile PBS (200 ml) in a sterile beaker, sealed with parafilm 
wiped in ethanol and equilibrated under gentle stirring at room temperature for 
5 min.  Samples (100 µl) were collected from the IC or OC at different time 
points (0, 2, 4, 6, 8, 24 and 48 h) and stored at -20°C prior to analysis by BCA  
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Figure 5.1  Representative picture of the two-compartment PK-PD model 
using a Slide-a-lyzer dialysis cassette.  
 
 
 
 
 
Method 
development 
Inner compartment 
(IC; 3 ml) 
Outer compartment 
(OC; 200 ml) 
Sampling method used 
 
Phase 1:  
Method validation 
 
OligoG-colistin conjugates or 
colistin sulfate in PBS (10 mg/ml 
colistin equivalent). 
 
 
PBS 
 
Sample IC and OC; protein 
determination by BCA assay. 
Phase 2:  
Method validation 
MH broth OligoG-colistin conjugates or 
colistin sulfate in MH broth (1 
µg/ml colistin equivalent). 
Sample IC; colistin determination 
by ELISA. 
Sample OC; sterility testing. 
Phase 3:  
Time-to-kill (TTK) 
model 
A. baumannii 7789 in MH broth 
(1 x 107 or 5 x 105 CFU/ml). 
OligoG-colistin conjugates or 
colistin sulfate in MH broth (1 
or 2 x MIC).  
Sample IC; CFU/ml determination 
by colony count. 
Sample OC; sterility testing. 
 
 
Table 5.2  Developmental phases of the PK-PD model using the Slide-a-lyzer dialysis cassettes.  
 
1
3
4
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assay as previously described (Section 2.6.2.3).  
 
5.3.1.2 Phase 2: Method validation using the dialysis cassettes 
To validate and determine the feasibility of the model for TTK studies, total 
colistin content in the IC after 24 h was determined by colistin ELISA as 
described in Chapter 2 (Section 2.6.4.5).  In this instance, the IC contained MH 
broth and the OC contained OligoG-A-colistin, OligoG-E-colistin or colistin 
sulfate (1 µg/ml colistin equivalent) in MH broth.  Sterility of the OC was 
confirmed by sampling a 5 µl drop of the liquid phase and plating it onto a TSA 
plate.  No visible growth following overnight incubation at 37°C was considered 
acceptable. 
 
5.3.1.3 Phase 3: TTK model using the dialysis cassettes 
To analyse the antimicrobial activity of a single dose of free- and OligoG-
conjugated colistin over 8 or 24 h, A. baumannii 7789 (1 x 107 or 5 x 105 
CFU/ml) was added to MH broth in the IC, while the OC contained OligoG-A-
colistin, OligoG-E-colistin or colistin sulfate at 1 or 2 x MIC in MH broth.  The 
colistin equivalent concentrations used were: 
• OligoG-A-colistin: 0.125, 0.25 µg/ml 
• OligoG-E-colistin: 0.125, 0.25 µg/ml  
• Colistin sulfate: 0.25, 0.5, 4 µg/ml (16 x MIC) 
A growth control, with MH broth in the OC, was analysed for up to 24 h.  A 
range of dialysis cassettes with MWCOs of 2,000, 10,000 and 20,000 g/mol 
were tested in the model to facilitate diffusion across the membrane.  Sterility 
of the OC was monitored over 48 h (as described in Section 5.3.1.2).  Samples 
collected at various time points from the IC were characterised for the number 
of colony forming units (CFU/ml) according to the Miles and Misra method 
(Miles et al., 1938).  Briefly, TSA plates were dried in a laminar air flow cabinet 
for 15 min prior to use.  Aliquots of the IC were serially diluted (1:10 in PBS) 
up to 10-8 and 20 µl of each dilution was dropped onto the surface of the dried 
TSA plates in triplicate, allowing the drop to spread naturally.  The TSA plates 
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were left undisturbed to dry, then inverted and incubated at 37°C for 18-20 h.  
The dilution sector with the highest number of discrete, full size colonies 
(usually 2-20 colonies) was recorded and the colony count calculated using 
the formula below:  
CFU/ml = Mean number of colonies counted x 50 x dilution factor 
 
5.3.2 Development of a two-compartment PK-PD model using a dialysis 
bag  
A second PK-PD model was constructed using a regenerated cellulose dialysis 
membrane (MWCO 10,000 g/mol; 24 mm flat width) instead of the Slide-a-
lyzer cassette.  The dialysis membrane was washed and pre-soaked in dH2O 
for 10 min, one end was secured with sterile surgical thread then filled with the 
IC solution (5 ml) before tying the open end in the same way.  The dialysis bag 
was then suspended in a 25 ml beaker containing the OC solution (15 ml) and 
sealed with parafilm, as shown in Figure 5.2.  The beaker was placed in a 
shaking incubator using an orbital agitation of 70 rpm, at 37°C for 48 h.  
Samples (100 µl) were collected from the IC or OC at different time points (0, 
2, 4, 6, 8, 24 and 48 h) and stored at -20°C prior to analysis.  All model systems 
were prepared and maintained under aseptic conditions.  A summary of the 
model development is presented in Table 5.3. 
 
5.3.2.1 Phase 1: Method validation using the dialysis bag model 
To validate the model set-up, a modified version of the method described in 
5.3.1.1 was used.  The model was set up as described in Table 5.3 and 
samples were analysed over 48 h for protein content by BCA assay (Section 
2.6.2.3).  
 
5.3.2.2 Phase 2: TTK model using the dialysis bag 
To assess TTK, A. baumannii 7789 (5 x 105 CFU/ml) was added to the MH 
broth in the OC, while the IC contained OligoG-A-colistin or OligoG-E-colistin 
at 1 or 2 x MIC or colistin sulfate at 1 x MIC (considering the total volume in 
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Figure 5.2  Representative picture of the two-compartment PK-PD model 
using a dialysis bag.  
 
 
 
 
 
 
 
Method 
development 
Inner compartment  
(IC; 5 ml) 
Outer compartment  
(OC; 15 ml) 
Sampling method used 
 
Phase 1:  
Method validation 
 
OligoG-colistin conjugates or 
colistin sulfate in PBS (10 
mg/ml colistin equivalent). 
 
 
PBS 
 
Sample IC and OC; protein 
determination by BCA assay. 
Phase 2:  
Time-to-kill (TTK) 
model 
OligoG-colistin conjugates or 
colistin sulfate in PBS (1 or 2 x 
MIC). 
 
A. baumannii 7789 in MH 
broth (5 x 105 CFU/ml). 
Sample OC; CFU/ml determination 
by colony count. 
 
Table 5.3  Developmental phases of the PK-PD model using the dialysis bag.  
 
1
3
8
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the system) in PBS.  The colistin equivalent concentrations used were: 
• OligoG-A-colistin: 0.125, 0.25 µg/ml 
• OligoG-E-colistin: 0.125, 0.25 µg/ml  
• Colistin sulfate: 0.25 µg/ml 
A growth control, with PBS in the IC, was analysed for up to 48 h.  Sterility of 
the OC was tested over 48 h (as described in Section 5.3.1.2).  Samples 
collected at various time points from OC were characterised for the bacterial 
number of colony forming units (CFU/ml) as described in Section 5.3.1.3.  
Antibiotics were considered bactericidal if the reduction in viable bacterial 
counts was ≥ 3 log10 CFU/ml (equivalent to 99.9% of the initial inoculum) and 
bacteriostatic if the decrease was < 3 log10 CFU/ml (CLSI, 1999, Levison and 
Levison, 2009). 
 
5.4 Results  
5.4.1 Characterisation of the two-compartment PK-PD model using Slide-
a-lyzer dialysis cassettes 
Phase 1:  Typically, the protein concentration in the IC markedly decreased 
over the 48 h time period which mostly correlated with a reciprocal increase of 
the protein concentration in the OC (Figures 5.3 and 5.4).  As expected, the 
diffusion of free colistin was faster and greater than that of the (much larger) 
conjugates.  When OligoG-colistin conjugates were placed inside the 2,000 
g/mol MWCO dialysis cassettes, the protein content in the OC remained below 
the limit of quantification throughout the experiment.  In contrast, while 
conjugate diffusion using the 10,000 g/mol MWCO dialysis cassette was 
greater, it still failed to reach the same levels as that of the free colistin, and 
neither the ester- or amide- linked colistin conjugates caused a substantial 
increase in protein concentration in the OC (Figures 5.3b and 5.4b).  Also, the 
levels of both conjugates failed to fall below 4 mg/ml using the 2,000 g/mol 
MWCO dialysis cassettes from the 8 h time point onwards, (possibly 
suggestive of membrane saturation or blockage) whilst levels using the larger 
10,000 g/mol MWCO dialysis cassette continued to fall over the duration of  
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(a) 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 5.3  Phase 1 method validation: Colistin concentration, measured 
by BCA assay, in the (a) IC and (b) OC following diffusion through 2,000 
g/mol MWCO dialysis cassettes over 48 h.  Data represents mean colistin 
concentration ± SD (n = 3).  
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Figure 5.4  Phase 1 method validation: Colistin concentration, measured 
by BCA assay, in the (a) IC and (b) OC following diffusion through 10,000 
g/mol MWCO dialysis cassettes over 48 h.  Data represents mean colistin 
concentration ± SD (n = 3). 
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the 48 h experiment. 
Phase 2:  Colistin content in the IC was only determined at the 24 h time point, 
as formation of a large pellet after centrifugation of the samples during colistin 
extraction caused substantial variation in the colistin concentrations detected 
by the ELISA (Figure 5.5).  Despite these issues however, up to ~73% of the 
original dose was detected in the IC after 24 h (Table 5.4).  
 
Diffusion of colistin into the IC was significantly lower than that of the OligoG-
E-colistin conjugate for both MWCO membranes (p < 0.05).  When the OligoG-
A-colistin conjugate was placed in the OC, the colistin concentration in the IC 
at 24 h was greater than seen with colistin sulfate, but still less than with the 
ester-linked conjugate.  While the MWCO of the membrane (2,000 or 10,000 
g/mol) did not greatly alter the colistin concentration in the IC in the 
experiments using either OligoG-E-colistin or colistin, markedly more colistin 
was detected in the IC when OligoG-A-colistin was tested using the 10,000 
MWCO cassette however this was not significant, (p > 0.05), according to an 
unpaired t-test.  
Phase 3:  When A. baumannii 7789 were added to the IC, growth in the IC and 
sterility of the OC was maintained for up to 48 h.  However, as previously 
determined using either 1 or 2 x MIC, OligoG-colistin conjugates (amide and 
ester linked) or colistin sulfate had no effect in reducing viable bacterial colony 
counts using either the 2,000 or 10,000 g/mol MWCO dialysis cassettes with 
a starting bacterial inoculum of 1 x 107 CFU/ml (Figures 5.6 and 5.7).  Even 
when the starting inoculum was reduced to 5 x 105 CFU/ml and colistin sulfate  
    Treatment 
% of original dose in IC at 24 h 
2,000 MWCO 10,000 MWCO 
OligoG-A-colistin 14.7 34.3 
OligoG-E-colistin 72.6 65.6 
Colistin sulfate 1.1 4.9 
 
Table 5.4  Summary of the percentage of the original colistin dose detected in 
the IC after 24 h. 
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Figure 5.5 Phase 2 method validation: Quantification of colistin 
concentration, measured by ELISA, in the IC after 24 h using (a) 2,000 and 
(b) 10,000 g/mol MWCO dialysis cassettes.  Data represents mean ± SD 
(n = 2).  Significant difference is indicated by *, where *p < 0.05, **p < 0.01, 
***p < 0.001.  (One-way ANOVA and Tukey’s multiple comparisons tests). 
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Figure 5.6  Phase 3: Effect of antibiotic treatments (at 1 x MIC) on the cell 
viability of A. baumannii 7789 in a TTK model using (a) 2,000 g/mol and 
(b) 10,000 g/mol MWCO dialysis cassettes.  Data represents mean 
bacterial colony count ± SD (n = 3).  The lower limit of detection (102 
CFU/ml) is represented by the dotted line.  
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Figure 5.7  Phase 3: Effect of antibiotic treatments (at 2 x MIC) on the cell 
viability of A. baumannii 7789 in a TTK model using (a) 2,000 g/mol and 
(b) 10,000 g/mol MWCO dialysis cassettes.  Data represents mean 
bacterial colony count ± SD (n = 3).  The lower limit of detection (102 
CFU/ml) is represented by the dotted line. 
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was tested using dialysis cassettes with a MWCO of up to 20,000 g/mol, no 
difference in bacterial viability counts was observed (Figure 5.8).  Interestingly, 
no viable bacterial colonies were detected over 24 h when colistin sulfate was 
tested at 16 x MIC using the 10,000 MWCO cassette, proving that the model 
was effective when the antibiotic concentration used was sufficiently high 
(Figure 5.8).   
 
5.4.2 Characterisation of the two-compartment PK-PD model using 
dialysis tubing 
Phase 1:  As observed in previous experiments, an increase in the 
concentration of colistin in the OC was mirrored by a decrease in its 
concentration in the IC and this was also true of the PK-PD model using 
dialysis tubing described here (Figure 5.9).  The concentration of colistin 
detected in the OC was significantly higher than that detected in experiments 
using dialysis cassettes (p < 0.05, according to unpaired t-test).  In addition, 
using the dialysis bag model, the colistin concentration increased faster when 
colistin sulfate was placed in the IC, compared to the OligoG-colistin 
conjugates (time to reach 1 mg/ml in the OC: 2.83 h [colistin] < 10.47 h [OligoG-
E-colistin] < 17.35 h [OligoG-A-colistin]). 
Phase 2:  When A. baumannii 7789 were added to the OC, growth in the IC 
and sterility of the IC was maintained for up to 48 h.  Colistin sulfate, at its 
previously determined MIC (0.25 µg/ml) and OligoG-E-colistin conjugate at 2 
x MIC (0.25 µg/ml) showed rapid bacterial killing that reached a maximum 
reduction in viable bacterial counts after 4 h.  For both treatments, colony 
counts were ~5-fold lower than the control and ~2-fold lower than the initial 
starting bacterial concentration (Figure 5.10).  No significant effect on bacterial 
growth was observed with OligoG-A-colistin conjugates, even at 2 x MIC. 
 
5.5 Discussion 
An in vitro two-compartment PK-PD model was developed and validated to 
compare the diffusion and antimicrobial effectiveness of free- and OligoG-
conjugated colistin.  The two conjugates resulting from the different  
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Figure 5.8  Phase 3: Effect of colistin sulfate on the viability of A. 
baumannii 7789 in a TTK model using 2,000-20,000 g/mol MWCO dialysis 
cassettes.  All experiments were performed using 2 x MIC or 16 x MIC, 
except for the 20,000 g/mol MWCO experiment, which used colistin at 1 x 
MIC.  Data represents mean bacterial colony count ± SD (n = 3).  The lower 
limit of detection (102 CFU/ml) is represented by the dotted line. 
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Figure 5.9  Phase 1 method validation: Colistin concentration, measured 
by BCA assay, in the (a) IC and (b) OC following diffusion through dialysis 
tubing over 48 h.  Data represents mean colistin concentration ± SD (n = 
3). 
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Figure 5.10  Phase 2: Effect of antibiotic treatments on the viability of A. 
baumannii 7789 in a TTK model using dialysis tubing.  Data represents 
mean bacterial colony count ± SD (n = 3).  Lower limit of detection (102 
CFU/ml) is presented as dotted line. 
150 
 
conjugation chemistries using the reversible (ester) or irreversible (amide) 
linkers were analysed to determine whether complete release of colistin at the 
site of infection is required for full re-instatement of antibacterial activity.   
Initially, dialysis cassettes were employed for studying the PK-PD profile of 
free- and OligoG-conjugated colistin.  However, it soon became apparent that 
they presented specific limitations compared to the dialysis bag model.  A 
major issue observed in these studies was potential binding of colistin to the 
dialysis cassette. Although the dialysis membrane used in Slide-a-lyzer 
cassettes is made of low binding regenerated cellulose, (which is the same 
material as that used in the dialysis tubing), the casing of the cassettes is made 
of acrylonitrile butadiene styrene (ABS) plastic.  Previous studies have shown 
that colistin adsorbs to the surface of a wide range of plastics, which can 
significantly alter the accuracy of susceptibility testing, including MIC and TTK 
assays (Karvanen et al., 2017).  The extent of colistin adherence to the surface 
of the plastics is highly dependent on the nature of the plastic, as well as the 
coating and the surface charge applied during the manufacturing processes 
(Albur et al., 2014).  Colistin quantification in a “sham” TTK assay in the 
absence of bacteria performed using liquid chromatography-tandem mass 
spectrometry (LC-MS/MS), had previously shown substantial binding and loss 
of antibiotic activity in polystyrene test tubes (Karvanen et al., 2017).  The 
addition of a surfactant, such as polysorbate 80, has been shown to counter 
such effects, reducing polymyxin adherence to the surface of polystyrene 
plates, and leading to 4-8-fold lower estimation of MIC values against 
Enterobacteriaceae, Acinetobacter spp. and P. aeruginosa pathogens (Hindler 
and Humphries, 2013, Sader et al., 2012).  Polysorbate 80 was not used in 
these studies.  Due to the amphiphilic structure and cationic charge of 
polymyxins, it is not surprising that colistin readily adheres to the negatively- 
charged surfaces of commonly used laboratory materials made from 
polystyrene or polypropylene.  As expected, a reduction in the cationic charge 
of colistin by covalent attachment of OligoG did not improve the diffusion of the 
antibiotic or neither there was a difference between the ester- and amide-
linked conjugates during the validation phase. 
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Another challenge encountered in these studies was the large quantity of 
sediment produced following centrifugation during the colistin extraction 
process, which affected not only the accuracy but also the reliability of the 
results from the colistin ELISA.  MH broth is a complex medium containing a 
high concentration (17.5 g/L) of proteins and peptides, which may account for 
the precipitate. Quantification of polymyxins in biological fluids using 
conventional methods has proved to be limited due to their lack of sensitivity, 
weak UV absorption and the absence of intrinsic fluorescence requiring the 
derivatisation of the molecule (Li et al., 2001).  Previous studies have 
established a high-performance liquid chromatography (HPLC) method, based 
on the formation of fluorescent derivatives of polymyxin B, colistin sulfate or 
CMS, for reproducible and rapid antibiotic quantification in human plasma or 
urine (Cao et al., 2008, Li et al., 2002, Li et al., 2001).  Recently, a liquid 
chromatography-mass spectrometry method was developed and validated for 
polymyxin B quantification in MH and tryptone soya broths (Cheah et al., 
2014).  The accuracy and reliability of the method was not affected by the 
presence of high bacterial numbers of A. baumannii, P. aeruginosa or K. 
pneumoniae or by co-administration of different classes of antibiotics with 
polymyxin B, all factors indicative of the better applicability and higher 
sensitivity of this method compared to the MaxSignal® ELISA kit that was 
actually used here.  Nevertheless, significantly less colistin was detected in the 
IC in the colistin sulfate experiments, compared to the OligoG-colistin 
conjugates, perhaps due to higher protein binding in the MH broth.  Also, the 
concentration of colistin detected in the IC from OligoG-E-colistin was 
markedly higher than with OligoG-A-colistin, presumably due to colistin release 
by hydrolysis of the ester bond.  
Non-specific binding to the dialysis cassette housing, as well as the low MIC 
values (< 0.25 µg/ml) of colistin and both of the conjugates, might explain the 
lack of activity observed in the TTK assays against A. baumannii 7789.  In 
addition, premature degradation of colistin sulfate or OligoG-colistin 
conjugates, as well as the decreased surface area to volume ratio due to 
sampling, might further have caused a significant loss of activity of free- and 
OligoG-conjugated colistin.  Even though the dialysis cassettes offered a 
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simple and fast method for a PK-PD characterisation of OligoG-colistin 
conjugates, these studies have proved the lack of feasibility of the model for 
microbiological use.  
Several technical aspects such as the volume, time, MWCO of the dialysis 
membrane, temperature and agitation rate were considered for reproducible 
and reliable PK-PD model development.  For instance, the volume ratio of 1: 
4 between the inner and outer compartments created a concentration gradient 
for passive diffusion and maximised the surface area/volume ratio (White, 
2001).  An incubation time of 48 h was chosen for determination of viable 
bacterial counts to allow sufficient time to observe whether the OligoG-colistin 
conjugates exhibited the prolonged efficacy and controlled release of colistin 
that was previously observed with dextrin-colistin conjugates (Azzopardi et al., 
2015).  A dialysis membrane with a MWCO of 10,000 g/mol was chosen to 
allow efficient diffusion of colistin between compartments, but that was also 
able to restrict the transfer of bacteria to the IC (Nielsen and Friberg, 2013).  
Bacterial infections are commonly characterised by disrupted “leaky” 
vasculature at sites of infection which occur due to large gaps between the 
endothelial cell junctions that vary from 20 to 200 kDa (Markovsky et al., 2012).  
Thus, the 10 kDa MWCO dialysis membrane provided a clinically-relevant pore 
size that would model a key aspect of infected tissues.  Many different types 
of the dialysis membranes (artificial and natural) have been used in the 
development of the PK-PD models (Gloede et al., 2010), but due to better 
chemical compatibility, heat stability, hydrophilicity and high purity, 
Spectra/Por® 7 regenerated cellulose membrane was selected to prevent loss 
and non-specific binding of the antibiotic (Li et al., 2003b).  A temperature of 
37°C and agitation rate of 70 rpm was selected to ensure homogenous mixing 
and optimum bacterial growth, while preventing bacterial attachment and 
blockage of the membrane (Azzopardi et al., 2015, Schwartz et al., 2008).   
As expected, due to its lower molecular weight, diffusion of colistin was 
considerably faster than that of either of the OligoG conjugates and was 
mirrored by an increase in drug concentration in the OC over 48 h.  Also, the 
diffusion of colistin when OligoG-E-colistin conjugate was contained in the IC 
153 
 
was more pronounced than that of the amide linked conjugate, presumably 
due to the lability of the ester bond.  The suitability of the dialysis bag model 
for characterisation of the TTK profile of OligoG-colistin conjugates and colistin 
sulfate was confirmed by the growth control of A. baumannii 7789 over the 
time-course of the experiment, reaching the stationary growth phase between 
108-109 CFU/ml.  The TTK curves demonstrated rapid and substantial bacterial 
killing in the presence of colistin sulfate at its MIC (0.25 µg/ml) and the OligoG-
E-colistin conjugate at 2 x MIC (0.25 µg/ml), although marked bacterial re-
growth was observed at 24 h.  Previous TTK studies demonstrated hetero-
resistance of A. baumannii clinical isolates to colistin that contributed to 
significant bacterial regrowth at 24 h at 32 x MIC (Li et al., 2006) and 64 x MIC 
(Owen et al., 2007).  In these studies, the maximum efficacy of colistin sulfate 
and OligoG-E-colistin conjugate was achieved at 4 h, however, since the viable 
bacterial counts were reduced by < 3 log10 CFU/ml compared to the initial 
inoculum, this was indicative of bacteriostatic activity only.  Similarly, previous 
TTK studies have also demonstrated the bacteriostatic activity of colistin at its 
MIC in A. baumannii clinical isolates, showing a 2-fold decrease in CFU/ml 4-
6 h post-dose (Tan et al., 2007).  Colistin only becomes bactericidal at higher 
drug concentrations (Owen et al., 2007), for instance, significant bactericidal 
activity was observed when carbapenem-resistant A. baumannii isolates were 
treated with colistin at ≥ 4 x MIC (Song et al., 2007).  These observations 
support the clinical limitations of conventional colistin dosing due to 
concentration-dependent nephrotoxicity, which may limit the amount of drug 
that can safely be administered.   
The findings of this study suggest that the OligoG-E-colistin conjugate may be 
more suitable clinically as it exhibited equivalent antimicrobial activity to colistin 
at 0.25 µg/ml, but with significantly lower cytotoxicity in human kidney cells 
(Chapter 3). After systemic administration of CMS, plasma colistin 
concentration at steady-state is typically between 0.5 to 4 µg/ml (Garonzik et 
al., 2011, Nation et al., 2016).  As nephrotoxicity is the clinically limiting factor 
in colistin dosing, a plasma concentration of 2 µg/ml has been recommended 
as a target for bacterial pathogens with MIC values ≤ 1 μg/ml (Landersdorfer 
and Nation, 2015).  Similarly, a plasma concentration threshold of 2.42 µg/ml 
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has been defined to avoid acute kidney injury (Horcajada et al., 2016, Sorlí et 
al., 2013).  Meanwhile, the clinical susceptibility breakpoint for Acinetobacter 
spp. against colistin is 2 µg/ml (CLSI, 2018, EUCAST, 2018), which suggests 
a very narrow therapeutic index in vivo.  Since the OligoG-E-colistin conjugates 
are expected to accumulate to higher concentrations within infected tissues 
due to the EPR effect, higher bactericidal concentrations (> 0.25 µg/ml, 
equivalent to > 2 x MIC) could theoretically be achieved more readily than the 
conventional antibiotic.  Moreover, prolonged antimicrobial activity of the 
conjugate, as well as reduced cytotoxicity and emergence of resistance 
support the suitability of OligoG-conjugated antibiotics for therapeutic use.   
Using a similar two-compartment PK-PD model, sustained release of colistin 
over 48 h as well as a concentration-dependant effect was also reported for 
dextrin-colistin conjugates (Azzopardi et al., 2015).  As the dextrin-colistin 
conjugate contained an amide bond, ‘unmasking’ of colistin relied on α-
amylase-mediated degradation of dextrin. The α-amylase triggered activation 
of dextrin-EGF conjugate has also been shown to cause controlled release of 
growth factor in chronic wound fluid over 48 h (Hardwicke et al., 2010).  Since 
alginate lyase is only secreted by specific bacteria and was not added to this 
PK-PD model, this might explain the lack of antimicrobial efficacy observed 
with the OligoG-A-colistin conjugate.  These findings suggest that ‘unmasking’ 
or release of colistin is required for, and indeed a pre-requisite for, 
reinstatement of antibiotic activity.  Nevertheless, alginate lyase, isolated from 
cystic fibrosis patients infected with K. pneumoniae and P. aeruginosa, was 
able to degrade alginate (Simpson et al., 1993), suggesting that locally- 
triggered degradation of OligoG at sites of bacterial infection could readily 
release colistin from the conjugate at the target site.  While these findings 
confirm the potential suitability of these conjugates for therapeutic utility, they 
also demonstrate that colistin release from amide-linked conjugates relies on 
passive targeting to sites of infection by the EPR effect and the existence of 
alginate lyase-producing bacteria in these infected tissues.  What is more, the 
OligoG-A-colistin conjugate might also exhibit reduced activity due to 
remaining sugar residues attached to the antibiotic, which would not be 
present on colistin released from the ester-linked conjugates. 
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5.6 Conclusions  
The two-compartment PK-PD dialysis bag system has been developed and 
validated, showing the compatibility and reproducibility of the model to 
characterise OligoG-colistin conjugates in respect of in vitro drug release and 
antimicrobial activity.  Although no significant activity was observed with 
OligoG-A-colistin conjugates, up to 2 x MIC, a substantial reduction in viable 
A. baumannii 7789 was observed in the presence of OligoG-E-colistin at 2 x 
MIC (0.25 µg/ml).  Furthermore, whilst OligoG-E-colistin exhibited equivalent 
antimicrobial efficacy to conventional colistin, conjugates have the added 
advantage of reduced nephrotoxicity.  Passive targeting and accumulation of 
OligoG-colistin conjugates at sites of infection, followed by release of the 
antibiotic would maximise therapeutic effectiveness and minimise systemic 
side effects.  Due to its intrinsic antimicrobial activity, Chapter 6 aimed to 
investigate the diffusion, distribution and efficacy of OligoG in bacterial 
biofilms. 
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Diffusion Modelling and  
Antimicrobial Activity of OligoG  
in Bacterial Biofilms 
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6.1 Introduction 
According to the Centers for Disease Control and Prevention, more than 65% 
of human bacterial infections are associated with biofilm formation (Potera, 
1999).  Chronic respiratory diseases are commonly characterised by 
colonisation of opportunistic pathogens such as P. aeruginosa, which further 
contributes to inflammation and severity of the disease and eventually, 
accelerates the decline in pulmonary function (Bhagirath et al., 2016).  Since 
OligoG exhibits intrinsic antibacterial activity, this chapter aimed to develop a 
diffusion model to investigate the ability of OligoG to alter biofilm structure and 
architecture.  Initial experiments examined biofilm formation of a cystic fibrosis 
isolate P. aeruginosa NH57388A using a Transwell model.   
Secretion of extracellular polymeric substance (EPS) by bacterial pathogens 
such as E. coli facilitates, not only the adhesion of bacteria to solid surfaces, 
but also plays an important role in biofilm development and maturation 
(Tsuneda et al., 2003).  In additional experiments, confocal microscopy was 
employed to visualise the localisation, antimicrobial activity and interaction of 
the alginate oligomers with EPS using fluorescently-labelled OligoG in E. coli 
IR57 biofilms. 
 
6.1.1 Extracellular polymeric substance (EPS)  
Genotypic adaptations in bacteria that result in transition from acute to chronic 
infection are associated with phenotypic alterations in a number of factors, 
including biofilm formation, EPS production, antibiotic resistance, quorum 
sensing, virulence factors production, hypermutability and formation of small 
colony variants (Cullen and McClean, 2015).  The EPS is a complex, highly 
heterogeneous biopolymer whose secretion is initiated by bacteria during the 
attachment stage of biofilm formation and continues throughout maturation of 
the biofilm (Vu et al., 2009).  Water accounts for up to 97% of the composition 
of EPS and plays a major role in nutrient distribution within the biofilm matrix 
(Sutherland, 2001b).  The remaining constituents of EPS, such as proteins, 
polysaccharides, glycolipids and nucleic acids, provide structural stability and 
rigidity for the biofilm.  The proportion of bacterial cells in a biofilm typically 
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varies from 5% to 35% while the remaining 65% to 95% of the volume 
constitutes the EPS matrix (Jamal et al., 2018).  The chemical composition of 
EPS in Gram-negative bacteria is composed of various functional groups such 
as amino, phosphate or carboxyl, which contribute to the neutral or polyanionic 
nature of the matrix (Tsuneda et al., 2003).  In addition, the abundance of ketal-
linked pyruvates and uronic acids such as D-glucuronic, D-galacturonic or 
mannuronic acid in EPS further enhances the negative charge of the structure 
(Vu et al., 2009).  EPS chelates divalent cations such as calcium and 
magnesium and facilitates cross-linking in the biofilm (Aslam et al., 2008).  
Conversely, the EPS in Gram-positive bacteria such as Staphylococci is 
mostly cationic in nature (Donlan, 2002).  Importantly, EPS acts as a protective 
barrier against antimicrobial agents, environmental stress and the host 
immune response, and also promotes the sorption of organic compounds or 
inorganic ions, facilitates the exchange of genetic information within the biofilm 
and provides a source of carbon, nitrogen and phosphorus for energy 
(Flemming, 2016, Flemming et al., 2016).  
Previous studies have shown the ability of OligoG to bind to the cell surface of 
Gram-negative bacteria (Powell et al., 2014) and facilitate the disruption of 
mucoid P. aeruginosa NH57388A biofilms EPS matrix (Powell et al., 2018).  
Therefore, it was interesting in these studies to establish whether OligoG can 
also interact with the EPS component and thus, initiate the disruption of other 
Gram-negative biofilms such as E. coli.  
 
6.1.2 Selection of fluorescent probes  
Fluorescent labelling has been used extensively to analyse real-time bacterial 
responses to antimicrobial agents and to monitor actual localisation of these 
antibiotics within biofilms (Stone et al., 2018).  Previously, intrinsically 
fluorescent antibiotics such as tetracyclines or fluoroquinolones were 
employed to study the movement of drugs across the bacterial membrane and 
determine their intracellular accumulation (Du Buy et al., 1964, Kaščáková et 
al., 2012).  However, for antibiotics with no intrinsic fluorescence, the covalent 
coupling of a fluorophore to the antimicrobial agent is required.  Selection of 
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an appropriate fluorescent probe is essential to ensure successful visualisation 
of OligoG within the bacterial biofilm.  Several important characteristics such 
as initial brightness, photostability, molecular weight, availability of functional 
groups and hydrophilicity of the fluorescent probe need to be considered.  
Ideally, conjugation of a fluorophore to an antimicrobial agent should not alter 
its physicochemical features, conformation, cellular distribution or efficacy 
(Stone et al., 2018).   
Previous studies have shown the propensity of hydrophobic probes to adhere 
to the cell surface by non-specific interactions (Zanetti-Domingues et al., 2013) 
which could significantly modify the localisation and anti-biofilm effectiveness 
of the antimicrobial to which they are coupled. Therefore, in the case of OligoG, 
Texas Red (TxRd) and Oregon Green (OrGr) (Table 6.1) were chosen for 
conjugation as they have been extensively used to study the cellular 
internalisation of various polymers and therapeutic drugs (Chvatal et al., 2008, 
Richardson et al., 2008, Seib et al., 2007).  To study the effect of polymer 
architecture on cellular pharmacokinetics, OrGr-labelled linear and branched 
polyethylenimines (PEIs) and cationic polyamidoamine (PAMAM) dendrimers 
were analysed in B16F10 murine melanoma cells using flow cytometry and 
confocal microscopy (Seib et al., 2007).  The localisation and intracellular fate 
of OrGr-labelled dextrin, HPMA and PEG has been studied in several different 
cell lines (Richardson et al., 2008).  Additionally, the internalisation and 
endocytic fate of OrGr-labelled dextrin-phospholipase A2 conjugate in the 
breast cancer cell line, MCF-7, was also analysed using confocal microscopy 
and flow cytometry (Ferguson et al., 2010b).   
In addition, TxRd labelling has previously been used to analyse gentamicin 
uptake and intracellular accumulation in S. aureus biofilms (Henry-Stanley et 
al., 2014) and E. coli (Cui et al., 2016).  In addition, TxRd-labelled dextran was 
used to confirm the localisation and trafficking of highly-fluorescent 
nanoparticles to lysosomes in a mouse macrophage cell line (Fernando et al., 
2010).  Binding of TxRd-labelled lectin to specific sugar residues within the 
EPS structure of Sphingomonas biofilms has also been demonstrated 
(Johnsen et al., 2000).  
 
 
 
Fluorescent probe  
properties 
Texas Red Oregon Green 
 
Molecular weight (g/mol) 
 
 
690.87 
 
496.47 
Molecular formula 
 
C36H42N4O6S2 C26H22F2N2O6 
Reactive group 
 
Primary amine Primary amine 
Solubility  
 
DMSO or DMF DMF 
Molar extinction coefficient  
(cm−1M−1) 
 
90,000 75,000 
Excitation/emission (nm) 
  
596/615 485/520 
Fluorescent quenching 
 
Minimal concentration- and pH-dependent 
fluorescent quenching 
 
Minimal concentration- and pH-dependent 
fluorescent quenching 
Previous studies using 
labelled polymers  
Alginate (Powell et al., 2018), pentosan 
polysulphate (Anees, 1996), poly(methyl 
methacrylate) (Roth et al., 2009), dextran (Lin et al., 
2017, Lou et al., 2016), poly(tert-butyl acrylate)-
block-poly[(2-hydroxyethyl methacrylate)-random-
(succinyloxyethyl meth acrylate) (Li et al., 2002) 
 
Dextrin, PEG, HPMA  (Richardson et al., 2008, 
Barz et al., 2010a), poly(β-amino ester) 
(Bechler and Lynn, 2011), PGA (Eldar-Boock et 
al., 2011), PEIs, PAMAM dendrimers (Morris et 
al., 2017, Seib et al., 2007), p(HPMA)-b- 
poly(L-lactide) copolymers (Barz et al., 2010b) 
 DMF, N,N-dimethylformamide. 
Table 6.1  Characteristics of Texas Red (TxRd) and Oregon Green (OrGr) fluorescent probes and their use in previous polymer-
labelling studies. 
1
6
0
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To investigate localisation of the fluorescently-labelled OligoG within the 
biofilm structure, it was important for selected probes to display both minimal 
concentration- and pH-dependence of fluorescent output, which otherwise, 
could trigger fluorescent quenching of the probe.  Previous studies have shown 
a less than optimal bell-shaped concentration-dependent fluorescent 
quenching of free- and HPMA copolymer-bound doxorubicin which on the 
other hand, was independent of pH 5.4-7.4 (Seib et al., 2006).  In contrast, 
minimal concentration- and pH-dependent fluorescent quenching was 
reported for both OrGr-labelled linear and branched PEIs and cationic PAMAM 
dendrimers (Seib et al., 2007).  Furthermore, a linear correlation between 
TxRd concentration and fluorescence yield was demonstrated which was 
unaffected at both pH 5 and 7 (Pritchard, 2014).  
Fluorescent stains can also be used to target different, specific components of 
the biofilm structure including metabolic enzymes, DNA, proteins or 
polysaccharides to, for example, assess bacterial viability after exposure to 
various antimicrobial agents (Baudin et al., 2017, Palmer and Sternberg, 1999, 
Zhou et al., 2014).  Here, to more fully elucidate the role of OligoG in biofilm 
disruption, SYTO-9 (green fluorescent nucleic acid stain) and Concanavalin A 
(ConA; red fluorescent α-D-mannose and α-D-glucose EPS stain) were used 
to evaluate the localisation and disruption of E. coli IR57 biofilms by TxRd-
OligoG or OrGr-OligoG, respectively, using confocal laser scanning 
microscopy (CLSM). 
 
6.2 Experimental aims and objectives 
The specific aims of this study were: 
• To develop a Transwell diffusion model to assess the disruption of P. 
aeruginosa NH57388A biofilms after OligoG treatment. 
• To synthesise and characterise TxRd- and OrGr-labelled OligoG.  
• To assess the disruption of E. coli IR57 biofilms after exposure to 
OligoG. 
• To study the localisation of TxRd-OligoG conjugate in E. coli IR57 
biofilms. 
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• To study the interaction of OrGr-OligoG conjugate with the EPS 
component of E. coli IR57 biofilms. 
 
6.3 Methods  
For details of strains used in this study refer to Chapter 4 (Table 4.1). 
 
6.3.1. Development of a Transwell diffusion model 
A Transwell model system was constructed to measure the diffusion of 
rhodamine through a biofilm after exposure to an antimicrobial agent where 
greater diffusion of the fluorescent probe corresponded to greater disruption of 
the biofilm.  The model used 6.5 mm Transwell inserts, where the upper 
(donor) and lower (acceptor) compartments (wells) were separated by a 
microporous membrane (0.4 µm pore size) as shown in Figure 6.1. 
 
6.3.1.1 Validation of the Transwell diffusion model 
To begin with, the feasibility of using the Transwell model for biofilm disruption 
studies was analysed.  Overnight bacterial cultures (Section 2.6.4.3) of P. 
aeruginosa NH57388A were adjusted to 1 x 108, 1 x 106, 1 x 104 and 1 x 102 
CFU/ml in MH broth and added to the upper donor well (100 µl per well).  After 
incubating the plate at room temperature for 1 h, 150 µl of MH broth was placed 
into the donor well and 1.1 ml into the acceptor well.  The plate was wrapped 
in parafilm and incubated statically at 37°C for 48 h.  After incubation, the 
Transwell inserts were moved to clean wells.  The supernatant from the donor 
wells was removed, biofilms were then washed with 200 µl of PBS and 1.1 ml 
of PBS was added to the acceptor wells.  Finally, 140 µl of rhodamine solution 
(30 µg/ml in PBS; prepared from 5 mg/ml stock solution in dH2O) was added 
to the upper donor wells and the plate was incubated statically at 37°C.  
Samples (100 µl) were taken from the lower acceptor wells at various time 
points (1, 2, 4, 6, 24 and 48 h) and placed into a Grenier glass-bottom 96-well 
black plate for fluorescence reading (excitation: 534 nm, emission: 547 nm, 
gain 1000).  After each sample was taken/removed, 100 µl of PBS was added 
to the lower acceptor well.  In addition to these test samples, the fluorescence  
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(a) 
 
 
 
 
 
 
 
(b)  
Figure 6.1  Schematic diagram of the Transwell biofilm diffusion model, 
indicating (a) start (with the fluorescent probe added to the donor 
compartment) and (b) end (with the fluorescent probe diffused throughout 
the acceptor well) of the experiment.  
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of rhodamine at the initial concentration used in the experiment (diluted 1:10) 
and at 0.125-4 µg/ml (to prepare a calibration graph) were also measured.  
Rhodamine diffusion (%) through the biofilm was calculated using the formula 
below: 
 
 
where concentration of rhodamine in the samples collected at different time 
points was calculated from the calibration curve; the total volume in the system 
was 1.24 ml; sampling volume was 0.1 ml; initial concentration of rhodamine 
was 30 µg/ml and volume of rhodamine solution added to the upper donor well 
was 0.14 ml. 
As a control, it was important to ensure that rhodamine diffusion through the 
microporous membrane (without biofilm) was not affected by the presence of 
OligoG or EDTA alone.  For this, 1.1 ml of PBS was placed in the lower 
acceptor well and 140 µl of rhodamine (30 µg/ml in PBS) with and without 
OligoG (0.5% or 1%) or EDTA (1 mM, 50 mM or 100 mM) was added to the 
upper donor well.  Rhodamine diffusion was again calculated as described 
above.  
 
6.3.1.2 Transwell biofilm diffusion model using rhodamine 
The Transwell biofilm model system was set up as described in Section 6.3.1.1 
using an overnight culture of P. aeruginosa NH57388A adjusted to 1 x 108 
CFU/ml in MH broth.  After 48 h growth, 150 µl of MH broth alone or containing 
1% OligoG, 1 mM, 50 mM or 100 mM EDTA was added to the upper donor 
well.  The plate was incubated statically at 37°C for 4 h.  After treatment, the 
supernatant was removed. Biofilms treated with EDTA were washed once, 
while OligoG-treated biofilms were tested with and without the washing step.  
After addition of the rhodamine solution, samples were collected for up to 24 
h, as previously described. 
% = (
(conc.  of rhodamine ×  total volume) +  (conc.  of rhodamine ×  sampling volume)
initial conc.  of rhodamine ×  volume of rhodamine added
) × 100 
 
t t-1 
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6.3.2 Biofilm disruption assay 
To study the ability of OligoG to disrupt established biofilms, overnight bacterial 
cultures of E. coli IR57 were standardised to 107 CFU/ml and 10 μl was added 
to the wells of a Greiner glass-bottomed optical 96-well plate containing 90 μl 
of MH broth.  The plate was wrapped in parafilm and incubated for 24 h on a 
rocker (20 rpm) at 37°C.  Subsequently, half the supernatant was removed (50 
μl) and replaced with MH broth containing OligoG (0.5%, 2% or 6%).  The plate 
was then re-wrapped in parafilm and incubated for 4 or 24 h on a rocker (20 
rpm) at 37°C.  Sterility and growth controls were also included in the plate.  
After the treatment, the supernatant was carefully removed and biofilms were 
stained for 10 min with either LIVE/DEAD viability stain (as described in 
Chapter 4; Section 4.3.7) or ConA (α-D-glucose and α-D-mannose specific; 
red) and SYTO 9 (the nucleic acid specific LIVE component of the LIVE/DEAD 
viability stain; green).  For the latter, 50 µl of ConA was added per well (0.15 
mg/ml in PBS) and left for 1 h.  The ConA solution was subsequently removed 
and 5 µl of SYTO 9 (7.5 µM in PBS) was added and the plate incubated for a 
further 10 min.  Finally, the biofilms were washed and 50 µl of PBS added.  
CLSM was performed immediately using x63 objective magnification under oil, 
a resolution of 512 x 512, line averaging of 1 and a step size of 0.69 µm.  In 
addition, zoom factor 2 was used for EPS visualisation in E. coli IR57 biofilms.  
The excitation/emission ranges used were 485/498 nm for SYTO 9 and 
632/647 nm for ConA.  Experiments were performed in triplicate and 5 images 
per well were taken.  The fluorescence intensity of the biofilm z-stack images 
was quantified using the image analysis software Imaris.  
 
6.3.4 Fluorescent labelling of OligoG 
The conjugation methods used for synthesis of the TxRd- or OrGr-OligoG 
conjugates are summarised in Figure 6.2.  Table 6.2 summarises the 
quantities of reactants used for each conjugation.  OligoG was dissolved in 1 
ml of PBS (pH 7.4) in a 10 ml round-bottomed flask.  To this, EDC and sulfo-
NHS were added and the mixture was stirred for 15 min.  Next, 1 ml of  
 
 
 
OligoG
EDC
+
O-Acylisourea
Sulfo-NHS
Amine-reactive 
sulfo-NHS ester 
OligoG-amide-TxRd
OligoG-amide-OrGr
TxRd cadaverine
OrGr cadaverine
Figure 6.2  Schematic diagram showing synthesis of the TxRd- or OrGr-OligoG conjugates. 
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Next, 1 ml of fluorescent probe solution was added (5 mg/ml; TxRd in DMSO, 
OrGr in PBS), followed by dropwise addition of NaOH (0.5 M) to raise the pH 
to 8.0.  The reaction mixture was left stirring in the dark for 5 h at room 
temperature.  Samples (5 µl) were collected hourly, made up to 50 µg/ml in 
PBS and stored at -20°C prior to analysis by size exclusion chromatography 
(SEC; PD-10 column).  The final conjugate was purified by SEC using PD-10 
desalting columns (containing Sephadex G-25 medium).  Briefly, the PD-10 
column was equilibrated with 25 ml dH2O before the entire reaction mixture 
was added and 4.5 ml (TxRd conjugate) or 5 ml (OrGr conjugate) of the eluted 
dH2O was collected, lyophilised and stored at -20°C.  Due to the high residual 
content of OrGr after the initial purification, a second purification step was 
necessary for OligoG-OrGr (4.5 ml elution). 
 
6.3.5 Characterisation of the fluorescently labelled OligoG 
To monitor the reaction progress and estimate the proportion of free and bound 
fluorescent probe present in the conjugates, samples of crude reaction mixture 
and purified conjugates (prepared at 5 mg/ml in PBS) were characterised by 
SEC using PD-10 columns.  The PD-10 desalting columns were equilibrated 
with 25 ml PBS prior to placing the sample onto the column.  Fractions (0.5 ml) 
were collected in 0.5 ml microcentrifuge tubes (total 47 fractions).  A sample 
of each fraction (100 µl) was placed in duplicate into a black 96-well microtitre 
plate and fluorescence measured using a fluorescent plate reader.  The 
excitation/emission wavelengths used were 596/615 nm for TxRd and 485/520 
Reactant 
Weight (mg) of reactant  
TxRd-OligoG OrGr-OligoG 
OligoG 139.2 193.6 
EDC (10 molar equiv.) 13.9 19.3 
Sulfo-NHS (10 mol equiv.) 15.7 21.9 
TxRd or OrGr cadaverine (2 mol equiv.) 5.0 5.0 
 
Table 6.2  Quantities (mg) of reactants used for TxRd-OligoG and OrGr-
OligoG conjugation. 
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nm for OrGr (gain 1000).  Fluorescence intensity was then plotted against 
retention volume (ml) and the percentage of bound TxRd or OrGr was 
expressed as percentage of total fluorescence measured for all fractions.  
UV spectroscopy was used to quantify the total TxRd or OrGr content.  
Fluorescently labelled conjugates were prepared at 5 mg/ml in PBS and 
analysed by UV spectroscopy.  TxRd or OrGr loading was determined from 
interpolation of the calibration curves (0.1-10 µg/ml in PBS).  Specific activity 
(µg TxRd/OrGr per mg of TxRd-/OrGr-labelled conjugate) was calculated as 
follows: 
 
6.3.6 The effect of fluorescently labelled OligoG on biofilm disruption 
CLSM was employed to study localisation of TxRd-OligoG in E. coli IR57 
biofilms and to study the interaction of OrGr-OligoG with the EPS components.  
Biofilms were prepared as previously described in Section 6.3.2.  After 24 h of 
growth, biofilms were treated with TxRd-OligoG (0.5% and 6%) or OrGr-
OligoG (4.8%) for a further 24 h by application to the surface of the biofilm.  
Control wells were prepared containing TxRd (0.841 µg/ml; equivalent to that 
contained in a 6% solution of TxRd-OligoG) or OrGr (0.123 µg/ml; equivalent 
to that contained in a 4.8% solution of OrGr-OligoG) alone.  Subsequently, 
biofilms treated with TxRd-OligoG were stained with 5 µl of SYTO 9 (1.5 μl/ml 
in PBS) for 10 min followed by the addition of 45 μl of PBS.  Biofilms treated 
with OrGr-OligoG were stained with 50 µl of ConA (30 μl/ml in PBS) for 1 h.  
Biofilms were then washed with 50 µl of PBS before adding 50 µl of PBS to 
each well.  CLSM was performed immediately as described in Section 6.3.2.  
In addition, single optical section images from the bottom of the biofilm were 
taken for TxRd-OligoG conjugate samples using a zoom factor of 4.5, line 
average of 2, a resolution of 1024 x 1024 and a step size of 0.1 µm.  For TxRd-
OligoG, experiments were performed in triplicate (n = 3), taking 5 images per 
well, but only once for OrGr-OligoG, due to the low yield of the conjugate. To 
confirm the stability of fluorescently labelled OligoG in bacterial culture 
Specific activity =  
µg TxRd (or OrGr) from UV ×  % TxRd (or OrGr) bound
100 x mg TxRd (or OrGr) − labelled conjugate
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medium, free TxRd or OrGr content in the supernatant at the end of the 
experiment was analysed using PD-10 columns as described in Section 6.3.5. 
 
6.4 Results  
6.4.1 Transwell biofilm diffusion assay 
First, the concentration of rhodamine present in the lower acceptor well at the 
different time points was calculated using a rhodamine calibration curve 
(Figure 6.3).  As expected, as the bacterial numbers in the inoculum 
decreased, rhodamine diffusion through P. aeruginosa NH57388A biofilms 
increased with time, reaching a maximum at 48 h (Figure 6.4).  Rhodamine 
diffusion in the absence of biofilm was not affected by the presence of 0.5 and 
1% OligoG (Figure 6.5a) or 1, 50 and 100 mM EDTA (Figure 6.5b).  However, 
after treatment of the biofilm with 1% OligoG, rhodamine diffusion was lower 
over the 24 h period compared to that in the untreated control (at every time 
point tested), irrespective of whether a washing step was performed or not 
(Figure 6.6a).  Significantly more rhodamine diffused to the lower 
compartment after 24 h when the biofilms were washed with PBS compared 
to the unwashed controls for both OligoG-treated and untreated biofilms (p < 
0.05).  Addition of EDTA caused a concentration-dependent decrease in 
rhodamine diffusion over 24 h (Figure 6.6b) although at the 24 h time point, 
these differences were minimal.  
 
6.4.2 Confocal Laser Scanning Microscopy of E. coli IR57 biofilm 
disruption studies 
In the biofilm disruption assay, CLSM images of LIVE/DEAD stained E. coli 
IR57 biofilms demonstrated a well-structured, homogeneous growth in the 
untreated controls grown for both 24 h and 48 h.  After 4 and 24 h treatment, 
no substantial decrease in biofilm thickness was observed with increasing 
OligoG concentration (0.5%-6%) (Figure 6.7).  However, following 4 h 
treatment, 2% and 6% OligoG caused a significant reduction in SYTO 9 
fluorescence intensity (p < 0.05; Figure 6.8a).  Surprisingly, following 24 h 
treatment, only 6% OligoG caused disruption and disorganisation of the biofilm  
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Figure 6.3  Typical Transwell assay calibration curve for rhodamine.  Data 
is expressed as mean ± SD (n = 3).  Error bars are within the size of data 
points. 
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Figure 6.4 Rhodamine diffusion through P. aeruginosa NH57388A 
biofilms grown at different seeding densities (1 x 102 to 1 x 108 CFU/ml).  
Data represents mean rhodamine diffusion ± SD (n = 3).   
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
(b)  
 
Figure 6.5  Rhodamine diffusion through a microporous membrane in the 
presence of (a) OligoG (0%, 0.5% or 1%) or (b) EDTA (0 mM, 1 mM, 50 
mM or 100 mM).  Data represents mean Rhodamine diffusion ± SD (n = 
3).   
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 Rhodamine diffusion through the P. aeruginosa NH57388A 
biofilms after (a) OligoG treatment with and without a washing step or (b) 
cell permeabiliser EDTA.  Data represents mean rhodamine diffusion ± SD 
(n = 3).  Significant difference is indicated by *, where *p < 0.05 and **p < 
0.01 compared to the equivalent unwashed control.  (Unpaired t-test.).  
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CONTROL 0.5% OligoG 6% OligoG2% OligoG
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Figure 6.7  Biofilm disruption assay showing LIVE (green)/DEAD (red) stained CLSM (aerial and cross-sectional views) of E. 
coli IR57 biofilms grown for 24 h, followed by (a) 4 h and (b) 24 h treatment with OligoG. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8 Median fluorescence intensity and interquartile ranges 
obtained from CLSM imaging of the E. coli IR57 biofilms stained with SYTO 
9 (Figure 6.7).  Biofilms were grown for 24 h, followed by (a) 4 h and (b) 
24 h treatment with OligoG.  Mean fluorescence intensity is indicated by +.  
Significant difference is indicated by *, where *p < 0.05 and ****p < 0.0001 
compared to untreated control.  (One-way ANOVA and Dunnett’s multiple 
comparisons tests).  
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structure, although this was rather uneven and not statistically significant (p > 
0.05; Figure 6.8b).  Furthermore, only a few dead bacterial cells were present 
within the biofilm structure after OligoG treatment, indicative of bacteriostatic 
rather than bactericidal effects. 
CLSM imaging of SYTO 9/ConA stained E. coli IR57 biofilms demonstrated no 
obvious change in EPS components (polysaccharides or nucleic acid) 
following 4 or 24 h OligoG treatment (Figure 6.9).  However, a significant 
decrease in the fluorescence intensity of ConA (red channel only) was 
observed after 24 h treatment with 0.5% OligoG (p < 0.05; Figure 6.10b), but 
not when tested at the higher concentrations (2 or 6%).  
 
6.4.3 Characterisation of TxRd or OrGr labelled OligoG  
Analysis of time versus yield of the TxRd-OligoG and OrGr-OligoG conjugates 
showed that the highest fluorescence output of the conjugation reaction was 
observed after 5 h (Figure 6.11).  Typical elution profiles of the crude reaction 
mixtures and purified fluorescently-labelled OligoG can be seen in Figure 
6.12.  Typically, fluorescently labelled OligoG eluted in the void volume of the 
PD-10 column (1.5-4 ml) whereas free TxRd or OrGr eluted at > 5 ml.  Analysis 
of total fluorescence indicated that following the first purification step, the 
TxRd-OligoG conjugate had 6.9% of free TxRd and OrGr-OligoG contained 
54.4% of free OrGr.  After repeating the purification step for OrGr-OligoG, the 
free OrGr content was reduced to 11.6%.  Typical calibration curves for the 
fluorescent probes are shown in Figure 6.13.  The characteristics of the 
fluorescently-labelled OligoG synthesised are summarised in Table 6.3.   
 
6.4.4 E. coli IR57 biofilm disruption studies using fluorescently labelled 
OligoG 
CLSM imaging following 24 h treatment, showed that 0.5% TxRd-OligoG did 
not cause any disruption of the biofilm, although at 6%, TxRd-OligoG 
demonstrated a noticeable decrease in biofilm thickness and caused bacterial 
clumping (Figure 6.14a).  CLSM images of the bottom of the biofilm confirmed 
the diffusion and penetration of TxRd-OligoG throughout the whole biofilm,  
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CONTROL 0.5% OligoG 6% OligoG2% OligoG
35 µm
35 µm
35 µm
35 µm
35 µm
35 µm
35 µm
35 µm
35 µm
35 µm 35 µm
35 µm
35 µm 35 µm
35 µm35 µm
Figure 6.9  Biofilm disruption assay showing SYTO 9 and ConA stained (nucleic acid [green] and EPS polysaccharides [red], 
respectively) CLSM imaging (aerial and cross-sectional views) of E. coli IR57 biofilms grown for 24 h, followed by (a) 4 h and 
(b) 24 h treatment with OligoG (zoom factor 2).  
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
(b)  
 
 
Figure 6.10 Median fluorescence intensity and interquartile ranges 
obtained from CLSM imaging of the E. coli IR57 biofilms stained with ConA 
(Figure 6.9).  Biofilms were grown for 24 h, followed by (a) 4 h and (b) 24 
h treatment with OligoG.  Mean fluorescence intensity is indicated by +.  
Significant difference is indicated by *, where *p < 0.05 compared to 
untreated control.  (One-way ANOVA and Dunnett’s multiple comparisons 
tests).  
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Figure 6.11  Analysis of the reaction time on the reaction yield of (a) TxRd-
OligoG and (b) OrGr-OligoG conjugates using a PD-10 column.  
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(b)  
 
 
Figure 6.12  Characterisation of the elution profile of crude and purified 
mixtures of (a) TxRd-OligoG and (b) OrGr-OligoG conjugates using a PD-
10 column. 
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Figure 6.13  Calibration curve for (a) TxRd cadaverine absorbance at a 
wavelength of 587 nm and (b) OrGr cadaverine absorbance at a 
wavelength of 493 nm. 
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Table 6.3  Characterisation of TxRd- or OrGr-labelled OligoG. 
 Conjugate 
Molar ratio 
(TxRd or OrGr: 
OligoG) 
Labelling efficiency 
(µg TxRd or OrGr/  
mg conjugate) 
Free TxRd  
or OrGr 
 (%) 
TxRd-OligoG 0.01 1.39 6.9 
OrGr-OligoG 0.02 2.55 11.6 
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CONTROL 0.5% TxRd-OligoG 6% TxRd-OligoG
TxRd (equivalent to
6% TxRd-OligoG)
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Figure 6.14  Biofilm disruption assay showing SYTO 9 (green) stained CLSM of E. coli IR57 biofilms grown for 24 h, followed 
by 24 h treatment with TxRd-OligoG.  (a) CLSM 3D imaging (aerial and cross-sectional views), (b) single optical section from 
the base of the biofilm (zoom factor 4.5). 
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even at 0.5%, although clearly there was considerably more Tx-Rd in the 6% 
sample (Figure 6.14b).   
Due to the low yield of OrGr-OligoG conjugate, insufficient material was 
available for analysis, so only preliminary results could be obtained (n = 1).  No 
change in the EPS component was observed following 24 h treatment with 
4.8% OrGr-OligoG (Figure 6.15).  However, it was noted that localisation of 
OrGr-labelled OligoG was more pronounced around the smaller clusters of 
EPS.  
In controls, both TxRd and OrGr fluorescent probes, added at equivalent 
concentrations to those contained in the corresponding conjugate, lacked 
fluorescence intensity and were more susceptible to photobleaching.  In each 
case, no change in biofilm or EPS structure was observed compared to the 
untreated control. 
After incubation of biofilms with the TxRd-OligoG conjugate, analysis of the 
biofilm supernatants on a PD-10 column estimated low free TxRd levels of 7.2 
and 7.4%, for 0.5% and 6% TxRd-OligoG, respectively (Figure 6.16a).  In 
contrast, a substantial increase in free OrGr content (57.9%) was observed for 
biofilms incubated with OrGr-labelled OligoG (Figure 6.16b). 
 
6.5 Discussion  
In this study, the anti-biofilm efficacy and localisation of OligoG was assessed 
using both a Transwell diffusion assay of P. aeruginosa NH57388A biofilms 
and by CLSM imaging of fluorescently-labelled OligoG in E. coli IR57 biofilms.  
The Transwell diffusion model has previously been employed to study the 
permeability of drugs and nanoparticles across the mucus barrier (Friedl et al., 
2013, Lock et al., 2018), as well as the dissolution behaviour and diffusion of 
inhaled corticosteroids (Rohrschneider et al., 2015).  Recently, a Transwell 
system was also used to study the diffusion of PEGylated tobramycin across 
the mucus network and determine its anti-biofilm activity in a P. aeruginosa 
biofilm (Bahamondez-Canas et al., 2018).  Since chronic and persistent 
pulmonary infections, especially those colonised with mucoid P. aeruginosa 
 
 
 
CONTROL 4.8% OrGr-OligoG
OrGr (equivalent to 
4.8% OrGr-OligoG)
35 µm
35 µm 35 µm35 µm
35 µm35 µm
Figure 6.15  CLSM image analysis (aerial and cross-sectional views) of E. coli IR57 biofilms grown for 24 h , followed by 24 h 
treatment with 4.8%OrGr-OligoG (green).  The EPS polysaccharide component of the biofilms was stained with ConA (red).  
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(a) 
 
 
 
 
 
 
 
 
 
 
(b)  
 
Figure 6.16  Characterisation of supernatant from E. coli IR57 biofilms 
grown for 24 h, followed by 24 h treatment with (a) TxRd-OligoG and (b) 
OrGr-OligoG using a PD-10 column.  
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strains are a primary concern in patients with compromised lung function, it 
was interesting to study whether OligoG was able to disrupt and penetrate the 
whole structure of the biofilm or whether it would remain predominantly on the 
biofilm surface.   
Several technical aspects needed to be considered for the development of a 
Transwell diffusion model using a highly fluorescent probe.  For instance, 
Transwells with 0.4 μm pore sizes were selected to both facilitate the formation 
of a thick P. aeruginosa NH57388A biofilm on the top of the membrane, while 
also preventing bacterial growth (and “seepage”) within/through the pores.  In 
addition, the duration of biofilm growth (48 h to achieve thick biofilm 
development) and seeding density used (1 x 108 CFU/ml) were chosen to more 
closely mimic the environment of severe infection.  Although the EPS matrix 
contains various functional groups which produce an overall negative charge 
in the biofilm (Sutherland, 2001a), diffusion coefficients of negatively charged 
fluorescent probes through a Streptococcus mutans biofilm have previously 
been shown to decrease as the negative charge of the probe increased (Zhang 
et al., 2011).  Therefore, in this study, it was hypothesised that the positively 
charged rhodamine probe would effectively be ‘pulled’ through the P. 
aeruginosa NH57388A biofilm structure due to decreased electrostatic 
repulsion between the fluorescent probe and the biofilm itself.   
The Transwell biofilm model system developed here demonstrated that 
rhodamine diffusion (up to 72% of initial concentration) through the un-treated 
biofilm network increased with time, proving the suitability of the model to study 
the anti-biofilm activity of OligoG.  Previous studies have shown bacterial 
clumping and disruption of established biofilms following OligoG treatment (≥ 
0.5%) in models of both non-mucoid P. aeruginosa PAO1 (Khan et al., 2012) 
and mucoid P. aeruginosa NH57388A (Powell et al., 2018).  It was, therefore, 
highly surprising to observe a decrease in rhodamine diffusion after treatment 
with 1% OligoG in these studies.  An interaction between the positively-
charged rhodamine and negatively-charged OligoG was excluded as the 
possible cause, since diffusion through the microporous membrane was not 
affected by either component.  Interestingly, a recent study by Powell et al., 
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(2018) employed a Transwell system (3.0 µm pore size) to study the diffusion 
of negatively-charged FluoSpheres through P. aeruginosa NH57388A biofilms 
grown for 24 h, followed by 4 h treatment with OligoG.  Results revealed that 
only the 2% OligoG treatment was able to produce a significant increase in 
fluorescence intensity in the lower acceptor well 1 h after addition of the 
FluoSpheres, with no effect noted for the 0.5 % OligoG dose.  It was, therefore, 
hypothesised that, as alginate oligomers are known to bind to divalent cations 
such as Mg2+ and Ca2+ (Borgogna et al., 2013), OligoG interaction with divalent 
cations in the MH broth may have caused cross-linking in the biofilm, which 
may in turn may have slowed down diffusion of the fluorescent probe.  To test 
this, EDTA was employed to facilitate disruption of biofilm structure and thus, 
enhance diffusion of rhodamine.  Previous studies have shown that while 1 
mM EDTA prevented P. aeruginosa biofilm formation (Alakomi et al., 2006) at 
50 mM, EDTA decreased the number of P. aeruginosa biofilm-associated cells 
by more than 99% (Banin et al., 2006).  Despite this however, in these studies, 
rhodamine diffusion after treatment with EDTA (1 mM, 50 mM and 100 mM) 
was similar to that of OligoG.  In fact, increasing the concentration of EDTA 
appeared to decrease rhodamine penetration through the biofilm, although the 
actual structure of the biofilm architecture was visibly disrupted.   
The data collected in this study suggested that both chelating agents, OligoG 
and EDTA, might substantially disrupt and alter the biofilm network of P. 
aeruginosa NH57388A.  However, the release of planktonic bacteria, along 
with release of cell debris/cellular contents, might then cause clogging of the 
Transwell membrane pores, and thus, interfere with, and actually impede 
rhodamine diffusion.  Hence, although the Transwell diffusion model appeared 
to offer a simple and fast method to analyse the efficacy of anti-biofilm agents 
such as OligoG, the heterogeneity of the biofilms and issues with the 
experimental set-up (such as charge and membrane pore blockage) suggest 
a need to re-evaluate the benefits of the model used in this study.   
Several other techniques have been described in the literature to quantify the 
diffusion of drugs, proteins, antibodies and fluorescent particles (Groo and 
Lagarce, 2014), including fluorescence recovery after photobleaching (FRAP) 
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(Nordgård et al., 2014, Pincet et al., 2016) or side-by-side diffusion cell 
systems (Bhat et al., 1996).  To assess the mechanical and micro-rheological 
properties of the biofilm, single or multiple particle tracking systems have also 
been described, which allows simultaneous tracking of particles undergoing 
Brownian motion using microscopy, without disturbing the actual EPS/biofilm 
structure (Alona et al., 2014, Cheng et al., 2017).  Importantly, these systems 
allow precise determination of the trajectory of a particle and calculation of the 
effective diffusion coefficient.  For example, the mobility and diffusion of 
differently charged nanoparticles has been studied using single particle 
tracking in CF sputum, as well as in Burkholderia multivorans and P. 
aeruginosa biofilms (Forier et al., 2012).  Thus, these might be better models 
to use to study bulk biofilm properties than the Transwell model actually used 
here.  
Biofilm-associated infections, especially those caused by Gram-negative 
opportunistic pathogens are a major cause of persistent chronic infection, 
leading to increased tolerance to antimicrobial agents, and are thus a 
significant threat to public health (Bowler, 2018).  Previous studies have shown 
the effectiveness of OligoG in P. aeruginosa biofilms (Powell et al., 2018, 
Pritchard et al., 2017).  Hence in this study, it was interesting to also investigate 
the anti-biofilm properties of OligoG against other bacterial pathogens, such 
as E. coli.  In this case, even though OligoG treatment apparently had no effect 
in reducing biofilm thickness in established multi-drug resistant E. coli IR57 
biofilms, a significant and dose-dependent reduction in fluorescence intensity 
using SYTO 9 staining was observed indicative of biofilm growth inhibition.  In 
addition, bacterial clumping, increased porosity and disorganisation of the 
biofilm structure were all clearly evident following OligoG treatment.  This 
study, alongside the work of (Pritchard et al., 2017), who reported synergistic 
potentiation of colistin activity in the presence of OligoG against P. aeruginosa 
NH57388A biofilms), supports the potential therapeutic benefit of OligoG use 
in combination with antibiotics, where OligoG disruption of the tight and 
compact biofilm network into a looser structure, may facilitate and enhance the 
diffusion and effectiveness of antibiotics. 
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Dose-dependent disruption of an established P. aeruginosa NH57388A biofilm 
was previously reported after treatment with OligoG, which corresponded to a 
decrease and disruption in both eDNA and polysaccharide content of the EPS 
matrix (Powell et al., 2018).  However, surprisingly in this study no significant 
changes in fluorescence intensity of ConA were observed following either 4 h 
or 24 h treatment with OligoG.  Nevertheless, smaller clusters of EPS were 
apparent after treatment with 4.8% OrGr-OligoG or 6% OligoG, which might 
indicate the ability of OligoG, especially at higher concentrations, to interact 
with and disrupt the larger sugar components of the EPS matrix.  This 
correlated with the reduced SYTO 9 fluorescence intensity observed after 4 h 
OligoG treatment and the disorganised biofilm structure observed after 24 h 
treatment, suggesting that its chelation of divalent cations might alter the EPS 
matrix and weaken the mechanical robustness of the biofilm.  Then again, the 
difference in OligoG efficacy observed in P. aeruginosa and E. coli biofilms 
might also be due to their significantly different exopolysaccharide 
compositions.  Analysis of the glycosyl composition of P. aeruginosa 
exopolysaccharides revealed that it is comprised of 80-90% mannose and 4-
7% glucose, while E. coli exopolysaccharides contain ~10% mannose and 
~40% glucose (Bales et al., 2013).  Hence, the suitability of ConA stain for this 
study may not have been ideal since the EPS of E. coli biofilms contains fairly 
low amounts of α-D-mannose and α-D-glucose residues, to which the probe 
predominantly binds, and this might explain the lack of significant efficacy 
observed following OligoG treatment.  It seems likely, therefore, that there may 
have been a considerable underestimate of EPS sugars in these samples.  
More specific probes are clearly required that unambiguously target the other 
EPS sugars present in E. coli biofilms such as galactose and glucuronic acid 
(Limoli et al., 2015).  Surprisingly, analysis of the bacterial growth medium 
revealed liberation of high proportion of free OrGr.  Although amide linkage is 
considered to be biologically stable, degradation of OligoG by bacterial 
enzymes would still leave the sugar residues attached to OrGr, which might 
have a similar elution profile to free OrGr.  Also, OrGr might only be bound to 
OligoG by electrostatic interactions, which might be separated in bacterial 
culture medium, resulting in release of free OrGr. 
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Following conjugation of TxRd or OrGr to OligoG the amount of free 
fluorescent probe in the conjugates should have been minimal.  However, up 
to 11.6% of free probe was detected.  A strong electrostatic interaction 
between the fluorescent probe and the negatively-charged OligoG, as well as 
nonspecific binding to the PD-10 column might explain the reduced 
conjugation efficiency and presence of free TxRd or OrGr following purification.   
CLSM imaging confirmed penetration of the TxRd-OligoG conjugate from the 
top (point of treatment) to the bottom of an established E. coli IR57 biofilm, 
which was not observed with free TxRd alone.  Surprisingly, a noticeable 
decrease in established E. coli IR57 biofilm thickness following 24 h treatment 
with 6% TxRd-OligoG was demonstrated.  It has previously been reported that 
OligoG treatment was associated with an increase in overall negative surface 
charge of Gram-negative bacteria alongside irreversible binding of OligoG to 
the bacterial surface and cell aggregation (Powell et al., 2014).  Therefore, 
TxRd conjugation might also increase the negative charge of OligoG and thus, 
enhance disruption of the structural assembly of the biofilm.  CLSM imaging at 
the very base of the biofilm demonstrated close binding of TxRd-OligoG to the 
surface of the bacterial cells, perhaps indicative of interaction between the 
TxRd’s positively-charged amino group and the negatively-charged bacterial 
membrane.  The stability of the TxRd-OligoG conjugate in the bacterial growth 
medium was confirmed by analysis of the supernatant by SEC using PD-10 
column.  No statistical analysis was performed for the biofilms treated with 
TxRd-OligoG, since OligoG antimicrobial efficacy may have been altered by 
conjugation with the fluorophore. 
 
6.6 Conclusions 
This study highlighted the limitations of the Transwell system for analysis of 
bacterial biofilm disruption.  The usefulness of applying fluorescent probe 
conjugation to investigate anti-biofilm therapeutics in conjunction with CLSM 
was confirmed, although only minimal, preliminary results could be obtained 
for OrGr-OligoG.  The biofilm disruption assays showed that OligoG was able 
to reorganise/disrupt the biofilm structure of E. coli IR57 in a dose-dependent 
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manner (> 0.5%), although unlike previous studies on OligoG disruption of P. 
aeruginosa biofilms, no real decrease in biofilm thickness was observed.  
These anti-biofilm effects were more obvious using the TxRd-OligoG 
conjugate treatment, higher reduction in biofilm thickness was noted at 6%.  
These inconclusive results could be due to altered activity of the OligoG-probe 
conjugates themselves.  Further work is required to examine these issues 
further.  
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Chapter 7 
 
General Discussion 
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7.1 Evaluation of the present study  
The basis of this thesis was to design and study a group of OligoG-polymyxin 
conjugates using irreversible (amide) and reversible (ester) linkers to explore 
the feasibility of engineering novel nanomedicines to support the clinical 
demand for new antibiotics against Gram-negative bacteria. 
Over recent years, polymer therapeutics has emerged as a promising strategy 
to combat Gram-negative infections (Cal et al., 2017).  Since the early 1990s, 
when polymyxin B was covalently linked to PEG to improve its stability and 
cytotoxicity, PEG has been the primary focus for such antimicrobial 
conjugations (Groves et al., 1990, Stebbins et al., 2014).  In subsequent years, 
penicillin V was conjugated to water-soluble poly(ether urethane), a derivative 
of PEG and L-lysine, which were attached via a hydrolytically-cleavable ester 
linkage.  The resulting conjugate exhibited equivalent antimicrobial activity to 
that of the free drug in S. aureus, Streptococcus pyogenes group A and 
Enterococcus faecalis (Nathan et al., 1993).  PEG-tobramycin conjugates also 
performed favourably, demonstrating 3.2-fold greater efficacy against Gram-
negative P. aeruginosa biofilms than tobramycin alone (Du et al., 2015).  More 
recently, a reversible, traceless PEGylated colistin conjugate showed potent 
antimicrobial activity against MDR P. aeruginosa and A. baumannii, with a 
corresponding absence of nephrotoxic side effects after systemic 
administration to mice (Zhu et al., 2017).  This further suggested that covalent 
conjugation of polymyxin antibiotics to water-soluble polymers, such as 
OligoG, could be used as systemic alternatives to CMS or polymyxin B.   
Although PEG is commonly employed as a polymeric carrier for bioactive 
molecules, its’ non-biodegradability (Section 1.7) and the presence up to two 
terminal functional groups per chain has limited its’ capacity for drug 
attachment (Khandare and Minko, 2006).  Therefore, selection of OligoG as 
the polymeric carrier for antibiotic conjugation was ideal due to its 
biocompatibility (Section 1.7.1) and intrinsic antimicrobial activity (Section 
3.1.1).  This thesis aimed to create a bi-functional polymer therapeutic that 
combined the antimicrobial properties of both, OligoG and polymyxin 
antibiotics, while reducing the latter’s systemic toxicity whilst increasing its  
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efficacy at sites of infection. 
OligoG-polymyxin conjugates were produced containing either an amide or 
ester linker to study whether complete release of the antibiotic was required to 
achieve maximal reinstatement of the antimicrobial activity of the individual 
components.  Both linking chemistries promoted reproducible synthesis of 
OligoG-polymyxin conjugates with similar antibiotic loading.  Release of the 
amide-linked polymyxin relies on enzymatic degradation of OligoG.  However, 
it is important to note that no alginate degrading mammalian enzymes have 
been reported, which might impose additional difficulties for clinical translation 
to patients requiring long-term treatment (Shen et al., 2017).  Nevertheless, 
alginate lyase from K. pneumoniae and P. aeruginosa found in CF patient 
lungs has been shown to effectively degrade alginate (Simpson et al., 1993), 
highlighting the possibility of harnessing such bacteria at sites of infection to 
trigger site-specific and target-specific degradation of alginate and release of 
the therapeutic payload.  
Previous studies have shown inefficient and incomplete conversion of the 
colistin prodrug, CMS into its active form, can result in a slow and/or delayed 
increase in colistin plasma concentration (Garonzik et al., 2011).  Although 
polymyxin B is used clinically as an antibiotic of last resort, studies have shown 
that it exhibits higher nephrotoxicity compared to CMS (Akajagbor et al., 2013).  
This further highlights the potential benefits of polymer conjugation to cytotoxic 
antibiotics, such as the polymyxins. 
Colonisation by MDR Gram-negative bacterial pathogens, especially P. 
aeruginosa and repeated exposure to antibiotics, can lead to reduced 
therapeutic options and a deterioration in lung function in patients with chronic 
respiratory diseases.  In addition, binding of sputum biomolecules in the 
airways is known to diminish the antimicrobial effectiveness of inhaled colistin 
(Schneider-Futschik et al., 2018, Weers, 2015).  Although OligoG conjugation 
did not inhibit mucin binding or alter the effect of nutrient-deficient media on 
colistin and polymyxin B (Chapter 4), the high local concentrations of inhaled 
OligoG-polymyxin conjugates may still drastically improve drug targeting and 
overcome the deleterious effects associated with systemic exposure to 
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polymyxins.  Both, amide- and ester-linked colistin described in this thesis 
displayed a broad spectrum of activity against a range of Gram-negative 
bacteria and delayed bacterial growth in a concentration-dependent manner.  
However, colistin linked to OligoG via ester bonding was notably more 
effective, especially in biofilm formation studies characterised by CLSM, 
causing bacterial clumping and disruption of the P. aeruginosa R22 biofilm 
structure, as well as inducing significantly higher cell death compared to the 
amide-linked antibiotic (Chapter 4).  It was also evident in the ‘time to kill’ (TTK) 
model using A. baumannii 7789, where only the OligoG-E-colistin conjugate 
exhibited an antimicrobial profile equivalent to that of colistin alone (Chapter 
5), suggesting that ester conjugation was likely to be more clinically beneficial 
at infected sites since it achieved complete separation of the parent molecules 
by esterase enzyme degradation and hydrolysis.   
Many polymer conjugates described in the literature have explored the 
feasibility of using enzymatic degradation of a polymer backbone to reinstate 
bioactivity of the masked payload, including dextrin-trypsin (Duncan et al., 
2008), dextrin-colistin (Ferguson et al., 2014), dextrin-phospholipase A2 
(Ferguson and Duncan, 2009), dextrin-recombinant human epidermal growth 
factor (Hardwicke et al., 2008), polyacetal-trypsin (Escalona et al., 2018), 
hyaluronic acid-trypsin (Ferguson et al., 2010a) or PGA-lysozyme (Talelli and 
Vicent, 2014) conjugates.  Considering that more than 90% of an established 
P. aeruginosa biofilm was eradicated after 1 h treatment with PEG-alginate 
lyase (Lamppa et al., 2011), the co-administration of OligoG-A-polymyxin with 
PEG-alginate lyase conjugate might provide additional therapeutic benefits as 
a novel antibiofilm treatment.  Unfortunately, conventional antimicrobial 
susceptibility techniques, such as the MIC and TTK assays, may 
underestimate the real antimicrobial efficacy of OligoG-polymyxin conjugates 
due to the altered PK-PD profile of the antibiotic.   
Targeted delivery and controlled release of antibiotics at the infected site due 
to EPR effect would significantly improve their therapeutic index in vivo and 
may reduce the total dose required for bacterial eradication.  Previous studies 
have shown that exposure to high concentrations of colistin at the beginning 
197 
 
of treatment induced rapid bactericidal activity against P. aeruginosa within the 
first 24 h (Rao et al., 2014).  Conversely, increasing the concentration of 
polymyxin B drastically amplified resistance in A. baumannii (Tsuji et al., 2016).  
Therefore, prolonged retention of bi-functional OligoG-polymyxin conjugates 
at the site of infection might maximise bacterial killing at lower doses, thereby 
minimising the emergence of resistance. 
It was deemed essential in this study to investigate localisation and interaction 
of OligoG within the biofilm network, to better understand its biofilm disruption 
properties.  The diffusion of TxRd-labelled OligoG through an E. coli IR57 
biofilm was confirmed by CLSM which was associated with bacterial clumping 
and alteration of the biofilm structure (Chapter 6).  Although TxRd conjugation 
was associated with non-specific interactions with the bacterial cell 
membranes themselves, presumably due to its positively-charged amino 
group, pronounced bacterial aggregation was also clearly demonstrated with 
the OligoG-E-colistin conjugate (Chapter 4) in the biofilm formation assay.  The 
significant reduction of the EPS polysaccharides (ConA staining) in OligoG 
treated established P. aeruginosa NH57388A biofilms was reported (Powell et 
al., 2018).  However, the inconclusive results observed in this study could be 
due to insufficient specificity of the ConA dye to stain all of the E. coli EPS 
sugars leading to an incomplete “capture” of EPS polysaccharide disruption in 
these biofilms.  Further studies using MIC assays would have been beneficial 
to confirm that fluorescent labelling (TxRd or OrGr) did not alter or enhanced 
the antimicrobial activity of OligoG. 
 
7.2 Suggestions for future development of OligoG-polymyxin conjugates 
The results presented in this thesis underline the potential clinical usefulness 
of OligoG-polymyxin conjugates.  However, some questions remain 
unanswered.  Therefore, the most important outstanding experiments in 
developing the OligoG-polymyxin conjugates are described here.  
Firstly, since OligoG-polymyxin conjugates comprise a polydisperse mixture of 
species (Chapter 3), establishing suitable, specific analytical techniques to 
characterise them would improve understanding of their structure/activity 
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relationships.  In future studies, the physicochemical properties of OligoG-
polymyxin conjugates, such as size, architecture and solution conformation 
should be investigated under physiologically-relevant conditions.  Previous 
studies using small-angle neutron scattering (SANS) have shown that 
differences in molecular structure of diethylstilbestrol-polyacetal conjugates 
significantly affected the solution behaviour and altered the biological output in 
vitro (Giménez et al., 2012).  SANS has also been employed to study the 
solution structure and conformation of polymer-drug conjugates including 
HPMA copolymer-doxorubicin (Paul et al., 2010) and PGA-doxycycline 
(Conejos-Sánchez et al., 2015) and therefore, would be a beneficial technique 
to use to further characterise both the amide and ester linked polymyxins.   
Translation of OligoG-polymyxin conjugates to the clinic will require 
considerable further investigation especially of the metabolic fate and 
preferential accumulation at sites of infection of these polymers.  Preliminary 
in vivo single or multiple dose-escalating animal (and ultimately human) 
studies would also be necessary for determining in vivo toxicity and 
pharmacokinetic profiles, as well as the maximum tolerated dose of the 
conjugates.  Animal studies with other polymer conjugates have previously 
been described in the literature.  For example, to identify an appropriate dosing 
interval, the pharmacokinetics of a single intravenous bolus dose of dextrin-
colistin conjugate (0.1 mg/kg colistin equivalent) was analysed in rats 
(Ferguson et al., 2014).  However, this study was limited by colistin-mediated 
adverse effects (0.5 mg/kg) during the first 2 h post-dose, which were not 
observed at the equivalent concentration of conjugate.  In another study, 
subcutaneous administration of colistin sulfate in mice was performed using 
single (5, 10, 20, or 40 mg/kg) and repeat dosing (5 to 160 mg/kg/day) studies 
against P. aeruginosa in both thigh and lung infection models (Dudhani et al., 
2010).  However, due to acute toxicity, the largest dose of colistin used in the 
study at any given time was 40 mg/kg.  Even when colistin at an accumulated 
dose of 40 mg/kg induced mild histological damage in mice kidney, no toxicity 
was observed using PEGylated colistin conjugate (40 mg/kg colistin 
equivalent) (Zhu et al., 2017).  It would therefore be extremely interesting to 
perform similar in vivo studies to determine the most suitable route of 
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administration (and tolerability) of free and OligoG-conjugated polymyxin, 
especially at higher concentrations.  
To obtain meaningful results about tissue distribution and drug 
pharmacokinetics from the preclinical studies, it will be important, and indeed 
essential, to develop sensitive and accurate methods for the quantification of 
free and conjugated antibiotic in biological samples.  Typically, the detection 
of antimicrobial cationic peptides, CMS and colistin concentration in plasma or 
urine has been studied using high-performance liquid chromatography (HPLC) 
or liquid chromatography-mass spectrometry (LC-MS) techniques (Ali et al., 
2009, Li et al., 2003a, Li et al., 2003b).  However, it was previously found that 
dextrin conjugation hindered colistin interaction with HPLC column, 
necessitating the use of a commercial colistin ELISA kit to quantify the colistin 
content of plasma and infected burn wound samples (Azzopardi et al., 2015. 
Ferguson et al., 2014).  Unfortunately, the ELISA kit can only detect the total 
colistin content of a sample, highlighting the real need for novel analytical 
detection methods to better characterise the pharmacokinetic profile of 
OligoG-polymyxin conjugates in both in vitro and in vivo studies.   
Although the antimicrobial activity of the OligoG-polymyxin conjugates was 
tested against polymyxin-resistant bacterial strains in this study, to date, no 
investigation into the development of bacterial resistance following prolonged 
exposure to the conjugate has yet been performed.  The limitations of 
conventional susceptibility testing methods have already been discussed in 
Chapter 4.  Recently, the Nordmann/Poirel (NP) test was developed for rapid 
identification of polymyxin resistance in Enterobacteriaceae, which relies on 
glucose metabolism by growing bacteria in the presence of a defined 
concentration of polymyxin antibiotic (Bakthavatchalam et al., 2016, Nordmann 
et al., 2016).  The formed acid metabolites can be detected within 2 h by a 
phenol red colour change from orange to yellow.  This method was 
successfully employed to detect colistin-resistant Enterobacteriaceae 
collected directly from blood cultures (Jayol et al., 2016).  Thus, it could be 
interesting to use the NP test to detect polymyxin sensitive and resistant 
Enterobacteriaceae isolates after treatment with OligoG-polymyxin 
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conjugates, to identify emergence of early resistance, especially in septic 
patients who require prolonged antibiotic therapies.   
Considering the results obtained in these studies from a broader view, as well 
as recent developments in the chemistry of polymer/antibiotic conjugates in 
the literature, a number of potential avenues for extending these studies are 
clear.  Due to lack of disease-specific targeting and toxicity in neutrophils, the 
antibiotic chloramphenicol has been attached via glutaric anhydride linker to 
the cationic antibacterial peptide fragment UBI29−41 which exhibited a high 
affinity towards both Gram-negative and Gram-positive bacteria (Chen et al., 
2015).  Therefore, it would be extremely interesting to assess the efficacy of 
UBI29−41 as a targeting ligand for OligoG-polymyxin conjugates to enhance 
their bacterial specificity.  Also, previous studies have shown that OligoG 
potentiates the antimicrobial activity of several other classes of antibiotics, 
including macrolides, tetracyclines and β-lactams against a range of MDR 
Gram-negative bacteria (Khan et al., 2012).  Thus, OligoG conjugation might 
be employed to improve the pharmacokinetics and efficacy of other toxic, 
water-insoluble or otherwise undeliverable drugs. 
 
7.3 Contribution of this thesis to antibiotic development  
The work in this thesis has demonstrated the feasibility of using OligoG 
conjugation as a means of reducing antibiotic toxicity, while maintaining its 
antimicrobial efficacy against a panel of MDR Gram-negative bacteria.  These 
studies have established, for the first time, that complete detachment of the 
polymer (via an ester linkage) from the bioactive agent is required to restore 
its full biological activity, and that residual sugars inhibit complete regeneration 
of activity. 
In conclusion, OligoG-polymyxin conjugates have shown exciting antimicrobial 
activity.  Not only has their inherent antimicrobial activity been demonstrated, 
but also the bi-functionality of these molecules, thanks to the intrinsic 
bactericidal activity of the antibiotic in conjunction with the bacteriostatic 
antimicrobial/anti-biofilm activity of OligoG.  Furthermore, both individual 
components have already undergone considerable in vivo safety testing.  
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Appendix 2  
 
Bacterial growth curves in the presence 
of colistin sulfate and OligoG-colistin 
conjugates 
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Appendix 2.1  Bacterial growth curves for K. pneumoniae KP05 506 (48 h) in the presence of (a) colistin sulfate, (b and f) 
OligoG-colistin conjugates (amide and ester linked). Controls used included (c and g) unconjugated colistin plus OligoG, (d and 
h) OligoG and (e and i) the high molecular weight alginate, PRONOVA, all at equivalent concentrations used in corresponding 
conjugates (n = 3).   
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Appendix 2.1  (continued). 
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Appendix 2.1  (continued). 
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Appendix 2.2  Bacterial growth curves for E. coli IR57 (48 h) in the presence of (a) colistin sulfate, (b and f) OligoG-colistin 
conjugates (amide and ester linked). Controls used included (c and g) unconjugated colistin plus OligoG, (d and h) OligoG and 
(e and i) the high molecular weight alginate, PRONOVA, all at equivalent concentrations used in corresponding conjugates (n 
= 3).   
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Appendix 2.2  (continued). 
 
  
  2
4
0
 
 (a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2.3  Bacterial growth curves for A. baumannii 7789 (48 h) in the presence of (a) colistin sulfate, (b and f) OligoG-
colistin conjugates (amide and ester linked). Controls used included (c and g) unconjugated colistin plus OligoG, (d and h) 
OligoG and (e and i) the high molecular weight alginate, PRONOVA, all at equivalent concentrations used in corresponding 
conjugates (n = 3).   
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Appendix 3 
 
Bacterial growth curves in the presence 
of OligoG or NaCl  
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Growth curves in the presence of OligoG or NaCl  
OligoG contains a high amount of sodium salt which may affect bacterial 
growth due to osmotic pressure.  The sodium content in each batch of OligoG 
was provided by Algipharma AS; mean concentration of ~110.5 µg/mg based 
on calculations from three different batches.  Previous studies have shown that 
increasing the concentration of NaCl caused a reciprocal decrease in the 
logarithmic growth of E. coli and S. aureus (Omotoyinbo and Omotoyinbo, 
2016).  Preliminary results observed in this thesis indicated that NaCl, at the 
equivalent concentration contained in a 10% w/v solution of OligoG, reduced 
growth of the Gram-negative bacteria and caused a faster onset of stationary 
phase (Appendix 3.1).  Fortunately, when lower salt concentrations, 
equivalent to what would be achieved with clinically relevant concentration of 
OligoG, were tested, bacterial growth was not affected, suggesting that the 
antimicrobial activity and mechanism of OligoG does not rely on salt content 
in the formulation. 
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Appendix 3.1  Bacterial growth curves (48 h) for (a) P. aeruginosa NH57388A, (b) K. pneumoniae KP05 506, (c) E. coli IR57 
and (d) A. baumannii 7789 in the presence of OligoG or NaCl, at equivalent concentration to the Na+ content of OligoG (n = 3).   
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Appendix 4 
 
MIC assays in the presence of Gram-positive 
antibiotics and OligoG against  
Gram-negative bacteria  
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Drug      OligoG (%) → 
MIC (µg/ml) 
P. aeruginosa 
PAO1, 
ATCC 15692 
P. aeruginosa  
MDR 301 
K. pneumoniae  
KP05 506 
E. coli 
AIM-1 
A. baumannii 
7789 
0 0.2 2 0 0.2 2 0 0.2 2 0 0.2 2 0 0.2 2 
Bacitracin ND ND ND > 4096 > 4096 > 4096 4096 4096 > 4096 512 512 1024 512 512 256 
Vancomycin ND ND ND > 4096 2048 2048 1024 512 1024 128 128 128 128 128 128 
Spiramycin ND ND ND 4096 4096 4096 1024 1024 1024 16 16 16 1024 512 256 
Spectinomycin 128 256 128 ND ND ND ND ND ND ND ND ND ND ND ND 
Rifampicin 512 512 512 ND ND ND ND ND ND ND ND ND ND ND ND 
 
Appendix 4.1  Microbiological efficacy of so called ‘Gram-positive antibiotics’ (i.e. those commonly prescribed for Gram-
positive bacteria) in the absence and presence of OligoG against Gram-negative bacteria. 
. 
ND, not determined.  Increased antimicrobial activity of antibiotic, where the MIC was at least 2-fold lower compared to control, 
is shown in red. 
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Optimisation of OligoG-bacitracin  
conjugates 
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Characterisation and optimisation of OligoG-A-bacitracin conjugates  
To provide ‘proof of principle’ for utilising alginate oligomers for cytotoxic 
antibiotic delivery, the polypeptide class antibiotic bacitracin was also attached 
to the OligoG via amide linkage to produce an OligoG-A-bacitracin conjugate.  
Surprisingly, the OligoG-bacitracin conjugate exhibited higher cytotoxicity in 
HK-2 cells compared to the free drug (Appendices 5.4 and 5.5).  This might 
be associated with the low antibiotic loading in the conjugate (4.3% w/w) and 
higher content of alginate polymer since only three positively charged amino 
groups were available for conjugation, leading to higher and more viscous cell 
culture medium.  It is also possible that OligoG-bacitracin conjugate 
purification was incomplete, and the toxicity observed was due to residual 
reactants.  As a result of these preliminary results, optimisation studies were 
performed to change the conjugation variables such as pH, ratio of EDC/ sulfo-
NHS or OligoG: bacitracin and duration of the reaction (Appendix 5.1).  The 
two reactions that produced the highest yield were chosen for further 
characterisation (Appendix 5.2).  However, in each case there was no 
significant increase in bacitracin loading (3.8% w/w and 5.7% w/w) or 
improvement (reduction) of cytotoxicity.  Since these proof of concept studies 
only used one conjugation method, it is also possible that optimisation of the 
OligoG-bacitracin conjugate synthesis using ester linkage may improve their 
cytotoxicity profile.  Similarly, neither bacitracin conjugate nor free drug was 
effective in MICs against most of the tested Gram-negative or Gram-positive 
bacterial strains (Appendix 5.3).  This was unsurprising since bacitracin is 
predominantly a ‘Gram-positive antibiotic’ which interferes with peptidoglycan 
synthesis.   It was very interesting to observe that two OligoG-bacitracin 
conjugates showed enhanced antimicrobial activity against the E. coli AIM-1 
pathogen tested.  
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Reaction 
number 
pH 
Molar 
equivalent of 
EDC/ sulfo-
NHS 
Ratio of 
OligoG: 
bacitracin 
Duration of 
reaction (h) 
 
     
Original 
method 
8 0.1 3:1 2 
1 8 0.1 2:1 1, 2, 3, 4, 5 
2 
No 
adjustment 
0.1 2:1 1, 2, 3, 4, 5 
3 9 0.1 2:1 1, 2, 3, 4, 5 
4 10 0.1 2:1 1, 2, 3, 4, 5 
5 8 0.2 2:1 1, 2, 3, 4, 5 
6 8 0.3 2:1 1, 2, 3, 4, 5 
7 8 0.1 1:1 1, 2, 3, 4, 5 
8 8 0.1 3:1 1, 2, 3, 4, 5 
 
Appendix 5.1  Optimisation of OligoG-A-bacitracin conjugate synthesis.  
Reaction ratios used previously for OligoG-colistin and -polymyxin B 
conjugation are highlighted in red.  Reactions that produced the highest 
yield are highlighted in blue. 
  
 
 
 
 
 
 
 
 
 
Tested 
compound 
Mw (g/mol)  
(PDI) by  
GPC 
Protein content 
(% w/w) 
Molar ratio  
(per bacitracin) 
Conjugated NH2 
per molecule 
Free protein 
(%) 
OligoG-A-bacitracin 
(original) 
27,500 (2.5) 4.3 9.8 2.1 0.7 
OligoG-A-bacitracin 
(reaction 5) 
25,500 (2.3) 3.8 11.1 2.6 5.6 
OligoG-A-bacitracin 
(reaction 6) 
26,500 (2.7) 5.7 7.3 2.8 4.6 
 
Appendix 5.2  Characterisation summary of OligoG-A-bacitracin conjugates. 
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Drug 
 
MIC (µg/ml) 
P. aeruginosa 
MDR 301 
K. pneumoniae 
KP05 506 
E. coli 
AIM-1 
A. baumannii 
7789 
S. aureus  
NCTC 6571 
S. aureus 
NCTC 12493 
OligoG-A-bacitracin 
(original) 
>512 512 32 512 ND ND 
OligoG-A-bacitracin 
(reaction 5) 
>512 >512 128 512 >512 256 
OligoG-A-bacitracin 
(reaction 6) 
>512 >512 >512 >512 >512 512 
Bacitracin >512 >512 >512 512 64 32 
 
 
Appendix 5.3  MIC determinations of OligoG-A-bacitracin conjugates against a range of Gram-negative and Gram-positive 
bacterial pathogens. 
Increased antimicrobial activity of conjugated bacitracin, where the MIC was at least 2-fold lower compared to bacitracin control, 
is shown in red. 
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Appendix 5.4  In vitro cytotoxicity of OligoG-A-bacitracin conjugates in HK-
2 cells.  Data is presented as % of normal growth compared with the 
untreated control cells ± SEM (n = 18).  Significant difference is indicated 
by *, where **p < 0.01, ***p < 0.001, ****p < 0.0001 compared to bacitracin.  
(Two-way ANOVA and Dunnett’s multiple comparisons tests).  
Compound IC50 (mg/ml) 
OligoG-A-bacitracin 
(original) 
0.309 ± 0.075 
OligoG-A-bacitracin 
(reaction 5) 
0.660 ± 0.020 
OligoG-A-bacitracin 
(reaction 6) 
0.955 ± 0.012 
Bacitracin > 1 
OligoG > 10 
 
Appendix 5.5  IC50 values (± SEM) of OligoG-A-bacitracin conjugates 
derived from MTT assay in HK-2 cells.   
 
 
